{"9eddbb7e1b7353bd19ec0666caaa86c7f90b0ad9": [["IntroductionMyocarditis is a non-specific inflammatory disease of the myocardium.", [["myocardium", "ANATOMY", 70, 80], ["Myocarditis", "DISEASE", 12, 23], ["inflammatory disease of the myocardium", "DISEASE", 42, 80], ["myocardium", "ORGAN", 70, 80], ["IntroductionMyocarditis", "PROBLEM", 0, 23], ["a non-specific inflammatory disease of the myocardium", "PROBLEM", 27, 80], ["Myocarditis", "OBSERVATION", 12, 23], ["non-specific", "OBSERVATION_MODIFIER", 29, 41], ["inflammatory", "OBSERVATION", 42, 54], ["myocardium", "ANATOMY", 70, 80]]], ["Its incidence in 65 the canine population is unknown, though a histopathologic diagnosis of myocarditis 66 was reported in 1.5% of dogs in a retrospective necropsy study [1] 73 toxins, immune-mediated diseases, trauma, heat stroke, hemodynamic shock, and 74 idiopathic myocarditis [1, 22, 33] .", [["myocarditis", "DISEASE", 92, 103], ["immune-mediated diseases", "DISEASE", 185, 209], ["trauma", "DISEASE", 211, 217], ["heat stroke", "DISEASE", 219, 230], ["hemodynamic shock", "DISEASE", 232, 249], ["idiopathic myocarditis", "DISEASE", 258, 280], ["canine", "ORGANISM", 24, 30], ["dogs", "ORGANISM", 131, 135], ["dogs", "SPECIES", 131, 135], ["canine", "SPECIES", 24, 30], ["myocarditis", "PROBLEM", 92, 103], ["a retrospective necropsy study", "TEST", 139, 169], ["toxins", "TEST", 177, 183], ["immune-mediated diseases", "PROBLEM", 185, 209], ["trauma", "PROBLEM", 211, 217], ["heat stroke", "PROBLEM", 219, 230], ["hemodynamic shock", "PROBLEM", 232, 249], ["74 idiopathic myocarditis", "PROBLEM", 255, 280], ["myocarditis", "OBSERVATION", 92, 103], ["diseases", "OBSERVATION", 201, 209], ["heat", "ANATOMY", 219, 223], ["stroke", "OBSERVATION", 224, 230], ["hemodynamic shock", "OBSERVATION", 232, 249], ["idiopathic", "OBSERVATION_MODIFIER", 258, 268], ["myocarditis", "OBSERVATION", 269, 280]]], ["Literature pertaining to presentation, diagnosis, and 75 treatment of myocarditis in canines is limited, consisting mostly of single case reports 76 and small case series focused on a single causative etiology.", [["myocarditis", "DISEASE", 70, 81], ["canines", "ORGAN", 85, 92], ["myocarditis", "PROBLEM", 70, 81], ["small case series", "PROBLEM", 153, 170], ["myocarditis", "OBSERVATION", 70, 81]]], ["There are no large-scale 77 studies reporting clinical features or outcome of myocarditis across multiple etiologies.", [["myocarditis", "DISEASE", 78, 89], ["myocarditis", "PROBLEM", 78, 89], ["no", "UNCERTAINTY", 10, 12], ["large", "OBSERVATION_MODIFIER", 13, 18], ["myocarditis", "OBSERVATION", 78, 89], ["multiple", "OBSERVATION_MODIFIER", 97, 105], ["etiologies", "OBSERVATION", 106, 116]]], ["78 Definitive diagnosis of myocarditis is based on histopathology demonstrating 79 myocardial inflammation, with or sometimes without myocyte necrosis; therefore, 80 definitive antemortem diagnosis requires endomyocardial biopsy [34] [35] [36] .", [["myocardial", "ANATOMY", 83, 93], ["myocyte", "ANATOMY", 134, 141], ["endomyocardial", "ANATOMY", 207, 221], ["myocarditis", "DISEASE", 27, 38], ["myocardial inflammation", "DISEASE", 83, 106], ["necrosis", "DISEASE", 142, 150], ["myocardial", "MULTI-TISSUE_STRUCTURE", 83, 93], ["myocyte", "CELL", 134, 141], ["myocarditis", "PROBLEM", 27, 38], ["histopathology", "TEST", 51, 65], ["79 myocardial inflammation", "PROBLEM", 80, 106], ["myocyte necrosis", "PROBLEM", 134, 150], ["endomyocardial biopsy", "TEST", 207, 228], ["myocarditis", "OBSERVATION", 27, 38], ["myocardial", "ANATOMY", 83, 93], ["inflammation", "OBSERVATION", 94, 106], ["without", "UNCERTAINTY", 126, 133], ["myocyte", "ANATOMY", 134, 141], ["necrosis", "OBSERVATION", 142, 150]]], ["Though more 81 routinely performed in humans [36, 37] , this procedure is rarely performed in dogs due to 82 limited availability of expertise and specialized equipment, combined with procedural 83 and anesthetic risk.", [["humans", "ORGANISM", 38, 44], ["dogs", "ORGANISM", 94, 98], ["humans", "SPECIES", 38, 44], ["humans", "SPECIES", 38, 44], ["this procedure", "TREATMENT", 56, 70]]], ["For this reason, the antemortem diagnosis of canine myocarditis is 84 generally presumptive and based on an individual clinician's interpretation of case 85 presentation and clinicopathologic information.", [["myocarditis", "DISEASE", 52, 63], ["canine", "ORGANISM", 45, 51], ["canine", "SPECIES", 45, 51], ["canine myocarditis", "PROBLEM", 45, 63], ["canine myocarditis", "OBSERVATION", 45, 63]]], ["Standardized antemortem diagnostic 86 criteria, as exist for canine endocarditis [38] , would be helpful to identify dogs with 87 suspected or possible myocarditis.", [["canine endocarditis", "DISEASE", 61, 80], ["myocarditis", "DISEASE", 152, 163], ["canine", "ORGANISM", 61, 67], ["dogs", "ORGANISM", 117, 121], ["dogs", "SPECIES", 117, 121], ["canine", "SPECIES", 61, 67], ["canine endocarditis", "PROBLEM", 61, 80], ["myocarditis", "PROBLEM", 152, 163], ["endocarditis", "OBSERVATION", 68, 80], ["possible", "UNCERTAINTY", 143, 151], ["myocarditis", "OBSERVATION", 152, 163]]], ["88 The primary objective of this study was to describe the clinical presentation, 89 diagnostic test results, suspected etiology, treatment, and outcome of dogs with a 90 presumptive diagnosis of myocarditis presenting to two tertiary care facilities.", [["myocarditis", "DISEASE", 196, 207], ["dogs", "ORGANISM", 156, 160], ["dogs", "SPECIES", 156, 160], ["this study", "TEST", 28, 38], ["diagnostic test", "TEST", 85, 100], ["treatment", "TREATMENT", 130, 139], ["myocarditis", "PROBLEM", 196, 207], ["myocarditis", "OBSERVATION", 196, 207]]], ["The two 91 tertiary care facilities were located in geographic areas not endemic to either 92 Trypanosoma cruzi or Leishmania infantum, the two vector-borne infectious diseases 93 most commonly linked to canine myocarditis.", [["Trypanosoma cruzi", "DISEASE", 94, 111], ["Leishmania infantum", "DISEASE", 115, 134], ["infectious diseases", "DISEASE", 157, 176], ["myocarditis", "DISEASE", 211, 222], ["Trypanosoma cruzi", "ORGANISM", 94, 111], ["Leishmania infantum", "ORGANISM", 115, 134], ["canine", "ORGANISM", 204, 210], ["Trypanosoma cruzi", "SPECIES", 94, 111], ["Leishmania infantum", "SPECIES", 115, 134], ["canine", "SPECIES", 204, 210], ["Trypanosoma cruzi", "SPECIES", 94, 111], ["Leishmania infantum", "SPECIES", 115, 134], ["canine", "SPECIES", 204, 210], ["Trypanosoma cruzi", "TEST", 94, 111], ["Leishmania infantum", "PROBLEM", 115, 134], ["borne infectious diseases", "PROBLEM", 151, 176], ["canine myocarditis", "PROBLEM", 204, 222], ["Leishmania infantum", "OBSERVATION", 115, 134], ["myocarditis", "OBSERVATION", 211, 222]]], ["A second study objective was to compare 94 clinical findings between institutions and between etiologies of myocarditis.", [["myocarditis", "DISEASE", 108, 119], ["A second study objective", "TEST", 0, 24], ["myocarditis", "PROBLEM", 108, 119], ["myocarditis", "OBSERVATION", 108, 119]]], ["A third study 95 objective was to use these findings in conjunction with postmortem results in confirmed 96 myocarditis cases to propose criteria that can be utilized for the antemortem diagnosis 97 of canine myocarditis. (n = 12), Labrador retriever (n = 10), golden retriever (n = 5), boxer (n = 4), collie (n = 3), 153 bullmastiff (n = 2), Pembroke Welsh Corgi (n = 2), pointer (n = 2), Jack Russell terrier (n = 2), Cavalier King Charles spaniel (n = 2), beagle (n = 2), and one each of 18 155 additional breeds.", [["myocarditis", "DISEASE", 108, 119], ["myocarditis", "DISEASE", 209, 220], ["Labrador retriever", "DISEASE", 232, 250], ["bullmastiff", "DISEASE", 322, 333], ["canine", "ORGANISM", 202, 208], ["canine", "SPECIES", 202, 208], ["Labrador retriever", "SPECIES", 232, 250], ["golden retriever", "SPECIES", 261, 277], ["Cavalier King Charles spaniel", "SPECIES", 420, 449], ["A third study", "TEST", 0, 13], ["the antemortem diagnosis", "TEST", 171, 195], ["canine myocarditis", "PROBLEM", 202, 220], ["golden retriever", "PROBLEM", 261, 277], ["Jack Russell terrier", "TEST", 390, 410], ["beagle (n", "TEST", 459, 468], ["myocarditis", "OBSERVATION", 209, 220], ["golden retriever", "OBSERVATION", 261, 277]]], ["There were no differences between institutions in terms of dog sex, 156 age, or weight.", [["dog", "ORGANISM", 59, 62], ["no", "UNCERTAINTY", 11, 13]]], ["(3/64, 5%), dyspnea or tachypnea (2/64, 3%), and decreased intensity of heart sounds 179 (2/64, 3%).", [["heart", "ANATOMY", 72, 77], ["dyspnea", "DISEASE", 12, 19], ["tachypnea", "DISEASE", 23, 32], ["heart", "ORGAN", 72, 77], ["dyspnea", "PROBLEM", 12, 19], ["tachypnea", "PROBLEM", 23, 32], ["decreased intensity of heart sounds", "PROBLEM", 49, 84], ["tachypnea", "OBSERVATION", 23, 32], ["decreased", "OBSERVATION_MODIFIER", 49, 58], ["intensity", "OBSERVATION_MODIFIER", 59, 68], ["heart", "ANATOMY", 72, 77]]], ["Location and timing of heart murmurs were further characterized in all 12 Table 1 . reported as mean \u00b1 standard deviation for normally-distributed data, and as median 6 (range) for non-normally-distributed data. cTnI, cardiac troponin I; E/A, ratio of early to", [["heart", "ANATOMY", 23, 28], ["cardiac", "ANATOMY", 218, 225], ["heart", "ORGAN", 23, 28], ["cTnI", "GENE_OR_GENE_PRODUCT", 212, 216], ["cardiac troponin I", "GENE_OR_GENE_PRODUCT", 218, 236], ["E/A", "GENE_OR_GENE_PRODUCT", 238, 241], ["cTnI", "PROTEIN", 212, 216], ["cardiac troponin I", "PROTEIN", 218, 236], ["heart murmurs", "PROBLEM", 23, 36], ["cTnI", "TEST", 212, 216], ["cardiac troponin I", "TEST", 218, 236], ["E/A", "TEST", 238, 241], ["heart", "ANATOMY", 23, 28], ["murmurs", "OBSERVATION", 29, 36], ["cardiac", "ANATOMY", 218, 225]]]], "11dfd91790da005937371365098de726ddfaec98": [["Etiologic fraction estimates presented in Figure 3 comparing results from attributable fraction (AF) and PERCH Integrated Analysis (PIA): output averaged across 500 simulated datasets Abbreviations: PIAN, results from PIA method using narrow sensitivity priors; PIAW, results from PIA method using wide sensitivity priors; CI, credible interval; RSME, root mean square error.Supplementala Estimate is defined as the mean etiologic estimate across the 500 datasets. b Bias is defined as the difference between the mean etiologic estimate and the true etiologic fraction values used to generate the data sets. c Standard deviation is defined as the square root of the variance across the 500 datasets. d Root mean square error (RMSE) is a measure of error, incorporating both bias and variance.", [["Etiologic fraction estimates", "TEST", 0, 28], ["attributable fraction", "PROBLEM", 74, 95], ["AF", "PROBLEM", 97, 99], ["PIA method", "TEST", 218, 228], ["narrow sensitivity priors", "TEST", 235, 260], ["PIA method", "TEST", 281, 291], ["wide sensitivity priors", "TEST", 298, 321], ["CI", "TEST", 323, 325], ["credible interval", "TEST", 327, 344], ["RSME", "TEST", 346, 350], ["root", "ANATOMY", 352, 356], ["deviation", "OBSERVATION", 619, 628], ["Root", "OBSERVATION_MODIFIER", 702, 706], ["both bias", "OBSERVATION", 769, 778]]], ["RMSE is calculated as the average of the squared differences between the mean etiologic estimate and the truth for each of the 500 datasets. e Coverage is defined as the observed fraction of the 95% credible intervals that cover the true etiology fractions out of the 500 replications. f Average length of the 95% credible intervals across the 500 datasets.", [["e Coverage", "TREATMENT", 141, 151], ["length", "OBSERVATION_MODIFIER", 296, 302]]], ["Etiologic fraction estimates using attributable fraction (AF) and PERCH Integrated Analysis (PIA), where AF calculated using two methods.SupplementalLegend: Distribution of the output from 500 simulated datasets by analysis method.", [["Etiologic fraction", "TEST", 0, 18], ["attributable fraction", "PROBLEM", 35, 56], ["AF", "PROBLEM", 58, 60], ["PERCH Integrated Analysis", "TEST", 66, 91], ["AF", "PROBLEM", 105, 107], ["the output", "TEST", 173, 183], ["analysis method", "TEST", 215, 230], ["output", "OBSERVATION_MODIFIER", 177, 183]]], ["AF Marginal calculated using odds ratios obtained from a logistic regression where only the single pathogen is used to predict case-control status.", [["AF", "PROBLEM", 0, 2], ["odds ratios", "TEST", 29, 40], ["a logistic regression", "PROBLEM", 55, 76], ["the single pathogen", "PROBLEM", 88, 107], ["Marginal", "OBSERVATION_MODIFIER", 3, 11]]], ["AF Conditional calculated using odds ratios obtained from a multi-variable logistic regression where the pathogen and all others predict case-control status.SupplementalDescription of boxplots: Bold black line = mean of the true value across the 500 datasets; Boxplots display the distribution of etiologic fraction point estimates from 500 simulated datasets: Diamond = average etiologic estimates across the 500 datasets; Vertical line through diamond = confidence interval around the etiologic estimates; Numbers above boxplots indicate the numeric value of the diamond; whiskers denote the 5th and 95th percentiles of the etiologic fraction point estimates.", [["odds ratios", "TEST", 32, 43], ["a multi-variable logistic regression", "PROBLEM", 58, 94], ["the pathogen", "PROBLEM", 101, 113], ["Bold black line", "TREATMENT", 194, 209], ["Vertical line through diamond", "TREATMENT", 424, 453], ["etiologic fraction", "OBSERVATION", 626, 644]]], ["Figure 2 : Dirichlet etiology priors for 30 etiology fractions (pathogens) at three hyperparameter values, alpha=0.1 (blue), 0.5 (green), 1(red).SupplementalLegend: Given alpha, 1,000 random realizations from the prior are shown, each by a light curve of identical color; the dotted curve lying at the center of the light curves, from left to right with decreasing etiologic importance, characterizes the average cumulative etiology fractions in a priori.SupplementalBayesian analysis uses the evidence in the data to calculate a posterior distribution for the unknowns from an input prior distribution.", [["30 etiology fractions", "PROBLEM", 41, 62], ["pathogens", "PROBLEM", 64, 73], ["alpha", "TEST", 107, 112], ["blue", "TEST", 118, 122], ["the dotted curve", "PROBLEM", 272, 288], ["SupplementalBayesian analysis", "TEST", 455, 484], ["the data", "TEST", 506, 514], ["left", "ANATOMY_MODIFIER", 335, 339], ["right", "ANATOMY_MODIFIER", 343, 348], ["decreasing", "OBSERVATION_MODIFIER", 354, 364], ["posterior", "ANATOMY_MODIFIER", 530, 539]]], ["Because the goal of this analysis is to elucidate the evidence in the case-control data about the unknown etiology fractions, we have used minimally informative priors so that the posterior mainly represents the PERCH evidence.", [["this analysis", "TEST", 20, 33], ["posterior", "ANATOMY_MODIFIER", 180, 189], ["PERCH", "OBSERVATION", 212, 217]]], ["Specifically, we use a Dirichlet prior distribution (extension to multiple pathogens of the uniform distribution) that assumes that: (1) every pathogen or pathogen combination is equally likely to be the cause for a given child; and (2) that roughly 85% of the cases will be caused by the 5 top pathogens.", [["every pathogen", "PROBLEM", 137, 151], ["pathogen", "PROBLEM", 155, 163], ["the 5 top pathogens", "PROBLEM", 285, 304]]], ["When using regression models to adjust for covariates, we use a (logistic-normal) prior distribution for the regression parameters that closely matches this Dirichlet.SupplementalThe blue curve shows that, in a priori, a Dirichlet prior with alpha=0.1 encourages a few large etiology fractions, leaving not much room for smaller ones.", [["the regression parameters", "TEST", 105, 130], ["The blue curve", "TEST", 179, 193], ["alpha", "TEST", 242, 247]]], ["This is evident from the fast plateaued cumulative curve for the largest, 2nd largest, 3rd largest, ... etiology fractions.", [["largest", "OBSERVATION_MODIFIER", 65, 72], ["largest", "OBSERVATION_MODIFIER", 78, 85], ["3rd largest", "OBSERVATION_MODIFIER", 87, 98]]], ["We show 1,000 realizations from this prior, each by a light blue curve.", [["a light blue curve", "TEST", 52, 70]]], ["On average (blue dashed lines), roughly 85% of all the cases are caused by 4 top pathogens; 95% of all the cases are caused by top 7 pathogens.SupplementalIncreasing alpha from 0.1 to 0.5 and 1 (blue, to green and red) admits tiny etiology fractions in a priori.", [["lines", "CELL", 24, 29], ["SupplementalIncreasing alpha", "GENE_OR_GENE_PRODUCT", 143, 171], ["SupplementalIncreasing alpha", "PROTEIN", 143, 171], ["average (blue dashed lines", "TREATMENT", 3, 29], ["4 top pathogens", "PROBLEM", 75, 90], ["top 7 pathogens", "PROBLEM", 127, 142], ["tiny etiology fractions", "PROBLEM", 226, 249], ["top 7", "OBSERVATION_MODIFIER", 127, 132], ["pathogens", "OBSERVATION", 133, 142], ["tiny", "OBSERVATION_MODIFIER", 226, 230], ["etiology fractions", "OBSERVATION_MODIFIER", 231, 249]]], ["A Dirichlet prior with alpha=0.5 assumes 17 top pathogens will fill 95% of the entire pie on average, and 21 pathogens when alpha=1.", [["alpha=1", "GENE_OR_GENE_PRODUCT", 124, 131], ["alpha", "TEST", 23, 28], ["alpha", "TEST", 124, 129]]], ["Figure 3 : Etiologic fraction estimates using PERCH Integrated Analysis (PIA) comparing narrow and wide sensitivity priors performed on 500 simulated datasets for a study that had only one specimen collected from 600 cases and 600 controls.b.", [["specimen", "ANATOMY", 189, 197], ["Etiologic fraction estimates", "TEST", 11, 39], ["PERCH Integrated Analysis", "TEST", 46, 71], ["wide sensitivity priors", "TEST", 99, 122], ["a study", "TEST", 163, 170]]], ["Distribution of etiologic estimates from PIA analyses of 500 simulated datasets, analyzed using narrow versus wide sensitivity priorsBold black line = mean of the true value across the 500 datasets; Boxplots display the distribution of etiologic fraction point estimates from 500 simulated datasets: Diamond = average etiologic estimates across the 500 datasets; Vertical line through diamond = confidence interval around the etiologic estimates; Numbers above boxplots indicate the numeric value of the diamond; whiskers denote the 5th and 95th percentiles of the etiologic fraction point estimates.c.", [["PIA analyses", "TEST", 41, 53], ["Bold black line", "TEST", 133, 148], ["the true value", "TEST", 159, 173], ["Vertical line through diamond", "TREATMENT", 363, 392], ["black line", "OBSERVATION", 138, 148], ["etiologic fraction", "OBSERVATION", 565, 583]]], ["PIA Method, Comparing Narrow and Wide Sensitivity PriorsPathogen Abbreviations: PIAN, results from PIA analysis, using narrow sensitivity priors; PIAW, results from PIA analysis, using wide sensitivity priors; CI, credible interval; RSME, root mean square error.c.", [["PIA Method", "TEST", 0, 10], ["PIA analysis", "TEST", 99, 111], ["narrow sensitivity priors", "TEST", 119, 144], ["PIA analysis", "TEST", 165, 177], ["wide sensitivity priors", "TEST", 185, 208], ["CI", "TEST", 210, 212], ["credible interval", "TEST", 214, 231], ["RSME", "TEST", 233, 237], ["root", "ANATOMY", 239, 243]]], ["PIA Method, Comparing Narrow and Wide Sensitivity Priorsa Estimate is defined as the mean etiologic estimate across the 500 datasets. b Bias is defined as the difference between the mean etiologic estimate and the true etiologic fraction values used to generate the data sets. c Standard deviation is defined as the square root of the variance across the 500 datasets. d Root mean square error (RMSE) is a measure of error, incorporating both bias and variance.", [["PIA Method", "TEST", 0, 10], ["deviation", "OBSERVATION", 288, 297], ["Root", "OBSERVATION_MODIFIER", 371, 375], ["both bias", "OBSERVATION", 438, 447]]], ["RMSE is calculated as the average of the squared differences between the mean etiologic estimate and the truth for each of the 500 datasets. e Coverage is defined as the observed fraction of the 95% credible intervals that cover the true etiology fractions out of the 500 replications. f Average length of the 95% credible intervals across the 500 datasets.", [["e Coverage", "TREATMENT", 141, 151], ["length", "OBSERVATION_MODIFIER", 296, 302]]], ["Output for simulation in Figure 4 presenting mean etiologic estimate, bias, SD, coverage, etc. Abbreviations: CI, credible interval; RSME, root mean square error.Supplementala.", [["SD", "DISEASE", 76, 78], ["Supplementala", "CHEMICAL", 162, 175], ["Output", "TEST", 0, 6], ["RSME", "TEST", 133, 137], ["Supplementala", "TREATMENT", 162, 175]]], ["Standard deviation is defined as the square root of the variance across the 500 datasets. d.", [["deviation", "OBSERVATION", 9, 18], ["square", "OBSERVATION_MODIFIER", 37, 43], ["root", "OBSERVATION_MODIFIER", 44, 48]]], ["Root mean square error (RMSE) is a measure of error, incorporating both bias and variance.", [["both bias", "OBSERVATION", 67, 76]]], ["Coverage is defined as the observed fraction of the 95% credible intervals that cover the true etiology fractions out of the 500 replications. f.", [["f.", "SPECIES", 143, 145]]], ["Average length of the 95% credible intervals across the 500 datasets.", [["Average length", "TEST", 0, 14], ["length", "OBSERVATION_MODIFIER", 8, 14]]], ["Table 3 : Impact of inaccurate or imprecise sensitivity priors on etiologic estimation from PERCH Integrated Analysis using 500 simulated datasets: output resultsa.", [["etiologic estimation", "TEST", 66, 86], ["output resultsa", "TEST", 148, 163]]], ["Underestimating Bronze-standard (BrS) sensitivity for a domnant pathogen (pathogen A)From the boxplot for Pathogen A in Figure 4a it may appear that the results very rarely cover the truth, but the coverage shown here is 98% indicating that 98% of the 500 analyses had results whose confidence interval covered the true value.", [["BrS", "DISEASE", 33, 36], ["a domnant pathogen", "PROBLEM", 54, 72], ["the true value", "TEST", 311, 325]]], ["This makes sense if you understand the boxplot in Figure 4a is presenting the distribution of the etiologic point estimates across the 500 analyses whereas the coverage value describes how often the 95% CI from any single analysis covers the truth.", [["any single analysis", "TEST", 211, 230]]], ["So the etiology estimate is very rarely in line with the truth of 36% (across the 500 datasets), but even when it's way off base (e.g., 43%) then 95% CI still covers the truth because of the length of the CI.", [["CI", "TEST", 150, 152], ["the CI", "TEST", 201, 207], ["very", "OBSERVATION_MODIFIER", 28, 32]]], ["Abbreviations: CI, credible interval; RSME, root mean square error.a.", [["CI", "TEST", 15, 17], ["credible interval", "TEST", 19, 36], ["RSME", "TEST", 38, 42], ["root", "ANATOMY", 44, 48]]], ["Underestimating Bronze-standard (BrS) sensitivity for a domnant pathogen (pathogen A)a.", [["BrS", "DISEASE", 33, 36], ["a domnant pathogen", "PROBLEM", 54, 72]]], ["Standard deviation is defined as the square root of the variance across the 500 datasets. d.", [["deviation", "OBSERVATION", 9, 18], ["square", "OBSERVATION_MODIFIER", 37, 43], ["root", "OBSERVATION_MODIFIER", 44, 48]]], ["Root mean square error (RMSE) is a measure of error, incorporating both bias and variance.", [["both bias", "OBSERVATION", 67, 76]]], ["Coverage is defined as the observed fraction of the 95% credible intervals that cover the true etiology fractions out of the 500 replications. f.", [["f.", "SPECIES", 143, 145]]], ["Average length of the 95% credible intervals across the 500 datasets.", [["Average length", "TEST", 0, 14], ["length", "OBSERVATION_MODIFIER", 8, 14]]], ["Figure 4 : Impact of imprecise sensitivity priors on etiologic estimation from PERCH Integrated Analysis: Bubble plot results from PIA analysis of a randomly selected dataset from (Supplemental Table 3d ) above, evaluating a wider SS sensitivity prior range for all pathogens with SS data (pathogens B1, B3, B4, C1, C3, D1, D3) Supplemental Figure 5 : Impact of poor specificity on etiologic estimation using PERCH Integrated Analysis (PIA) method: a sensitivity analysis.SupplementalPIA was performed on data (A) that had lower specificity (approximately 75%) for Bronzestandard measurements (e.g., NP/OP PCR).", [["C1", "PROTEIN", 312, 314], ["C3", "PROTEIN", 316, 318], ["etiologic estimation", "TEST", 53, 73], ["Bubble plot", "TEST", 106, 117], ["PIA analysis", "TEST", 131, 143], ["SS data", "TEST", 281, 288], ["pathogens", "TEST", 290, 299], ["B1", "TEST", 300, 302], ["B3", "TEST", 304, 306], ["B4", "TEST", 308, 310], ["C1", "TEST", 312, 314], ["etiologic estimation", "TEST", 382, 402], ["a sensitivity analysis", "TEST", 449, 471], ["Bronzestandard measurements", "TEST", 565, 592], ["NP/OP PCR", "TEST", 600, 609]]], ["Results are shown in grey boxplots (B) and are compared to data with higher specificity (white boxplots) where specificity was >90% for all pathogens except B4, which by design had non-informative Bronze-standard data (also shown in Figure 4a ).", [["white boxplots", "TEST", 89, 103], ["specificity", "TEST", 111, 122], ["all pathogens", "PROBLEM", 136, 149], ["B4", "PROBLEM", 157, 159]]], ["The boxplots show the distribution of results from PIA performed on 500 simulated datasets from each scenario.", [["PIA", "PROBLEM", 51, 54]]], ["Each of the 500 datasets contained results from 600 cases and 600 controls and were created by random sampling from 'populations' with the case and control pathogen prevalences produced based on the true etiology proportions and sensitivity and specificity values of each scenario.", [["sensitivity", "TEST", 229, 240]]], ["The performance of PIA on the 500 simulated datasets with low specificity is shown in (C), and results from one randomly selected dataset are shown as a bubble plot in (D).SupplementalA.", [["SupplementalA", "CHEMICAL", 172, 185], ["PIA", "PROBLEM", 19, 22], ["a bubble plot", "TEST", 151, 164], ["SupplementalA", "TREATMENT", 172, 185]]], ["Characteristics of the data for the scenario where specificity of BrS measurements was lowered to 75%, thus changing ORs to 1.", [["BrS", "DISEASE", 66, 69], ["BrS measurements", "TEST", 66, 82]]], ["Abbreviations: CI, credible interval; RSME, root mean square error. a.", [["a.", "SPECIES", 68, 70], ["RSME", "TEST", 38, 42]]], ["Standard deviation is defined as the square root of the variance across the 500 datasets. d.", [["deviation", "OBSERVATION", 9, 18], ["square", "OBSERVATION_MODIFIER", 37, 43], ["root", "OBSERVATION_MODIFIER", 44, 48]]], ["Root mean square error (RMSE) is a measure of error, incorporating both bias and variance.", [["both bias", "OBSERVATION", 67, 76]]], ["Coverage is defined as the observed fraction of the 95% credible intervals that cover the true etiology fractions out of the 500 replications. f.", [["f.", "SPECIES", 143, 145]]], ["Average length of the 95% credible intervals across the 500 datasets.", [["Average length", "TEST", 0, 14], ["length", "OBSERVATION_MODIFIER", 8, 14]]]], "443edc109644559a460ed76f2252d8c105d90201": [["IntroductionThe mammalian immune system has evolved arsenal and strategies to make a distinction between microbes that are either beneficial or benign or bad, an integral part of which is differential treatment of \"self\" and \"non-self.\"", [["The mammalian immune system", "TREATMENT", 12, 39]]], ["Whereas recognition of \"self\" as \"non-self\" can cause autoimmunity, the converse results in microbial colonization.", [["autoimmunity", "DISEASE", 54, 66], ["autoimmunity", "PROBLEM", 54, 66], ["microbial colonization", "PROBLEM", 92, 114]]], ["In fact the human gut does harbor multiple variety of microbes as natural part of the biological ecosystem (Scarpellini et al. 2015 ).", [["gut", "ANATOMY", 18, 21], ["human", "ORGANISM", 12, 17], ["gut", "ORGANISM_SUBDIVISION", 18, 21], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["microbes", "OBSERVATION", 54, 62]]], ["The recognized non-self are counteracted by adaptive and innate effectors of the immune system, using dedicated cells and biochemicals, which attempt to restrict the growth and impede colonization by the pathogen.", [["immune system", "ANATOMY", 81, 94], ["cells", "ANATOMY", 112, 117], ["immune system", "ANATOMICAL_SYSTEM", 81, 94], ["cells", "CELL", 112, 117], ["biochemicals", "TREATMENT", 122, 134], ["the growth", "PROBLEM", 162, 172], ["impede colonization", "PROBLEM", 177, 196], ["the pathogen", "PROBLEM", 200, 212]]], ["The innate response is nonspecific, while the secondary adaptive response is specific for the pathogen or closely related species.", [["the pathogen", "PROBLEM", 90, 102], ["closely related species", "PROBLEM", 106, 129], ["nonspecific", "OBSERVATION_MODIFIER", 23, 34]]], ["The cellular component includes innate immune cells like the monocytes/macrophages, neutrophils, and natural killer (NK) cells and adaptive immune cells like B-and T-lymphocytes, which coordinate for an effective response.", [["cellular", "ANATOMY", 4, 12], ["immune cells", "ANATOMY", 39, 51], ["monocytes", "ANATOMY", 61, 70], ["macrophages", "ANATOMY", 71, 82], ["neutrophils", "ANATOMY", 84, 95], ["natural killer (NK) cells", "ANATOMY", 101, 126], ["immune cells", "ANATOMY", 140, 152], ["B-", "ANATOMY", 158, 160], ["T-lymphocytes", "ANATOMY", 164, 177], ["cellular", "CELL", 4, 12], ["innate immune cells", "CELL", 32, 51], ["monocytes", "CELL", 61, 70], ["macrophages", "CELL", 71, 82], ["neutrophils", "CELL", 84, 95], ["natural killer (NK) cells", "CELL", 101, 126], ["adaptive immune cells", "CELL", 131, 152], ["B-and T-lymphocytes", "CELL", 158, 177], ["innate immune cells", "CELL_TYPE", 32, 51], ["monocytes", "CELL_TYPE", 61, 70], ["macrophages", "CELL_TYPE", 71, 82], ["neutrophils", "CELL_TYPE", 84, 95], ["natural killer (NK) cells", "CELL_TYPE", 101, 126], ["adaptive immune cells", "CELL_TYPE", 131, 152], ["B-and T-lymphocytes", "CELL_TYPE", 158, 177], ["The cellular component", "TEST", 0, 22], ["innate immune cells", "PROBLEM", 32, 51], ["the monocytes", "TEST", 57, 70], ["macrophages", "TEST", 71, 82], ["neutrophils", "TEST", 84, 95], ["adaptive immune cells", "TEST", 131, 152], ["B", "TEST", 158, 159], ["cellular", "OBSERVATION_MODIFIER", 4, 12], ["component", "OBSERVATION_MODIFIER", 13, 22], ["innate immune cells", "OBSERVATION", 32, 51], ["monocytes", "ANATOMY", 61, 70], ["macrophages", "ANATOMY", 71, 82], ["natural killer", "OBSERVATION", 101, 115], ["immune cells", "OBSERVATION", 140, 152], ["lymphocytes", "ANATOMY", 166, 177]]], ["Cytokines are a dedicated group of biochemicals involved in this coordination and include interferons (IFNs), interleukins (ILs), and chemokines that are responsible for synchronizing the initiation, regulation, and termination of an immune response.", [["interferons", "GENE_OR_GENE_PRODUCT", 90, 101], ["IFNs", "GENE_OR_GENE_PRODUCT", 103, 107], ["interleukins", "GENE_OR_GENE_PRODUCT", 110, 122], ["ILs", "GENE_OR_GENE_PRODUCT", 124, 127], ["Cytokines", "PROTEIN", 0, 9], ["interferons", "PROTEIN", 90, 101], ["IFNs", "PROTEIN", 103, 107], ["interleukins", "PROTEIN", 110, 122], ["ILs", "PROTEIN", 124, 127], ["chemokines", "PROTEIN", 134, 144], ["interferons (IFNs)", "TREATMENT", 90, 108], ["interleukins (ILs", "TREATMENT", 110, 127], ["chemokines", "TREATMENT", 134, 144]]], ["A group (~100) of small polypeptides (<20 kDa) produced predominantly although not exclusively by immune cells like macrophages and lymphocytes, cytokines are secreted out exerting their function by engaging respective cell-surface receptors and depending on biological function are labeled as either pro-inflammatory (PIC) or antiinflammatory (AIC) cytokines (Turner et al. 2014 ).", [["immune cells", "ANATOMY", 98, 110], ["macrophages", "ANATOMY", 116, 127], ["lymphocytes", "ANATOMY", 132, 143], ["cell", "ANATOMY", 219, 223], ["surface", "ANATOMY", 224, 231], ["immune cells", "CELL", 98, 110], ["macrophages", "CELL", 116, 127], ["lymphocytes", "CELL", 132, 143], ["cell", "CELL", 219, 223], ["PIC", "GENE_OR_GENE_PRODUCT", 319, 322], ["immune cells", "CELL_TYPE", 98, 110], ["macrophages", "CELL_TYPE", 116, 127], ["lymphocytes", "CELL_TYPE", 132, 143], ["cytokines", "PROTEIN", 145, 154], ["cell-surface receptors", "PROTEIN", 219, 241], ["PIC", "PROTEIN", 319, 322], ["antiinflammatory (AIC) cytokines", "PROTEIN", 327, 359], ["small polypeptides", "PROBLEM", 18, 36], ["macrophages", "PROBLEM", 116, 127], ["lymphocytes", "PROBLEM", 132, 143], ["cytokines", "PROBLEM", 145, 154], ["pro-inflammatory (PIC)", "TREATMENT", 301, 323], ["antiinflammatory (AIC) cytokines", "TREATMENT", 327, 359], ["macrophages", "OBSERVATION", 116, 127], ["lymphocytes", "ANATOMY", 132, 143]]], ["On the one hand, several cytokines are functionally redundant, and on the other hand, some cells can express receptors for multiple cytokines.The Positive-Sense Single-Stranded RNA VirusesViruses with positive-sense single-stranded RNA as genome can either be enveloped (Togaviridae, Flaviviridae, and Coronaviridae) or non-enveloped (Astroviridae, Caliciviridae, and Picornaviridae), and several from either group cause severe human pathology (Fields et al. 2013) .", [["cells", "ANATOMY", 91, 96], ["cells", "CELL", 91, 96], ["human", "ORGANISM", 428, 433], ["cytokines", "PROTEIN", 25, 34], ["cytokines", "PROTEIN", 132, 141], ["Positive-Sense Single-Stranded RNA VirusesViruses", "DNA", 146, 195], ["human", "SPECIES", 428, 433], ["human", "SPECIES", 428, 433], ["multiple cytokines", "PROBLEM", 123, 141], ["Stranded RNA VirusesViruses", "TEST", 168, 195], ["Togaviridae", "TREATMENT", 271, 282], ["Flaviviridae", "TREATMENT", 284, 296], ["Coronaviridae", "TREATMENT", 302, 315], ["Astroviridae", "TREATMENT", 335, 347], ["Caliciviridae", "TREATMENT", 349, 362], ["Picornaviridae", "TREATMENT", 368, 382], ["severe human pathology", "PROBLEM", 421, 443], ["cytokines", "OBSERVATION", 25, 34], ["redundant", "OBSERVATION", 52, 61]]], ["Entry into human host can be by diverse means including mucosal contact (gut in enteroviruses) or vectorial inoculation (e.g., in dengue and JEV) or parenteral blood transfer (e.g., hepatitis C virus).", [["mucosal", "ANATOMY", 56, 63], ["gut", "ANATOMY", 73, 76], ["blood", "ANATOMY", 160, 165], ["dengue", "DISEASE", 130, 136], ["JEV", "DISEASE", 141, 144], ["hepatitis C virus", "DISEASE", 182, 199], ["human", "ORGANISM", 11, 16], ["mucosal", "ORGANISM_SUBDIVISION", 56, 63], ["gut", "ORGANISM_SUBDIVISION", 73, 76], ["JEV", "ORGANISM", 141, 144], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["hepatitis C virus", "ORGANISM", 182, 199], ["human", "SPECIES", 11, 16], ["hepatitis C virus", "SPECIES", 182, 199], ["human", "SPECIES", 11, 16], ["dengue", "SPECIES", 130, 136], ["JEV", "SPECIES", 141, 144], ["hepatitis C virus", "SPECIES", 182, 199], ["mucosal contact (gut in enteroviruses", "PROBLEM", 56, 93], ["vectorial inoculation (e.g., in dengue and JEV", "PROBLEM", 98, 144], ["parenteral blood transfer", "TREATMENT", 149, 174], ["hepatitis C virus", "PROBLEM", 182, 199]]], ["Immobilization by interaction with extracellular matrix components like glycosaminoglycan is followed by tropism determinant cognate receptor-mediated entry (Chen et al. 1997; Olenina et al. 2005; Tan et al. 2013) .", [["extracellular matrix", "ANATOMY", 35, 55], ["glycosaminoglycan", "CHEMICAL", 72, 89], ["extracellular matrix", "CELLULAR_COMPONENT", 35, 55], ["glycosaminoglycan", "SIMPLE_CHEMICAL", 72, 89], ["cognate receptor", "PROTEIN", 125, 141], ["Immobilization", "TREATMENT", 0, 14], ["extracellular matrix components", "TREATMENT", 35, 66], ["glycosaminoglycan", "OBSERVATION", 72, 89]]], ["In enveloped viruses, the envelope fuses with the endosomal membrane, while non-enveloped viruses breach the membrane of either the cell or the endosome using specific cofactors, ultimately releasing viral genome into the host cytosol (Kumar et al. 2018; Plemper 2011) .", [["endosomal membrane", "ANATOMY", 50, 68], ["membrane", "ANATOMY", 109, 117], ["cell", "ANATOMY", 132, 136], ["endosome", "ANATOMY", 144, 152], ["cytosol", "ANATOMY", 227, 234], ["endosomal membrane", "CELLULAR_COMPONENT", 50, 68], ["membrane", "CELLULAR_COMPONENT", 109, 117], ["cell", "CELL", 132, 136], ["endosome", "CELLULAR_COMPONENT", 144, 152], ["cytosol", "CELLULAR_COMPONENT", 227, 234], ["viral genome", "DNA", 200, 212], ["the endosomal membrane", "TREATMENT", 46, 68], ["enveloped", "OBSERVATION_MODIFIER", 3, 12], ["viruses", "OBSERVATION", 13, 20], ["endosomal membrane", "OBSERVATION", 50, 68]]], ["A culmination of the following steps results in direct translation of the genomic RNA to produce a polyprotein, which is cleaved by virus-derived and host-origin proteases to yield the multiple structural and nonstructural proteins (Fields et al. 2013Infection, Intimation, and Initiation of InflammationAlthough viruses can replicate in multiple types of cells, the pathological outcome manifests in only one or a few specific cell/tissue types.", [["cells", "ANATOMY", 356, 361], ["cell", "ANATOMY", 428, 432], ["tissue", "ANATOMY", 433, 439], ["Inflammation", "DISEASE", 292, 304], ["cells", "CELL", 356, 361], ["cell", "CELL", 428, 432], ["tissue", "TISSUE", 433, 439], ["genomic RNA", "RNA", 74, 85], ["virus-derived and host-origin proteases", "PROTEIN", 132, 171], ["nonstructural proteins", "PROTEIN", 209, 231], ["the genomic RNA", "PROBLEM", 70, 85], ["a polyprotein", "PROBLEM", 97, 110], ["the multiple structural and nonstructural proteins", "PROBLEM", 181, 231], ["Intimation", "TREATMENT", 262, 272], ["Inflammation", "PROBLEM", 292, 304], ["viruses", "PROBLEM", 313, 320], ["genomic RNA", "OBSERVATION", 74, 85], ["multiple", "OBSERVATION_MODIFIER", 185, 193], ["nonstructural proteins", "OBSERVATION", 209, 231], ["Inflammation", "OBSERVATION", 292, 304], ["viruses", "OBSERVATION", 313, 320], ["tissue types", "OBSERVATION_MODIFIER", 433, 445]]], ["Independent of organismal entry site, the likeliest primary encounter of a virus is with mononuclear-phagocytic cells like monocytes, macrophages (M\u03d5), and dendritic cells (DCs).", [["mononuclear-phagocytic cells", "ANATOMY", 89, 117], ["monocytes", "ANATOMY", 123, 132], ["macrophages", "ANATOMY", 134, 145], ["M\u03d5", "ANATOMY", 147, 149], ["dendritic cells", "ANATOMY", 156, 171], ["DCs", "ANATOMY", 173, 176], ["mononuclear-phagocytic cells", "CELL", 89, 117], ["monocytes", "CELL", 123, 132], ["macrophages", "CELL", 134, 145], ["M\u03d5", "CELL", 147, 149], ["dendritic cells", "CELL", 156, 171], ["DCs", "CELL", 173, 176], ["mononuclear-phagocytic cells", "CELL_TYPE", 89, 117], ["monocytes", "CELL_TYPE", 123, 132], ["macrophages", "CELL_TYPE", 134, 145], ["M\u03d5", "CELL_TYPE", 147, 149], ["dendritic cells", "CELL_TYPE", 156, 171], ["DCs", "CELL_TYPE", 173, 176], ["a virus", "PROBLEM", 73, 80], ["monocytes", "TEST", 123, 132], ["macrophages", "PROBLEM", 134, 145], ["dendritic cells", "PROBLEM", 156, 171], ["virus", "OBSERVATION", 75, 80], ["phagocytic cells", "OBSERVATION", 101, 117], ["dendritic cells", "OBSERVATION", 156, 171]]], ["M\u03d5 and DCs are tissue-localized cells constituting the first line of cellular defense, which when infected can undertake antiviral steps in addition to \"informing\" the other effectors of the innate and adaptive immune system (Pohl et al. 2007; Ginhoux and Jung 2014) .", [["M\u03d5", "ANATOMY", 0, 2], ["DCs", "ANATOMY", 7, 10], ["tissue", "ANATOMY", 15, 21], ["cells", "ANATOMY", 32, 37], ["cellular", "ANATOMY", 69, 77], ["M\u03d5", "GENE_OR_GENE_PRODUCT", 0, 2], ["DCs", "CELL", 7, 10], ["tissue", "TISSUE", 15, 21], ["cells", "CELL", 32, 37], ["cellular", "CELL", 69, 77], ["M\u03d5", "CELL_TYPE", 0, 2], ["DCs", "CELL_TYPE", 7, 10], ["tissue-localized cells", "CELL_TYPE", 15, 37], ["localized cells", "PROBLEM", 22, 37], ["cellular defense", "PROBLEM", 69, 85], ["antiviral steps", "TREATMENT", 121, 136], ["localized cells", "OBSERVATION", 22, 37], ["first line", "OBSERVATION_MODIFIER", 55, 65], ["cellular defense", "OBSERVATION", 69, 85]]], ["Activated DCs shift to lymph nodes, process viral antigen, and \"present\" or display it for clonal expansion of cognate lymphocytes population.", [["DCs", "ANATOMY", 10, 13], ["lymph nodes", "ANATOMY", 23, 34], ["lymphocytes", "ANATOMY", 119, 130], ["DCs", "CELL", 10, 13], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 23, 34], ["clonal", "CELL", 91, 97], ["lymphocytes", "CELL", 119, 130], ["DCs", "CELL_TYPE", 10, 13], ["viral antigen", "PROTEIN", 44, 57], ["cognate lymphocytes population", "CELL_TYPE", 111, 141], ["lymph nodes", "TEST", 23, 34], ["process viral antigen", "TEST", 36, 57], ["clonal expansion of cognate lymphocytes population", "PROBLEM", 91, 141], ["lymph nodes", "OBSERVATION", 23, 34], ["cognate lymphocytes population", "OBSERVATION", 111, 141]]], ["M\u03d5, which can be either tissue-resident or differentiated from afferent monocytes postinfection, play a more regulatory role and are important determinants of the outcome of the inflammatory response (Ginhoux and Jung 2014; Mercer and Greber 2013; Hou et al. 2012; Schulz et al. 2012) .", [["tissue", "ANATOMY", 24, 30], ["afferent monocytes", "ANATOMY", 63, 81], ["M\u03d5", "GENE_OR_GENE_PRODUCT", 0, 2], ["tissue", "TISSUE", 24, 30], ["afferent monocytes", "CELL", 63, 81], ["M\u03d5", "PROTEIN", 0, 2], ["afferent monocytes", "CELL_TYPE", 63, 81], ["afferent monocytes postinfection", "PROBLEM", 63, 95], ["afferent monocytes postinfection", "OBSERVATION", 63, 95]]], ["Tissue-resident M\u03d5 , which are a distinct population from monocyte-derived ones, include microglial cells in CNS, liver Kupffer cells, skin Langerhans cells, etc. (Davies et al. 2013) Monocytes/M\u03d5 (and many other cell types) express molecular detector proteins called pattern recognition receptors (PRRs), specialized for interacting with signature motifs on microbe-derived molecules, termed as pathogen-associated molecular pattern (PAMP).", [["Tissue", "ANATOMY", 0, 6], ["M\u03d5", "ANATOMY", 16, 18], ["monocyte", "ANATOMY", 58, 66], ["microglial cells", "ANATOMY", 89, 105], ["CNS", "ANATOMY", 109, 112], ["liver Kupffer cells", "ANATOMY", 114, 133], ["skin Langerhans cells", "ANATOMY", 135, 156], ["Monocytes", "ANATOMY", 184, 193], ["cell", "ANATOMY", 213, 217], ["Tissue", "TISSUE", 0, 6], ["M\u03d5", "GENE_OR_GENE_PRODUCT", 16, 18], ["monocyte", "CELL", 58, 66], ["microglial cells", "CELL", 89, 105], ["CNS", "CELL", 109, 112], ["liver Kupffer cells", "CELL", 114, 133], ["skin Langerhans cells", "CELL", 135, 156], ["Monocytes", "CELL", 184, 193], ["M\u03d5", "GENE_OR_GENE_PRODUCT", 194, 196], ["cell", "CELL", 213, 217], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 268, 297], ["PRRs", "GENE_OR_GENE_PRODUCT", 299, 303], ["pathogen-associated molecular pattern", "GENE_OR_GENE_PRODUCT", 396, 433], ["PAMP", "GENE_OR_GENE_PRODUCT", 435, 439], ["Tissue-resident M\u03d5", "CELL_TYPE", 0, 18], ["monocyte", "CELL_TYPE", 58, 66], ["microglial cells", "CELL_TYPE", 89, 105], ["liver Kupffer cells", "CELL_TYPE", 114, 133], ["skin Langerhans cells", "CELL_TYPE", 135, 156], ["Monocytes", "CELL_TYPE", 184, 193], ["M\u03d5", "CELL_TYPE", 194, 196], ["molecular detector proteins", "PROTEIN", 233, 260], ["pattern recognition receptors", "PROTEIN", 268, 297], ["PRRs", "PROTEIN", 299, 303], ["microbe-derived molecules", "PROTEIN", 359, 384], ["pathogen-associated molecular pattern", "PROTEIN", 396, 433], ["PAMP", "PROTEIN", 435, 439], ["microglial cells in CNS", "PROBLEM", 89, 112], ["Monocytes", "TEST", 184, 193], ["microglial cells", "OBSERVATION", 89, 105], ["CNS", "ANATOMY", 109, 112], ["liver", "ANATOMY", 114, 119], ["Kupffer cells", "OBSERVATION", 120, 133], ["skin", "ANATOMY", 135, 139], ["Langerhans cells", "OBSERVATION", 140, 156]]], ["Viral PAMPs include double-stranded (dsRNA) RNA (replication-intermediate formed during replication) and 5\u2032-ppp (uncapped genomic RNA polymerized by de novo replication).", [["5\u2032-ppp", "GENE_OR_GENE_PRODUCT", 105, 111], ["Viral PAMPs", "PROTEIN", 0, 11], ["double-stranded (dsRNA) RNA", "RNA", 20, 47], ["5\u2032", "DNA", 105, 107], ["ppp", "DNA", 108, 111], ["uncapped genomic RNA", "RNA", 113, 133], ["Viral PAMPs", "PROBLEM", 0, 11], ["double-stranded (dsRNA) RNA", "TREATMENT", 20, 47], ["ppp (uncapped genomic RNA polymerized", "TREATMENT", 108, 145]]], ["Cellular PRRs specific for these include toll-like receptors (TLRs) like TLR3 (dsRNA) and RIG-I-like receptors (RLRs) like RIG-I, MDA5 (dsRNA, 5\u2032-ppp end on RNA) (Jensen and Thomsen 2012) .", [["Cellular", "ANATOMY", 0, 8], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 41, 60], ["TLRs", "GENE_OR_GENE_PRODUCT", 62, 66], ["TLR3", "GENE_OR_GENE_PRODUCT", 73, 77], ["RIG-I-like receptors", "GENE_OR_GENE_PRODUCT", 90, 110], ["RLRs", "GENE_OR_GENE_PRODUCT", 112, 116], ["RIG-I", "GENE_OR_GENE_PRODUCT", 123, 128], ["MDA5", "GENE_OR_GENE_PRODUCT", 130, 134], ["5\u2032-ppp", "GENE_OR_GENE_PRODUCT", 143, 149], ["PRRs", "PROTEIN", 9, 13], ["toll-like receptors", "PROTEIN", 41, 60], ["TLRs", "PROTEIN", 62, 66], ["TLR3", "PROTEIN", 73, 77], ["dsRNA", "PROTEIN", 79, 84], ["RIG-I-like receptors", "PROTEIN", 90, 110], ["RLRs", "PROTEIN", 112, 116], ["RIG-I", "PROTEIN", 123, 128], ["MDA5", "PROTEIN", 130, 134], ["dsRNA", "DNA", 136, 141], ["5\u2032", "PROTEIN", 143, 145], ["TLR3 (dsRNA", "TREATMENT", 73, 84], ["MDA5 (dsRNA", "TREATMENT", 130, 141], ["MDA5", "ANATOMY", 130, 134]]], ["Nod-like receptors or NLRs form another class of cytosolic PRRs that can detect virus infection, albeit in an indirect manner (Takeuchi and Akira 2010; Ichinohe et al. 2013) .", [["cytosolic", "ANATOMY", 49, 58], ["infection", "DISEASE", 86, 95], ["Nod-like receptors", "GENE_OR_GENE_PRODUCT", 0, 18], ["NLRs", "GENE_OR_GENE_PRODUCT", 22, 26], ["Nod-like receptors", "PROTEIN", 0, 18], ["NLRs", "PROTEIN", 22, 26], ["cytosolic PRRs", "PROTEIN", 49, 63], ["cytosolic PRRs", "PROBLEM", 49, 63], ["virus infection", "PROBLEM", 80, 95]]], ["Physical engagement with PAMPs activates the respective PRRs, stimulating alterations in conformation of these sensors that allow them to interact with adapter molecules mediating the assembly of multi-protein complexes called inflammosome, in parallel to activating the expression of cytokine genes coding for type-1 interferons (IFNs) and NF\u03baB target genes (Kawai et al. 2005; Pichlmair and Reis e Sousa 2007; Chen and Ichinohe 2015; Seth et al. 2005) .", [["inflammosome", "ANATOMY", 227, 239], ["PAMPs", "GENE_OR_GENE_PRODUCT", 25, 30], ["PRRs", "GENE_OR_GENE_PRODUCT", 56, 60], ["inflammosome", "GENE_OR_GENE_PRODUCT", 227, 239], ["type-1 interferons", "GENE_OR_GENE_PRODUCT", 311, 329], ["IFNs", "GENE_OR_GENE_PRODUCT", 331, 335], ["NF\u03ba", "GENE_OR_GENE_PRODUCT", 341, 344], ["B", "GENE_OR_GENE_PRODUCT", 344, 345], ["PAMPs", "PROTEIN", 25, 30], ["PRRs", "PROTEIN", 56, 60], ["adapter molecules", "PROTEIN", 152, 169], ["multi-protein complexes", "PROTEIN", 196, 219], ["cytokine genes", "DNA", 285, 299], ["type-1 interferons", "PROTEIN", 311, 329], ["IFNs", "PROTEIN", 331, 335], ["NF\u03ba", "PROTEIN", 341, 344], ["B target genes", "DNA", 344, 358], ["PAMPs", "TREATMENT", 25, 30], ["stimulating alterations", "PROBLEM", 62, 85], ["cytokine genes", "TREATMENT", 285, 299], ["type-1 interferons (IFNs)", "TREATMENT", 311, 336]]], ["Secreted type-I IFNs attach specific receptors, in a paracrine or autocrine manner, thereby activating the expression of many interferon-sensitive genes (ISGs) with diverse functions that confer antiviral property to their activity (Schneider et al. 2014; Schoggins and Rice 2011) .", [["type-I IFNs", "GENE_OR_GENE_PRODUCT", 9, 20], ["Secreted type-I IFNs", "PROTEIN", 0, 20], ["interferon-sensitive genes", "DNA", 126, 152], ["ISGs", "DNA", 154, 158], ["many interferon", "TREATMENT", 121, 136], ["diverse functions", "TREATMENT", 165, 182], ["antiviral property", "TREATMENT", 195, 213]]], ["ISGs include PRR-coding genes producing a feed-forward loop and aggravating inflammation.", [["inflammation", "DISEASE", 76, 88], ["ISGs", "DNA", 0, 4], ["PRR-coding genes", "DNA", 13, 29], ["PRR", "TREATMENT", 13, 16], ["forward loop", "PROBLEM", 47, 59], ["aggravating inflammation", "PROBLEM", 64, 88], ["inflammation", "OBSERVATION", 76, 88]]], ["In parallel, NF\u03baB enhances expression of pro-inflammatory genes like TNF-\u03b1, IL-1\u03b2, COX2, IL6, IL-12p40, or IL-12 besides components of NLRP3 (Tak and Firestein 2001; Bauernfeind et al. 2009 ).", [["NF\u03baB", "GENE_OR_GENE_PRODUCT", 13, 17], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 69, 74], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 76, 81], ["COX2", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL6", "GENE_OR_GENE_PRODUCT", 89, 92], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 94, 102], ["IL-12", "GENE_OR_GENE_PRODUCT", 107, 112], ["NLRP3", "GENE_OR_GENE_PRODUCT", 135, 140], ["NF\u03baB", "PROTEIN", 13, 17], ["pro-inflammatory genes", "DNA", 41, 63], ["TNF", "PROTEIN", 69, 72], ["COX2", "DNA", 83, 87], ["IL6", "DNA", 89, 92], ["IL-12", "DNA", 107, 112], ["NLRP3", "PROTEIN", 135, 140], ["pro-inflammatory genes", "TEST", 41, 63], ["TNF", "TEST", 69, 72], ["IL", "TEST", 76, 78], ["COX2", "TEST", 83, 87], ["IL6", "TEST", 89, 92], ["IL", "TEST", 94, 96], ["IL", "TEST", 107, 109], ["NLRP3", "PROBLEM", 135, 140], ["pro-inflammatory genes", "OBSERVATION", 41, 63]]], ["Upon assembly the NLRP3 inflammosome catalyzes caspase-1 activation, a protease which slices the precursor form of pleiotropic pro-inflammatory cytokines like IL-1\u03b2 and IL-18 generating their active secreted forms (Garlanda et al. 2013; Biet et al. 2002) .", [["NLRP3", "GENE_OR_GENE_PRODUCT", 18, 23], ["caspase-1", "GENE_OR_GENE_PRODUCT", 47, 56], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 159, 164], ["IL-18", "GENE_OR_GENE_PRODUCT", 169, 174], ["NLRP3 inflammosome", "PROTEIN", 18, 36], ["caspase-1", "PROTEIN", 47, 56], ["protease", "PROTEIN", 71, 79], ["pleiotropic pro-inflammatory cytokines", "PROTEIN", 115, 153], ["IL-1\u03b2", "PROTEIN", 159, 164], ["IL-18", "PROTEIN", 169, 174], ["the NLRP3 inflammosome catalyzes caspase", "TREATMENT", 14, 54], ["a protease", "TREATMENT", 69, 79], ["pleiotropic pro-inflammatory cytokines", "TREATMENT", 115, 153], ["IL", "TEST", 159, 161], ["IL", "TREATMENT", 169, 171]]], ["IL-1\u03b2 potentiates the antiviral response by multiple ways in addition to inducing expression of type-I IFNs and ISGs in DCs (Ben-Sasson et al. 2011; Aarreberg et al. 2018) .", [["DCs", "ANATOMY", 120, 123], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["type-I IFNs", "GENE_OR_GENE_PRODUCT", 96, 107], ["DCs", "CELL", 120, 123], ["IL-1\u03b2", "PROTEIN", 0, 5], ["type-I IFNs", "PROTEIN", 96, 107], ["ISGs", "DNA", 112, 116], ["DCs", "CELL_TYPE", 120, 123], ["antiviral response", "OBSERVATION", 22, 40]]], ["Chemokines (chemotactic cytokines) flag/point to the site of infection by a concentration gradient, attracting leukocytes like neutrophils, monocytes, and lymphocytes, subsequently activating them to release more cytokines thereby amplifying the inflammatory response (Sokol and Luster 2015; Ley 2014) .", [["leukocytes", "ANATOMY", 111, 121], ["neutrophils", "ANATOMY", 127, 138], ["monocytes", "ANATOMY", 140, 149], ["lymphocytes", "ANATOMY", 155, 166], ["infection", "DISEASE", 61, 70], ["leukocytes", "CELL", 111, 121], ["neutrophils", "CELL", 127, 138], ["monocytes", "CELL", 140, 149], ["lymphocytes", "CELL", 155, 166], ["Chemokines", "PROTEIN", 0, 10], ["chemotactic cytokines", "PROTEIN", 12, 33], ["leukocytes", "CELL_TYPE", 111, 121], ["neutrophils", "CELL_TYPE", 127, 138], ["monocytes", "CELL_TYPE", 140, 149], ["lymphocytes", "CELL_TYPE", 155, 166], ["cytokines", "PROTEIN", 213, 222], ["Chemokines (chemotactic cytokines) flag", "TREATMENT", 0, 39], ["infection", "PROBLEM", 61, 70], ["a concentration gradient", "TEST", 74, 98], ["neutrophils", "TEST", 127, 138], ["monocytes", "TEST", 140, 149], ["lymphocytes", "TEST", 155, 166], ["the inflammatory response", "PROBLEM", 242, 267], ["infection", "OBSERVATION", 61, 70], ["lymphocytes", "ANATOMY", 155, 166], ["inflammatory", "OBSERVATION_MODIFIER", 246, 258]]], ["Among these IL-12 and IL-2 (produced predominantly by DCs) have crucial immunomodulatory functions.", [["DCs", "ANATOMY", 54, 57], ["IL-12", "GENE_OR_GENE_PRODUCT", 12, 17], ["IL-2", "GENE_OR_GENE_PRODUCT", 22, 26], ["DCs", "CELL", 54, 57], ["IL-12", "PROTEIN", 12, 17], ["IL-2", "PROTEIN", 22, 26], ["DCs", "CELL_TYPE", 54, 57], ["these IL", "TEST", 6, 14], ["immunomodulatory functions", "OBSERVATION", 72, 98]]], ["IL-12 attracts CD4+ T-helper (Th) cells influencing their differentiation into IFN-\u03b3 secreting Th 1 cells in addition to augmenting the cytotoxic activity of CD8+ T cells and NK cells (Athie- Morales et al. 2004; Henry et al. 2008 ).", [["CD4+ T-helper (Th) cells", "ANATOMY", 15, 39], ["Th 1 cells", "ANATOMY", 95, 105], ["CD8+ T cells", "ANATOMY", 158, 170], ["NK cells", "ANATOMY", 175, 183], ["IL-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 15, 18], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 79, 84], ["Th 1 cells", "CELL", 95, 105], ["CD8", "GENE_OR_GENE_PRODUCT", 158, 161], ["NK cells", "CELL", 175, 183], ["IL-12", "PROTEIN", 0, 5], ["CD4+ T-helper (Th) cells", "CELL_TYPE", 15, 39], ["IFN-\u03b3 secreting Th 1 cells", "CELL_LINE", 79, 105], ["CD8+ T cells", "CELL_TYPE", 158, 170], ["NK cells", "CELL_TYPE", 175, 183], ["IL", "TEST", 0, 2], ["CD4", "TEST", 15, 18], ["IFN", "TEST", 79, 82], ["the cytotoxic activity", "TEST", 132, 154], ["CD8", "TEST", 158, 161], ["T cells", "PROBLEM", 163, 170], ["NK cells", "TEST", 175, 183], ["Athie", "TEST", 185, 190], ["cytotoxic activity", "OBSERVATION", 136, 154], ["NK cells", "OBSERVATION", 175, 183]]], ["IL-2 on the other hand increases NK-cell sensitivity to IL-12 by receptor upregulation (Wang et al. 2000) .", [["hand", "ANATOMY", 18, 22], ["NK-cell", "ANATOMY", 33, 40], ["IL-2", "GENE_OR_GENE_PRODUCT", 0, 4], ["NK-cell", "CELL", 33, 40], ["IL-12", "GENE_OR_GENE_PRODUCT", 56, 61], ["IL-2", "PROTEIN", 0, 4], ["IL-12", "PROTEIN", 56, 61], ["IL", "TREATMENT", 0, 2]]], ["IFN-\u03b3 which in contrast to type-I IFNs is produced exclusively by immune cells (T and NK cells) has pleiotropic antiviral effect including the capacity to polarize existing or newly recruited M\u03d5 to M1 phenotype (Hu and Ivashkiv 2009; Verreck et al. 2004 ).", [["immune cells", "ANATOMY", 66, 78], ["T", "ANATOMY", 80, 81], ["NK cells", "ANATOMY", 86, 94], ["M\u03d5", "ANATOMY", 192, 194], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["type-I IFNs", "GENE_OR_GENE_PRODUCT", 27, 38], ["immune cells", "CELL", 66, 78], ["T", "CELL", 80, 81], ["NK cells", "CELL", 86, 94], ["M\u03d5", "GENE_OR_GENE_PRODUCT", 192, 194], ["IFN", "PROTEIN", 0, 3], ["\u03b3", "PROTEIN", 4, 5], ["type-I IFNs", "PROTEIN", 27, 38], ["immune cells", "CELL_TYPE", 66, 78], ["T and NK cells", "CELL_TYPE", 80, 94], ["IFN", "TEST", 0, 3], ["pleiotropic antiviral effect", "PROBLEM", 100, 128], ["the capacity", "PROBLEM", 139, 151], ["antiviral effect", "OBSERVATION", 112, 128]]], ["M\u03d5 either resident or monocyte-derived can acquire either an M1 or an M2 phenotype differing in ontology, phenotype, and secretome, with unidirectional plasticity from M1 to M2 (Halstead et al. 2010; Guiducci et al. 2005; Smith et al. 2016 ).", [["monocyte", "ANATOMY", 22, 30], ["M\u03d5", "GENE_OR_GENE_PRODUCT", 0, 2], ["monocyte", "CELL", 22, 30], ["M\u03d5", "PROTEIN", 0, 2], ["an M2 phenotype", "PROBLEM", 67, 82]]], ["M1-M\u03d5 promotes a Th 1 immune response which is necessary for resolution of infection, while the M2-M\u03d5 endorses tissue repair following inflammation, suggesting that a premature skew in abundance of M2-M\u03d5 at the expense of M1-M\u03d5 would limit viral clearance leading to chronic infection and prolonged inflammatory response (Klenerman and Hill 2005 ).", [["tissue", "ANATOMY", 111, 117], ["infection", "DISEASE", 75, 84], ["inflammation", "DISEASE", 135, 147], ["infection", "DISEASE", 275, 284], ["M1-M\u03d5", "GENE_OR_GENE_PRODUCT", 0, 5], ["Th 1", "GENE_OR_GENE_PRODUCT", 17, 21], ["M2-M\u03d5", "GENE_OR_GENE_PRODUCT", 96, 101], ["tissue", "TISSUE", 111, 117], ["M2-M\u03d5", "GENE_OR_GENE_PRODUCT", 198, 203], ["M1-M\u03d5", "GENE_OR_GENE_PRODUCT", 222, 227], ["M1", "PROTEIN", 0, 2], ["M\u03d5", "PROTEIN", 3, 5], ["M2", "PROTEIN", 96, 98], ["M\u03d5", "PROTEIN", 99, 101], ["M2", "PROTEIN", 198, 200], ["M\u03d5", "PROTEIN", 201, 203], ["M1", "PROTEIN", 222, 224], ["infection", "PROBLEM", 75, 84], ["tissue repair", "TREATMENT", 111, 124], ["inflammation", "PROBLEM", 135, 147], ["a premature skew", "PROBLEM", 165, 181], ["viral clearance", "PROBLEM", 240, 255], ["chronic infection", "PROBLEM", 267, 284], ["prolonged inflammatory response", "PROBLEM", 289, 320], ["infection", "OBSERVATION", 75, 84], ["tissue", "ANATOMY", 111, 117], ["repair", "OBSERVATION", 118, 124], ["inflammation", "OBSERVATION", 135, 147], ["premature", "OBSERVATION_MODIFIER", 167, 176], ["M1", "ANATOMY", 222, 224], ["chronic", "OBSERVATION_MODIFIER", 267, 274], ["infection", "OBSERVATION", 275, 284], ["inflammatory", "OBSERVATION_MODIFIER", 299, 311]]], ["An emerging concept in modulation of inflammation involves the role of bacterial surface components like lipopolysaccharide on concurrent viral infection (Smith et al. 2016; Wilks and Golovkina 2012) .", [["surface", "ANATOMY", 81, 88], ["inflammation", "DISEASE", 37, 49], ["lipopolysaccharide", "CHEMICAL", 105, 123], ["viral infection", "DISEASE", 138, 153], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 105, 123], ["inflammation", "PROBLEM", 37, 49], ["bacterial surface components", "PROBLEM", 71, 99], ["lipopolysaccharide", "PROBLEM", 105, 123], ["concurrent viral infection", "PROBLEM", 127, 153], ["inflammation", "OBSERVATION", 37, 49], ["bacterial", "OBSERVATION_MODIFIER", 71, 80], ["surface", "OBSERVATION_MODIFIER", 81, 88], ["lipopolysaccharide", "OBSERVATION_MODIFIER", 105, 123], ["viral", "OBSERVATION_MODIFIER", 138, 143], ["infection", "OBSERVATION", 144, 153]]], ["Alterations in gut microbiome have been reported and potential influences this might have on disease outcome have been suggested (Preveden et al. 2017; Banks et al. 2015) .Infection, Intimation, and Initiation of InflammationThough it is difficult to ascertain the number of asymptomatic infections for any given virus, the percentage of symptomatic infection vis-\u00e0-vis asymptomatic ones is often a multivariate variable, being known for only a few.", [["gut microbiome", "ANATOMY", 15, 29], ["Inflammation", "DISEASE", 213, 225], ["infections", "DISEASE", 288, 298], ["infection", "DISEASE", 350, 359], ["gut microbiome", "MULTI-TISSUE_STRUCTURE", 15, 29], ["Alterations in gut microbiome", "PROBLEM", 0, 29], ["Infection", "PROBLEM", 172, 181], ["Intimation", "TREATMENT", 183, 193], ["Inflammation", "PROBLEM", 213, 225], ["asymptomatic infections", "PROBLEM", 275, 298], ["virus", "PROBLEM", 313, 318], ["symptomatic infection", "PROBLEM", 338, 359], ["Inflammation", "OBSERVATION", 213, 225], ["asymptomatic", "OBSERVATION_MODIFIER", 275, 287], ["infections", "OBSERVATION", 288, 298], ["symptomatic", "OBSERVATION_MODIFIER", 338, 349], ["infection", "OBSERVATION", 350, 359]]], ["For example, only 1 among 4 individuals infected with DENV shows febrile symptoms.", [["DENV", "DISEASE", 54, 58], ["febrile symptoms", "DISEASE", 65, 81], ["individuals", "ORGANISM", 28, 39], ["DENV", "ORGANISM", 54, 58], ["DENV", "SPECIES", 54, 58], ["DENV", "PROBLEM", 54, 58], ["febrile symptoms", "PROBLEM", 65, 81], ["DENV", "OBSERVATION", 54, 58], ["febrile", "OBSERVATION_MODIFIER", 65, 72]]], ["This suggests a success for the antiviral immune mechanisms in the majority of individuals.", [["the antiviral immune mechanisms", "TREATMENT", 28, 59], ["antiviral immune", "OBSERVATION", 32, 48]]], ["Animal studies using gene knockout models have given evidence of this efficacy for many viruses (Suthar et al. 2010; Samuel and Diamond 2005; Lazear et al. 2011; Deonarain et al. 2004; Burdeinick-Kerr et al. 2007 ).", [["Animal studies", "TEST", 0, 14], ["gene knockout models", "TREATMENT", 21, 41]]], ["In case of humans, these information are complicated by differential efficacy of these pathways, protecting or predisposing individuals under the influence of genotype, environment, etc. (Paalani et al. 2011; Mitchell and Aneshensel 2016; Liu and Taioli 2015) Besides, there are few studies that indicate potential influence of medication or noninfectious ailments or societal stress on the outcome of infection through an influence on the immune system (Mehrbod et al. 2014; Gilbert et al. 2005; Htun et al. 2015; Jean et al. 2007 ).Liver Damage Due to Hepatitis C Virus and Dengue Virus InfectionHCV and DENV infection can cause liver damage through a chronic and acute infection regime, respectively (Samanta and Sharma 2015; Axley et al. 2018) .", [["Liver", "ANATOMY", 534, 539], ["liver", "ANATOMY", 631, 636], ["infection", "DISEASE", 402, 411], ["Hepatitis C Virus", "DISEASE", 554, 571], ["Dengue Virus InfectionHCV", "DISEASE", 576, 601], ["DENV infection", "DISEASE", 606, 620], ["liver damage", "DISEASE", 631, 643], ["chronic and acute infection", "DISEASE", 654, 681], ["humans", "ORGANISM", 11, 17], ["Liver", "ORGAN", 534, 539], ["Hepatitis C Virus", "ORGANISM", 554, 571], ["Dengue Virus InfectionHCV", "ORGANISM", 576, 601], ["DENV", "ORGANISM", 606, 610], ["liver", "ORGAN", 631, 636], ["humans", "SPECIES", 11, 17], ["Hepatitis C Virus", "SPECIES", 554, 571], ["Dengue Virus", "SPECIES", 576, 588], ["humans", "SPECIES", 11, 17], ["Hepatitis C Virus", "SPECIES", 554, 571], ["Dengue Virus", "SPECIES", 576, 588], ["DENV", "SPECIES", 606, 610], ["these pathways", "TREATMENT", 81, 95], ["medication", "TREATMENT", 328, 338], ["noninfectious ailments", "PROBLEM", 342, 364], ["societal stress", "PROBLEM", 368, 383], ["infection", "PROBLEM", 402, 411], ["Liver Damage", "PROBLEM", 534, 546], ["Hepatitis C Virus", "PROBLEM", 554, 571], ["Dengue Virus InfectionHCV", "PROBLEM", 576, 601], ["DENV infection", "PROBLEM", 606, 620], ["liver damage", "PROBLEM", 631, 643], ["a chronic and acute infection regime", "PROBLEM", 652, 688], ["noninfectious", "OBSERVATION_MODIFIER", 342, 355], ["infection", "OBSERVATION", 402, 411], ["Damage", "OBSERVATION", 540, 546], ["Hepatitis", "OBSERVATION", 554, 563], ["Dengue Virus", "OBSERVATION", 576, 588], ["DENV", "OBSERVATION_MODIFIER", 606, 610], ["infection", "OBSERVATION", 611, 620], ["liver", "ANATOMY", 631, 636], ["damage", "OBSERVATION", 637, 643], ["chronic", "OBSERVATION_MODIFIER", 654, 661], ["acute", "OBSERVATION_MODIFIER", 666, 671], ["infection", "OBSERVATION", 672, 681]]], ["Liver as an organ is characterized by a high capacity to regenerate; however, chronic injury/scarring can lead to fibrosis, steatosis, or even hepatocellular carcinoma resulting in liver failure (Forbes and Newsome 2016).", [["Liver", "ANATOMY", 0, 5], ["organ", "ANATOMY", 12, 17], ["hepatocellular carcinoma", "ANATOMY", 143, 167], ["liver", "ANATOMY", 181, 186], ["scarring", "DISEASE", 93, 101], ["fibrosis", "DISEASE", 114, 122], ["steatosis", "DISEASE", 124, 133], ["hepatocellular carcinoma", "DISEASE", 143, 167], ["liver failure", "DISEASE", 181, 194], ["Liver", "ORGAN", 0, 5], ["organ", "ORGAN", 12, 17], ["hepatocellular carcinoma", "CANCER", 143, 167], ["liver", "ORGAN", 181, 186], ["a high capacity", "PROBLEM", 38, 53], ["chronic injury", "PROBLEM", 78, 92], ["scarring", "PROBLEM", 93, 101], ["fibrosis", "PROBLEM", 114, 122], ["steatosis", "PROBLEM", 124, 133], ["hepatocellular carcinoma", "PROBLEM", 143, 167], ["liver failure", "PROBLEM", 181, 194], ["organ", "ANATOMY", 12, 17], ["high capacity", "OBSERVATION_MODIFIER", 40, 53], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["injury", "OBSERVATION", 86, 92], ["scarring", "OBSERVATION", 93, 101], ["fibrosis", "OBSERVATION", 114, 122], ["steatosis", "OBSERVATION", 124, 133], ["hepatocellular", "ANATOMY", 143, 157], ["carcinoma", "OBSERVATION", 158, 167], ["liver", "ANATOMY", 181, 186], ["failure", "OBSERVATION", 187, 194]]], ["Hepatocytes constitute twothirds of all liver cells and are associated with all major liver functions besides playing a crucial role in innate immune signaling (Kmiec 2001; Zhou et al. 2016) .Liver Damage Due to Hepatitis C Virus and Dengue Virus InfectionHepatocytes are permissible to both HCV and DENV, the latter being reported to additionally infect Kupffer cells (Chang et al. 2003; Zehender et al. 1997; Boisvert et al. 2001; Caussin-Schwemling et al. 2001; Goutagny et al. 2003; Marianneau et al. 1999; de Macedo et al. 2006; Huerre et al. 2001) .", [["Hepatocytes", "ANATOMY", 0, 11], ["liver cells", "ANATOMY", 40, 51], ["liver", "ANATOMY", 86, 91], ["Liver", "ANATOMY", 192, 197], ["Hepatocytes", "ANATOMY", 256, 267], ["Kupffer cells", "ANATOMY", 355, 368], ["Liver Damage", "DISEASE", 192, 204], ["Hepatitis C Virus", "DISEASE", 212, 229], ["Dengue Virus", "DISEASE", 234, 246], ["Hepatocytes", "CELL", 0, 11], ["liver cells", "CELL", 40, 51], ["liver", "ORGAN", 86, 91], ["Liver", "ORGAN", 192, 197], ["Hepatitis C Virus", "ORGANISM", 212, 229], ["Dengue Virus", "ORGANISM", 234, 246], ["Hepatocytes", "CELL", 256, 267], ["HCV", "ORGANISM", 292, 295], ["DENV", "ORGANISM", 300, 304], ["Kupffer cells", "CELL", 355, 368], ["liver cells", "CELL_TYPE", 40, 51], ["Kupffer cells", "CELL_TYPE", 355, 368], ["Hepatitis C Virus", "SPECIES", 212, 229], ["Dengue Virus", "SPECIES", 234, 246], ["Hepatitis C Virus", "SPECIES", 212, 229], ["Dengue Virus", "SPECIES", 234, 246], ["HCV", "SPECIES", 292, 295], ["DENV", "SPECIES", 300, 304], ["Hepatocytes", "TEST", 0, 11], ["all liver cells", "PROBLEM", 36, 51], ["Liver Damage", "PROBLEM", 192, 204], ["Hepatitis C Virus", "PROBLEM", 212, 229], ["Dengue Virus InfectionHepatocytes", "PROBLEM", 234, 267], ["HCV", "PROBLEM", 292, 295], ["DENV", "PROBLEM", 300, 304], ["all", "ANATOMY_MODIFIER", 36, 39], ["liver", "ANATOMY", 40, 45], ["cells", "OBSERVATION", 46, 51], ["liver", "ANATOMY", 86, 91], ["Liver", "ANATOMY", 192, 197], ["Damage", "OBSERVATION", 198, 204], ["Hepatitis", "OBSERVATION", 212, 221], ["HCV", "OBSERVATION", 292, 295], ["DENV", "OBSERVATION", 300, 304]]], ["In acute infection, the major damage is through apoptosis following direct infection of these cells, whereas establishment of a chronic infection usually causes a sustained inflammation leading to infiltration of polymorphonuclear cells and lymphocytes (Huerre et al. 2001; Lim et al. 2014; Masalova et al. 2017; Deng et al. 2008; Bala et al. 2012; Sung et al. 2012CNS Damage Due to JEV, WNV, Zika Virus Infection, and Sometimes DENV TooThe central nervous system (CNS) is physiologically isolated from the rest of the body by a specialized selectively permeable barricade called as the blood-brain barrier (BBB), which allows passage to selected metabolites, respiratory gases, and an extremely limited repertoire of circulatory tissue cells.", [["cells", "ANATOMY", 94, 99], ["polymorphonuclear cells", "ANATOMY", 213, 236], ["lymphocytes", "ANATOMY", 241, 252], ["central nervous system", "ANATOMY", 441, 463], ["CNS", "ANATOMY", 465, 468], ["body", "ANATOMY", 519, 523], ["blood-brain barrier", "ANATOMY", 587, 606], ["BBB", "ANATOMY", 608, 611], ["respiratory", "ANATOMY", 660, 671], ["circulatory tissue cells", "ANATOMY", 718, 742], ["acute infection", "DISEASE", 3, 18], ["infection", "DISEASE", 75, 84], ["chronic infection", "DISEASE", 128, 145], ["inflammation", "DISEASE", 173, 185], ["JEV", "DISEASE", 383, 386], ["Zika Virus Infection", "DISEASE", 393, 413], ["cells", "CELL", 94, 99], ["polymorphonuclear cells", "CELL", 213, 236], ["lymphocytes", "CELL", 241, 252], ["JEV", "ORGANISM", 383, 386], ["WNV", "ORGANISM", 388, 391], ["Zika Virus", "ORGANISM", 393, 403], ["central nervous system", "ANATOMICAL_SYSTEM", 441, 463], ["CNS", "ANATOMICAL_SYSTEM", 465, 468], ["body", "ORGANISM_SUBDIVISION", 519, 523], ["blood", "MULTI-TISSUE_STRUCTURE", 587, 592], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 593, 606], ["BBB", "MULTI-TISSUE_STRUCTURE", 608, 611], ["circulatory tissue cells", "CELL", 718, 742], ["polymorphonuclear cells", "CELL_TYPE", 213, 236], ["lymphocytes", "CELL_TYPE", 241, 252], ["circulatory tissue cells", "CELL_TYPE", 718, 742], ["JEV", "SPECIES", 383, 386], ["WNV", "SPECIES", 388, 391], ["DENV", "SPECIES", 429, 433], ["acute infection", "PROBLEM", 3, 18], ["the major damage", "PROBLEM", 20, 36], ["apoptosis", "PROBLEM", 48, 57], ["direct infection of these cells", "PROBLEM", 68, 99], ["a chronic infection", "PROBLEM", 126, 145], ["a sustained inflammation", "PROBLEM", 161, 185], ["infiltration of polymorphonuclear cells", "PROBLEM", 197, 236], ["lymphocytes", "PROBLEM", 241, 252], ["Damage", "PROBLEM", 369, 375], ["JEV", "PROBLEM", 383, 386], ["WNV", "PROBLEM", 388, 391], ["Zika Virus Infection", "PROBLEM", 393, 413], ["DENV", "PROBLEM", 429, 433], ["the blood", "TEST", 583, 592], ["respiratory gases", "TEST", 660, 677], ["circulatory tissue cells", "PROBLEM", 718, 742], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["infection", "OBSERVATION", 9, 18], ["major", "OBSERVATION_MODIFIER", 24, 29], ["damage", "OBSERVATION", 30, 36], ["chronic", "OBSERVATION_MODIFIER", 128, 135], ["infection", "OBSERVATION", 136, 145], ["sustained", "OBSERVATION_MODIFIER", 163, 172], ["inflammation", "OBSERVATION", 173, 185], ["infiltration", "OBSERVATION_MODIFIER", 197, 209], ["polymorphonuclear cells", "OBSERVATION", 213, 236], ["lymphocytes", "ANATOMY", 241, 252], ["JEV", "OBSERVATION", 383, 386], ["central", "ANATOMY_MODIFIER", 441, 448], ["nervous system", "ANATOMY", 449, 463], ["brain", "ANATOMY", 593, 598], ["circulatory tissue cells", "OBSERVATION", 718, 742]]], ["This isolation is necessary for protection of low regeneration capacity neuronal cells from systemic inflammation, which can also upset the structural and functional plasticity of neurons that is dependent on cytokine signaling (Arnett et al. 2001; Gougeon et al. 2013; Mason et al. 2001; Fischer et al. 2011; Brissoni et al. 2006) .", [["neuronal cells", "ANATOMY", 72, 86], ["neurons", "ANATOMY", 180, 187], ["inflammation", "DISEASE", 101, 113], ["neuronal cells", "CELL", 72, 86], ["neurons", "CELL", 180, 187], ["neuronal cells", "CELL_TYPE", 72, 86], ["cytokine", "PROTEIN", 209, 217], ["This isolation", "TREATMENT", 0, 14], ["low regeneration capacity neuronal cells", "PROBLEM", 46, 86], ["systemic inflammation", "PROBLEM", 92, 113], ["low regeneration", "OBSERVATION_MODIFIER", 46, 62], ["capacity neuronal cells", "OBSERVATION", 63, 86], ["systemic", "OBSERVATION_MODIFIER", 92, 100], ["inflammation", "OBSERVATION", 101, 113], ["functional plasticity", "OBSERVATION", 155, 176]]], ["The CNS can have either neuronal or non-neuronal glial cells; the latter provide vital functional support and include microglia (macrophage-like immune cells), oligodendrocytes (which provide insulation for neurons), and astrocytes (responsible for repair of damaged neuronal tissue).", [["CNS", "ANATOMY", 4, 7], ["neuronal", "ANATOMY", 24, 32], ["non-neuronal glial cells", "ANATOMY", 36, 60], ["microglia", "ANATOMY", 118, 127], ["macrophage", "ANATOMY", 129, 139], ["immune cells", "ANATOMY", 145, 157], ["oligodendrocytes", "ANATOMY", 160, 176], ["neurons", "ANATOMY", 207, 214], ["astrocytes", "ANATOMY", 221, 231], ["neuronal tissue", "ANATOMY", 267, 282], ["CNS", "ANATOMICAL_SYSTEM", 4, 7], ["neuronal", "CELL", 24, 32], ["non-neuronal glial cells", "CELL", 36, 60], ["microglia", "CELL", 118, 127], ["macrophage-like immune cells", "CELL", 129, 157], ["oligodendrocytes", "CELL", 160, 176], ["neurons", "CELL", 207, 214], ["astrocytes", "CELL", 221, 231], ["neuronal tissue", "TISSUE", 267, 282], ["neuronal or non-neuronal glial cells", "CELL_TYPE", 24, 60], ["microglia", "CELL_TYPE", 118, 127], ["macrophage", "CELL_TYPE", 129, 139], ["immune cells", "CELL_TYPE", 145, 157], ["oligodendrocytes", "CELL_TYPE", 160, 176], ["astrocytes", "CELL_TYPE", 221, 231], ["neuronal or non-neuronal glial cells", "PROBLEM", 24, 60], ["microglia (macrophage", "TEST", 118, 139], ["immune cells", "PROBLEM", 145, 157], ["oligodendrocytes", "PROBLEM", 160, 176], ["astrocytes", "PROBLEM", 221, 231], ["repair", "TREATMENT", 249, 255], ["damaged neuronal tissue", "PROBLEM", 259, 282], ["CNS", "ANATOMY", 4, 7], ["non-neuronal glial cells", "OBSERVATION", 36, 60], ["damaged neuronal tissue", "OBSERVATION", 259, 282]]], ["Microglial cells have immunomodulatory function in suppressing a pathogenic inflammation (Seitz et al. 2018) .", [["Microglial cells", "ANATOMY", 0, 16], ["inflammation", "DISEASE", 76, 88], ["Microglial cells", "CELL", 0, 16], ["Microglial cells", "CELL_TYPE", 0, 16], ["Microglial cells", "PROBLEM", 0, 16], ["immunomodulatory function", "PROBLEM", 22, 47], ["a pathogenic inflammation", "PROBLEM", 63, 88], ["pathogenic", "OBSERVATION_MODIFIER", 65, 75], ["inflammation", "OBSERVATION", 76, 88]]], ["Multiple viruses in the +ve-ssRNA genome group, including Coronavirus, Picornavirus, Flaviviridae, and Togaviridae, cause opportunistic infection of CNS (Bergmann et al. 2006; Koyuncu et al. 2013; Fletcher and McKeating 2012) .CNS Damage Due to JEV, WNV, Zika Virus Infection, and Sometimes DENV TooIn the absence of a direct admission route, these viruses undergo limited replication in peripheral tissue, before entering through either peripheral nerves or BBB microvasculature or CNS infiltrating leukocytes (functioning as the proverbial \"Trojan horse\") (Koyuncu et al. 2013; Jeha et al. 2003) .", [["CNS", "ANATOMY", 149, 152], ["peripheral tissue", "ANATOMY", 388, 405], ["peripheral nerves", "ANATOMY", 438, 455], ["BBB microvasculature", "ANATOMY", 459, 479], ["CNS infiltrating leukocytes", "ANATOMY", 483, 510], ["opportunistic infection", "DISEASE", 122, 145], ["JEV", "DISEASE", 245, 248], ["Zika Virus Infection", "DISEASE", 255, 275], ["CNS", "ANATOMICAL_SYSTEM", 149, 152], ["JEV", "ORGANISM", 245, 248], ["WNV", "ORGANISM", 250, 253], ["Zika Virus", "ORGANISM", 255, 265], ["peripheral tissue", "TISSUE", 388, 405], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 438, 455], ["BBB microvasculature", "TISSUE", 459, 479], ["CNS infiltrating leukocytes", "CELL", 483, 510], ["horse", "ORGANISM", 550, 555], ["CNS infiltrating leukocytes", "CELL_TYPE", 483, 510], ["horse", "SPECIES", 550, 555], ["JEV", "SPECIES", 245, 248], ["WNV", "SPECIES", 250, 253], ["DENV", "SPECIES", 291, 295], ["Multiple viruses", "PROBLEM", 0, 16], ["ssRNA genome group", "TREATMENT", 28, 46], ["Coronavirus", "PROBLEM", 58, 69], ["Picornavirus", "TREATMENT", 71, 83], ["Flaviviridae", "TREATMENT", 85, 97], ["Togaviridae", "TREATMENT", 103, 114], ["opportunistic infection of CNS", "PROBLEM", 122, 152], ["Damage", "PROBLEM", 231, 237], ["JEV", "PROBLEM", 245, 248], ["WNV", "PROBLEM", 250, 253], ["Zika Virus Infection", "PROBLEM", 255, 275], ["these viruses", "PROBLEM", 343, 356], ["BBB microvasculature", "PROBLEM", 459, 479], ["CNS infiltrating leukocytes", "PROBLEM", 483, 510], ["viruses", "OBSERVATION", 9, 16], ["ssRNA genome", "OBSERVATION", 28, 40], ["opportunistic", "OBSERVATION_MODIFIER", 122, 135], ["infection", "OBSERVATION", 136, 145], ["peripheral tissue", "OBSERVATION_MODIFIER", 388, 405], ["peripheral", "ANATOMY_MODIFIER", 438, 448], ["nerves", "ANATOMY", 449, 455], ["BBB", "ANATOMY", 459, 462], ["CNS", "ANATOMY", 483, 486], ["infiltrating", "OBSERVATION", 487, 499]]], ["A feature common here is a breach of the vascular endothelial barrier at varying locations, e.g., BBB for JEV/WNV, blood retinal barrier for ZIKV, and endothelial barriers in lungs/ peritoneum for DENV.", [["vascular endothelial barrier", "ANATOMY", 41, 69], ["blood retinal", "ANATOMY", 115, 128], ["ZIKV", "ANATOMY", 141, 145], ["endothelial", "ANATOMY", 151, 162], ["lungs", "ANATOMY", 175, 180], ["peritoneum", "ANATOMY", 182, 192], ["vascular endothelial barrier", "TISSUE", 41, 69], ["BBB", "GENE_OR_GENE_PRODUCT", 98, 101], ["JEV", "ORGANISM", 106, 109], ["WNV", "ORGANISM", 110, 113], ["blood retinal barrier", "MULTI-TISSUE_STRUCTURE", 115, 136], ["endothelial", "TISSUE", 151, 162], ["lungs", "ORGAN", 175, 180], ["peritoneum", "MULTI-TISSUE_STRUCTURE", 182, 192], ["DENV", "ORGANISM", 197, 201], ["JEV", "SPECIES", 106, 109], ["WNV", "SPECIES", 110, 113], ["DENV", "SPECIES", 197, 201], ["the vascular endothelial barrier", "TREATMENT", 37, 69], ["JEV", "PROBLEM", 106, 109], ["WNV", "PROBLEM", 110, 113], ["blood retinal barrier", "TREATMENT", 115, 136], ["ZIKV", "PROBLEM", 141, 145], ["endothelial barriers in lungs/ peritoneum", "TREATMENT", 151, 192], ["DENV", "PROBLEM", 197, 201], ["vascular endothelial", "ANATOMY", 41, 61], ["lungs", "ANATOMY", 175, 180], ["peritoneum", "ANATOMY", 182, 192], ["DENV", "OBSERVATION", 197, 201]]], ["Breach in BBB is more common for some viruses (e.g., WNV, JEV, ZIKAV, poliovirus) correlating with fatality.", [["BBB", "MULTI-TISSUE_STRUCTURE", 10, 13], ["WNV", "ORGANISM", 53, 56], ["JEV", "ORGANISM", 58, 61], ["ZIKAV", "GENE_OR_GENE_PRODUCT", 63, 68], ["WNV", "SPECIES", 53, 56], ["JEV", "SPECIES", 58, 61], ["ZIKAV", "SPECIES", 63, 68], ["Breach in BBB", "PROBLEM", 0, 13], ["some viruses", "PROBLEM", 33, 45], ["WNV", "PROBLEM", 53, 56], ["JEV", "PROBLEM", 58, 61], ["ZIKAV", "PROBLEM", 63, 68], ["poliovirus", "PROBLEM", 70, 80], ["BBB", "ANATOMY", 10, 13], ["viruses", "OBSERVATION", 38, 45]]], ["Interestingly, WNV and JEV have been suggested to cause BBB disruption from inside the CNS (Li et al. 2015; Verma et al. 2009 ).", [["BBB", "ANATOMY", 56, 59], ["CNS", "ANATOMY", 87, 90], ["WNV", "ORGANISM", 15, 18], ["JEV", "ORGANISM", 23, 26], ["BBB", "MULTI-TISSUE_STRUCTURE", 56, 59], ["WNV", "SPECIES", 15, 18], ["JEV", "SPECIES", 23, 26], ["WNV", "PROBLEM", 15, 18], ["JEV", "PROBLEM", 23, 26], ["BBB disruption", "PROBLEM", 56, 70], ["WNV", "OBSERVATION", 15, 18], ["CNS", "ANATOMY", 87, 90]]], ["Still other reports suggest infected endothelial cells to secrete PICs that disrupt the BBB (Chen et al. 2014; Chang et al. 2017; Roach and Alcendor 2017) .", [["endothelial cells", "ANATOMY", 37, 54], ["endothelial cells", "CELL", 37, 54], ["BBB", "MULTI-TISSUE_STRUCTURE", 88, 91], ["infected endothelial cells", "CELL_TYPE", 28, 54], ["infected endothelial cells", "PROBLEM", 28, 54], ["infected endothelial cells", "OBSERVATION", 28, 54]]], ["The tissue damage is caused from a combination of either direct neuronal infection which activates intrinsic apoptosis or a hyperactive inflammatory response mediated by PICs or CD8+ cytotoxic T cells (CTLs) (Wang et al. 2003; Samuel et al. 2007) .", [["tissue", "ANATOMY", 4, 10], ["neuronal", "ANATOMY", 64, 72], ["PICs", "ANATOMY", 170, 174], ["CD8+ cytotoxic T cells", "ANATOMY", 178, 200], ["CTLs", "ANATOMY", 202, 206], ["tissue damage", "DISEASE", 4, 17], ["neuronal infection", "DISEASE", 64, 82], ["tissue", "TISSUE", 4, 10], ["neuronal", "CELL", 64, 72], ["PICs", "GENE_OR_GENE_PRODUCT", 170, 174], ["CD8", "GENE_OR_GENE_PRODUCT", 178, 181], ["PICs", "PROTEIN", 170, 174], ["CD8", "PROTEIN", 178, 181], ["cytotoxic T cells", "CELL_TYPE", 183, 200], ["CTLs", "CELL_TYPE", 202, 206], ["The tissue damage", "PROBLEM", 0, 17], ["direct neuronal infection", "PROBLEM", 57, 82], ["intrinsic apoptosis", "PROBLEM", 99, 118], ["a hyperactive inflammatory response", "PROBLEM", 122, 157], ["cytotoxic T cells", "PROBLEM", 183, 200], ["tissue", "ANATOMY", 4, 10], ["damage", "OBSERVATION", 11, 17], ["neuronal", "ANATOMY", 64, 72], ["infection", "OBSERVATION", 73, 82], ["hyperactive", "OBSERVATION_MODIFIER", 124, 135], ["inflammatory", "OBSERVATION_MODIFIER", 136, 148], ["cytotoxic T cells", "OBSERVATION", 183, 200]]], ["Infected neurons secrete chemokines that attract leukocytes like monocytes and lymphocytes (Klein et al. 2005; Shrestha and Diamond 2004; Glass et al. 2005; Kelley et al. 2003; Lim et al. 2011; Bardina et al. 2015; Durrant et al. 2015; Shrestha et al. 2008 ).", [["neurons", "ANATOMY", 9, 16], ["leukocytes", "ANATOMY", 49, 59], ["monocytes", "ANATOMY", 65, 74], ["lymphocytes", "ANATOMY", 79, 90], ["neurons", "CELL", 9, 16], ["leukocytes", "CELL", 49, 59], ["monocytes", "CELL", 65, 74], ["lymphocytes", "CELL", 79, 90], ["chemokines", "PROTEIN", 25, 35], ["leukocytes", "CELL_TYPE", 49, 59], ["monocytes", "CELL_TYPE", 65, 74], ["lymphocytes", "CELL_TYPE", 79, 90], ["Infected neurons secrete chemokines", "PROBLEM", 0, 35], ["leukocytes", "TEST", 49, 59], ["monocytes", "TEST", 65, 74], ["lymphocytes", "TEST", 79, 90], ["lymphocytes", "ANATOMY", 79, 90]]], ["The relation between a \"good\" and \"bad\" immune response is, however, very tricky when it comes to the CNS.", [["CNS", "ANATOMY", 102, 105], ["CNS", "ANATOMICAL_SYSTEM", 102, 105], ["CNS", "ANATOMY", 102, 105]]], ["Migration of CTLs expressing receptors for chemokines like CCL2, CCL3, CCL4, CCL5, CXCL9-11, as well as its timing with respect to establishment of infection, seems to play a crucial role in virus eradication and survival (Wang et al. 2003; Shrestha and Diamond 2004; Diamond et al. 2003; Sussman et al. 1989; Getts et al. 2010; Nansen et al. 2000; Chen et al. 2004; Liu et al. 2001; Zink et al. 2001; Winter et al. 2004) .", [["CTLs", "ANATOMY", 13, 17], ["infection", "DISEASE", 148, 157], ["CTLs", "CELL", 13, 17], ["CCL2", "GENE_OR_GENE_PRODUCT", 59, 63], ["CCL3", "GENE_OR_GENE_PRODUCT", 65, 69], ["CCL4", "GENE_OR_GENE_PRODUCT", 71, 75], ["CCL5", "GENE_OR_GENE_PRODUCT", 77, 81], ["CXCL9-11", "GENE_OR_GENE_PRODUCT", 83, 91], ["CTLs", "CELL_TYPE", 13, 17], ["chemokines", "PROTEIN", 43, 53], ["CCL2", "PROTEIN", 59, 63], ["CCL3", "PROTEIN", 65, 69], ["CCL4", "PROTEIN", 71, 75], ["CCL5", "PROTEIN", 77, 81], ["CXCL9", "PROTEIN", 83, 88], ["chemokines", "TEST", 43, 53], ["CCL2", "TEST", 59, 63], ["CCL3", "TEST", 65, 69], ["CCL4", "TEST", 71, 75], ["CCL5", "TEST", 77, 81], ["CXCL9", "TEST", 83, 88], ["infection", "PROBLEM", 148, 157], ["virus eradication", "TREATMENT", 191, 208], ["CCL4", "ANATOMY", 71, 75], ["CCL5", "ANATOMY", 77, 81], ["infection", "OBSERVATION", 148, 157]]], ["The CTLs exert their antiviral role by inducing cell death through either a perforin-dependent or Fas-FasL-mediated mechanism (Rossi et al. 1998; Shrestha and Diamond 2007) .", [["CTLs", "ANATOMY", 4, 8], ["cell", "ANATOMY", 48, 52], ["death", "DISEASE", 53, 58], ["CTLs", "CELL", 4, 8], ["cell", "CELL", 48, 52], ["perforin", "GENE_OR_GENE_PRODUCT", 76, 84], ["Fas-", "GENE_OR_GENE_PRODUCT", 98, 102], ["FasL", "GENE_OR_GENE_PRODUCT", 102, 106], ["CTLs", "CELL_TYPE", 4, 8], ["perforin", "PROTEIN", 76, 84], ["FasL", "PROTEIN", 102, 106], ["inducing cell death", "PROBLEM", 39, 58]]], ["In addition to CTLs, other PICs might also induce direct cell death in neurons (Dhanwani et al. 2012; Olmo et al. 2017; Baer et al. 2016; Kumar et al. 2010 ).Dengue Infection-Associated Vascular LeakageDengue virus causes a febrile illness with can turn fatal after a subsidence of the fever.", [["cell", "ANATOMY", 57, 61], ["neurons", "ANATOMY", 71, 78], ["Vascular", "ANATOMY", 186, 194], ["death", "DISEASE", 62, 67], ["Dengue", "DISEASE", 158, 164], ["Dengue virus", "DISEASE", 202, 214], ["febrile illness", "DISEASE", 224, 239], ["fever", "DISEASE", 286, 291], ["CTLs", "CELL", 15, 19], ["cell", "CELL", 57, 61], ["neurons", "CELL", 71, 78], ["Vascular", "MULTI-TISSUE_STRUCTURE", 186, 194], ["Dengue virus", "ORGANISM", 202, 214], ["CTLs", "CELL_TYPE", 15, 19], ["PICs", "PROTEIN", 27, 31], ["Dengue", "SPECIES", 158, 164], ["Dengue virus", "SPECIES", 202, 214], ["Dengue virus", "SPECIES", 202, 214], ["direct cell death in neurons", "PROBLEM", 50, 78], ["Dengue Infection", "PROBLEM", 158, 174], ["Associated Vascular Leakage", "PROBLEM", 175, 202], ["Dengue virus", "PROBLEM", 202, 214], ["a febrile illness", "PROBLEM", 222, 239], ["the fever", "PROBLEM", 282, 291], ["Infection", "OBSERVATION", 165, 174], ["Vascular", "ANATOMY", 186, 194], ["Leakage", "OBSERVATION", 195, 202], ["febrile", "OBSERVATION_MODIFIER", 224, 231], ["fever", "OBSERVATION", 286, 291]]], ["The severity emanates from leakage of fluid from the blood vessels by a breach of the vascular endothelium.", [["fluid", "ANATOMY", 38, 43], ["blood vessels", "ANATOMY", 53, 66], ["vascular endothelium", "ANATOMY", 86, 106], ["fluid", "ORGANISM_SUBSTANCE", 38, 43], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 53, 66], ["vascular endothelium", "TISSUE", 86, 106], ["The severity", "PROBLEM", 0, 12], ["leakage of fluid", "PROBLEM", 27, 43], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["leakage", "OBSERVATION", 27, 34], ["fluid", "OBSERVATION", 38, 43], ["blood vessels", "ANATOMY", 53, 66], ["vascular endothelium", "ANATOMY", 86, 106]]], ["Circulating in four serotypes, severe disease is mostly associated with secondary infection by a serotype different from the one causing primary infection.", [["infection", "DISEASE", 82, 91], ["primary infection", "DISEASE", 137, 154], ["Circulating in four serotypes", "PROBLEM", 0, 29], ["severe disease", "PROBLEM", 31, 45], ["secondary infection", "PROBLEM", 72, 91], ["a serotype", "PROBLEM", 95, 105], ["primary infection", "PROBLEM", 137, 154], ["four", "OBSERVATION_MODIFIER", 15, 19], ["serotypes", "OBSERVATION_MODIFIER", 20, 29], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["disease", "OBSERVATION", 38, 45], ["mostly associated with", "UNCERTAINTY", 49, 71], ["secondary", "OBSERVATION_MODIFIER", 72, 81], ["infection", "OBSERVATION", 82, 91], ["serotype different", "OBSERVATION_MODIFIER", 97, 115], ["primary", "OBSERVATION_MODIFIER", 137, 144], ["infection", "OBSERVATION", 145, 154]]], ["Neutralizing antibodies generated during primary infection incompletely neutralize the secondary infection virus and instead promote their uptake by monocytes, by a phenomenon called antibody-dependent enhancement or ADE (Katzelnick et al. 2017; Dejnirattisai et al. 2016 ).", [["monocytes", "ANATOMY", 149, 158], ["primary infection", "DISEASE", 41, 58], ["infection", "DISEASE", 97, 106], ["monocytes", "CELL", 149, 158], ["Neutralizing antibodies", "PROTEIN", 0, 23], ["monocytes", "CELL_TYPE", 149, 158], ["Neutralizing antibodies", "PROBLEM", 0, 23], ["primary infection", "PROBLEM", 41, 58], ["the secondary infection virus", "PROBLEM", 83, 112], ["a phenomenon", "TEST", 163, 175], ["antibody", "TEST", 183, 191], ["dependent enhancement", "PROBLEM", 192, 213], ["secondary", "OBSERVATION_MODIFIER", 87, 96], ["infection", "OBSERVATION", 97, 106]]], ["Notwithstanding a primary or secondary infection, the pathological symptoms are considered to be the result of an unbridled host immune response (Basu and Chaturvedi 2008; Rothman 2011).", [["infection", "DISEASE", 39, 48], ["secondary infection", "PROBLEM", 29, 48], ["the pathological symptoms", "PROBLEM", 50, 75], ["secondary", "OBSERVATION_MODIFIER", 29, 38], ["infection", "OBSERVATION", 39, 48]]], ["Different studies have reported a positive association of DHF/DSS development with extraordinarily augmented levels of different PICs that include macrophage migration inhibitory factor (MIF), IFN-\u03b1, TNF-\u03b1 (Green et al. 1999; Kurane et al. 1993; Huang et al. 2000; Chen et al. 2006) .", [["DHF", "DISEASE", 58, 61], ["DSS", "DISEASE", 62, 65], ["macrophage migration inhibitory factor", "GENE_OR_GENE_PRODUCT", 147, 185], ["MIF", "GENE_OR_GENE_PRODUCT", 187, 190], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 193, 198], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 200, 205], ["PICs", "PROTEIN", 129, 133], ["macrophage migration inhibitory factor", "PROTEIN", 147, 185], ["MIF", "PROTEIN", 187, 190], ["IFN", "PROTEIN", 193, 196], ["TNF", "PROTEIN", 200, 203], ["Different studies", "TEST", 0, 17], ["DHF", "PROBLEM", 58, 61], ["DSS development", "PROBLEM", 62, 77], ["extraordinarily augmented levels", "PROBLEM", 83, 115], ["different PICs", "PROBLEM", 119, 133], ["macrophage migration inhibitory factor", "PROBLEM", 147, 185], ["MIF", "TEST", 187, 190], ["IFN", "TEST", 193, 196], ["TNF", "TEST", 200, 203], ["DHF", "OBSERVATION", 58, 61], ["macrophage migration", "OBSERVATION", 147, 167]]], ["Although multiple reports have suggested correlation between specific PIC level and plasma leakage, the mechanism is still elusive and limited to association studies (Priyadarshini et al. 2010; Her et al. 2017; Sehrawat et al. 2018; Malavige et al. 2012 ).", [["plasma", "ANATOMY", 84, 90], ["PIC", "GENE_OR_GENE_PRODUCT", 70, 73], ["plasma", "ORGANISM_SUBSTANCE", 84, 90], ["PIC", "PROTEIN", 70, 73], ["specific PIC level", "PROBLEM", 61, 79], ["plasma leakage", "PROBLEM", 84, 98], ["plasma leakage", "OBSERVATION", 84, 98]]], ["Interestingly however, multiple similar association studies have suggested a positive association between levels of IL10 (an AIC) and severe/critical symptoms related to dengue infection (Malavige et al. 2013; Tsai et al. 2013; Flores-Mendoza et al. 2017 ).", [["dengue infection", "DISEASE", 170, 186], ["IL10", "GENE_OR_GENE_PRODUCT", 116, 120], ["IL10", "PROTEIN", 116, 120], ["dengue", "SPECIES", 170, 176], ["a positive association between levels of IL10 (an AIC)", "PROBLEM", 75, 129], ["severe/critical symptoms", "PROBLEM", 134, 158], ["dengue infection", "PROBLEM", 170, 186], ["severe", "OBSERVATION_MODIFIER", 134, 140]]], ["IL10, produced by multiple immune cells, suppresses immune response through upregulation of SOCS (suppressor of cytokine signaling) function and downregulation of IFN activity, the result being decreased T-cell cytotoxicity (Halstead et al. 2010; Katzelnick et al. 2017; Tsai et al. 2013; Azeredo et al. 2001; Brasier et al. 2012 ).", [["immune cells", "ANATOMY", 27, 39], ["T-cell", "ANATOMY", 204, 210], ["IL10", "GENE_OR_GENE_PRODUCT", 0, 4], ["immune cells", "CELL", 27, 39], ["SOCS", "GENE_OR_GENE_PRODUCT", 92, 96], ["IFN", "GENE_OR_GENE_PRODUCT", 163, 166], ["T-cell", "CELL", 204, 210], ["IL10", "PROTEIN", 0, 4], ["immune cells", "CELL_TYPE", 27, 39], ["SOCS", "PROTEIN", 92, 96], ["IFN", "PROTEIN", 163, 166], ["multiple immune cells", "TREATMENT", 18, 39], ["SOCS (suppressor of cytokine signaling", "TREATMENT", 92, 130], ["downregulation of IFN activity", "PROBLEM", 145, 175], ["immune cells", "OBSERVATION", 27, 39]]], ["The augmentation of IL10 level has been suggested to emanate from monocytes infected by the ADE route with additional influence from high viremia (Tsai et al. 2014) .", [["monocytes", "ANATOMY", 66, 75], ["viremia", "DISEASE", 138, 145], ["IL10", "GENE_OR_GENE_PRODUCT", 20, 24], ["monocytes", "CELL", 66, 75], ["IL10", "PROTEIN", 20, 24], ["monocytes", "CELL_TYPE", 66, 75], ["The augmentation of IL10 level", "TEST", 0, 30], ["monocytes", "PROBLEM", 66, 75], ["high viremia", "PROBLEM", 133, 145], ["augmentation", "OBSERVATION_MODIFIER", 4, 16], ["monocytes", "OBSERVATION", 66, 75], ["high viremia", "OBSERVATION", 133, 145]]], ["IL10 is a dominant regulator of the immune system that can prolong pathogen clearance through a subversion of the immune response (Couper et al. 2008 ).Lung Infection and Pathology by CoronavirusesCoronavirus infections are usually benign causing self-limiting mild flu-like symptoms.", [["immune system", "ANATOMY", 36, 49], ["Lung", "ANATOMY", 152, 156], ["Lung Infection", "DISEASE", 152, 166], ["Coronavirus infections", "DISEASE", 197, 219], ["flu-like symptoms", "DISEASE", 266, 283], ["IL10", "GENE_OR_GENE_PRODUCT", 0, 4], ["Lung", "ORGAN", 152, 156], ["IL10", "PROTEIN", 0, 4], ["Lung Infection", "PROBLEM", 152, 166], ["Pathology", "PROBLEM", 171, 180], ["CoronavirusesCoronavirus infections", "PROBLEM", 184, 219], ["self-limiting mild flu-like symptoms", "PROBLEM", 247, 283], ["dominant", "OBSERVATION", 10, 18], ["Infection", "OBSERVATION", 157, 166], ["CoronavirusesCoronavirus", "OBSERVATION", 184, 208], ["mild", "OBSERVATION_MODIFIER", 261, 265], ["flu", "OBSERVATION", 266, 269]]], ["However, recent outbreaks involving, e.g., severe acute respiratory syndrome coronavirus (SARS-CoV), which jumped species barrier through acquisition of minor genome mutations, have projected them as potentially severe human pathogens (Guan et al. 2004) .", [["acute respiratory syndrome coronavirus", "DISEASE", 50, 88], ["SARS", "DISEASE", 90, 94], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 43, 88], ["SARS-CoV", "ORGANISM", 90, 98], ["human", "ORGANISM", 219, 224], ["human", "SPECIES", 219, 224], ["severe acute respiratory syndrome coronavirus", "SPECIES", 43, 88], ["SARS-CoV", "SPECIES", 90, 98], ["human", "SPECIES", 219, 224], ["recent outbreaks", "PROBLEM", 9, 25], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 43, 88], ["minor genome mutations", "PROBLEM", 153, 175], ["severe human pathogens", "PROBLEM", 212, 234], ["outbreaks", "OBSERVATION", 16, 25], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["respiratory syndrome coronavirus", "OBSERVATION", 56, 88], ["genome mutations", "OBSERVATION", 159, 175], ["severe", "OBSERVATION_MODIFIER", 212, 218]]], ["Spread through aerosols, SARS-CoV primarily infect lung cells triggering an often fatal inflammatory response clinically called acute respiratory distress syndrome (ARDS) that starts with severe hypoxia, pulmonary edema progressing to systemic inflammation, and failure of multiple organs, culminating in high rate of mortality (Peiris et al. 2003; Lew et al. 2003; Tsushima et al. 2009; Farcas et al. 2005) .", [["lung cells", "ANATOMY", 51, 61], ["respiratory", "ANATOMY", 134, 145], ["pulmonary", "ANATOMY", 204, 213], ["organs", "ANATOMY", 282, 288], ["acute respiratory distress syndrome", "DISEASE", 128, 163], ["ARDS", "DISEASE", 165, 169], ["hypoxia", "DISEASE", 195, 202], ["pulmonary edema", "DISEASE", 204, 219], ["inflammation", "DISEASE", 244, 256], ["SARS-CoV", "ORGANISM", 25, 33], ["lung cells", "CELL", 51, 61], ["pulmonary", "ORGAN", 204, 213], ["organs", "ORGAN", 282, 288], ["lung cells", "CELL_TYPE", 51, 61], ["SARS-CoV", "SPECIES", 25, 33], ["Spread through aerosols", "PROBLEM", 0, 23], ["SARS", "PROBLEM", 25, 29], ["infect lung cells", "PROBLEM", 44, 61], ["an often fatal inflammatory response", "PROBLEM", 73, 109], ["acute respiratory distress syndrome", "PROBLEM", 128, 163], ["ARDS", "PROBLEM", 165, 169], ["severe hypoxia", "PROBLEM", 188, 202], ["pulmonary edema", "PROBLEM", 204, 219], ["systemic inflammation", "PROBLEM", 235, 256], ["failure of multiple organs", "PROBLEM", 262, 288], ["lung", "ANATOMY", 51, 55], ["cells", "OBSERVATION", 56, 61], ["fatal", "OBSERVATION_MODIFIER", 82, 87], ["inflammatory", "OBSERVATION", 88, 100], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["respiratory distress", "OBSERVATION", 134, 154], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["hypoxia", "OBSERVATION", 195, 202], ["pulmonary", "ANATOMY", 204, 213], ["edema", "OBSERVATION", 214, 219], ["systemic", "OBSERVATION_MODIFIER", 235, 243], ["inflammation", "OBSERVATION", 244, 256], ["failure", "OBSERVATION", 262, 269], ["multiple", "OBSERVATION_MODIFIER", 273, 281], ["organs", "ANATOMY", 282, 288], ["high", "OBSERVATION_MODIFIER", 305, 309]]], ["Although evidence suggests that SARS-CoV can infect multiple cell types, lung type-II pneumocytes and ciliated epithelial cells constitute primary sites of virus replication, consequent to which these cells undergo apoptotic and/or necrotic death attracting innate immune cells and activating them to secrete PICs (Sims et al. 2005; Chow et al. 2004; Nicholls et al. 2003) .", [["cell", "ANATOMY", 61, 65], ["lung type-II pneumocytes", "ANATOMY", 73, 97], ["epithelial cells", "ANATOMY", 111, 127], ["sites", "ANATOMY", 147, 152], ["cells", "ANATOMY", 201, 206], ["immune cells", "ANATOMY", 265, 277], ["SARS", "DISEASE", 32, 36], ["death", "DISEASE", 241, 246], ["SARS-CoV", "ORGANISM", 32, 40], ["cell", "CELL", 61, 65], ["lung type-II pneumocytes", "CELL", 73, 97], ["ciliated epithelial cells", "CELL", 102, 127], ["cells", "CELL", 201, 206], ["immune cells", "CELL", 265, 277], ["lung type-II pneumocytes", "CELL_TYPE", 73, 97], ["ciliated epithelial cells", "CELL_TYPE", 102, 127], ["innate immune cells", "CELL_TYPE", 258, 277], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 32, 36], ["CoV", "PROBLEM", 37, 40], ["multiple cell types", "PROBLEM", 52, 71], ["lung type-II pneumocytes", "PROBLEM", 73, 97], ["ciliated epithelial cells", "PROBLEM", 102, 127], ["primary sites of virus replication", "PROBLEM", 139, 173], ["apoptotic", "PROBLEM", 215, 224], ["necrotic death", "PROBLEM", 232, 246], ["evidence suggests", "UNCERTAINTY", 9, 26], ["SARS", "OBSERVATION", 32, 36], ["cell types", "OBSERVATION", 61, 71], ["lung", "ANATOMY", 73, 77], ["ciliated epithelial cells", "OBSERVATION", 102, 127], ["virus replication", "OBSERVATION", 156, 173], ["necrotic", "OBSERVATION_MODIFIER", 232, 240]]], ["The nature of inflammation following SARS-CoV infection is characterized by a prompt production of PICs through immediate NF\u03baB activation and a delayed expression of type-I IFN genes (Shi et al. 2014; Kong et al. 2009; Wong et al. 2004 ).", [["inflammation", "DISEASE", 14, 26], ["SARS-CoV infection", "DISEASE", 37, 55], ["SARS-CoV", "ORGANISM", 37, 45], ["NF\u03ba", "GENE_OR_GENE_PRODUCT", 122, 125], ["B", "GENE_OR_GENE_PRODUCT", 125, 126], ["type-I IFN", "GENE_OR_GENE_PRODUCT", 166, 176], ["PICs", "PROTEIN", 99, 103], ["immediate NF\u03ba", "PROTEIN", 112, 125], ["type-I IFN genes", "DNA", 166, 182], ["SARS-CoV", "SPECIES", 37, 45], ["inflammation", "PROBLEM", 14, 26], ["SARS", "PROBLEM", 37, 41], ["CoV infection", "PROBLEM", 42, 55], ["inflammation", "OBSERVATION", 14, 26], ["infection", "OBSERVATION", 46, 55]]], ["Severity of symptoms correlates positively with IL-6 levels while exhibiting negative correlation with that of IL-8 and TGF\u03b2 (Zhang et al. 2004) .", [["IL-6", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL-8", "GENE_OR_GENE_PRODUCT", 111, 115], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 120, 124], ["IL", "PROTEIN", 48, 50], ["IL-8", "PROTEIN", 111, 115], ["TGF", "PROTEIN", 120, 123], ["Severity of symptoms", "PROBLEM", 0, 20], ["IL", "TEST", 48, 50], ["IL", "TEST", 111, 113]]], ["As observed with many other viral pathogenesis models, macrophage polarization culminating in preferential enrichment of M2-macrophages has been suggested to be responsible for SARS-CoV pathogenesis (Page et al. 2012) .", [["macrophage", "ANATOMY", 55, 65], ["M2-macrophages", "ANATOMY", 121, 135], ["SARS-CoV pathogenesis", "DISEASE", 177, 198], ["macrophage", "CELL", 55, 65], ["M2", "GENE_OR_GENE_PRODUCT", 121, 123], ["SARS-CoV", "ORGANISM", 177, 185], ["M2", "PROTEIN", 121, 123], ["macrophages", "CELL_TYPE", 124, 135], ["SARS-CoV", "SPECIES", 177, 185], ["many other viral pathogenesis models", "PROBLEM", 17, 53], ["macrophage polarization", "PROBLEM", 55, 78], ["SARS", "PROBLEM", 177, 181], ["CoV pathogenesis", "PROBLEM", 182, 198], ["viral", "OBSERVATION", 28, 33], ["macrophage polarization", "OBSERVATION", 55, 78], ["preferential", "OBSERVATION_MODIFIER", 94, 106], ["enrichment", "OBSERVATION_MODIFIER", 107, 117], ["M2", "OBSERVATION_MODIFIER", 121, 123], ["suggested to be responsible for", "UNCERTAINTY", 145, 176]]], ["SARS-CoV infection is also associated with hemophagocytosis or engulfment of different types of blood cells by histiocytes (a class within macrophages), which is a clinical marker of immune system hyper-activation (Usmani et al. 2013 ).Therapeutic Approaches Using CytokineTraditionally prophylactic or therapeutic strategies for combating viral pathogenesis are designed using vaccines or directly acting antivirals (DAA), respectively.", [["blood cells", "ANATOMY", 96, 107], ["histiocytes", "ANATOMY", 111, 122], ["macrophages", "ANATOMY", 139, 150], ["immune system", "ANATOMY", 183, 196], ["SARS-CoV infection", "DISEASE", 0, 18], ["hemophagocytosis", "DISEASE", 43, 59], ["SARS-CoV", "ORGANISM", 0, 8], ["blood cells", "CELL", 96, 107], ["histiocytes", "CELL", 111, 122], ["macrophages", "CELL", 139, 150], ["Cytokine", "GENE_OR_GENE_PRODUCT", 265, 273], ["DAA", "SIMPLE_CHEMICAL", 418, 421], ["blood cells", "CELL_TYPE", 96, 107], ["histiocytes", "CELL_TYPE", 111, 122], ["macrophages", "CELL_TYPE", 139, 150], ["Cytokine", "PROTEIN", 265, 273], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV infection", "PROBLEM", 5, 18], ["hemophagocytosis", "PROBLEM", 43, 59], ["blood cells", "PROBLEM", 96, 107], ["histiocytes", "PROBLEM", 111, 122], ["immune system hyper-activation", "PROBLEM", 183, 213], ["Therapeutic Approaches", "TREATMENT", 236, 258], ["Cytokine", "TREATMENT", 265, 273], ["Traditionally prophylactic", "TREATMENT", 273, 299], ["therapeutic strategies", "TREATMENT", 303, 325], ["combating viral pathogenesis", "PROBLEM", 330, 358], ["vaccines", "TREATMENT", 378, 386], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 9, 18], ["associated with", "UNCERTAINTY", 27, 42], ["hemophagocytosis", "OBSERVATION", 43, 59], ["engulfment", "OBSERVATION_MODIFIER", 63, 73], ["different types", "OBSERVATION_MODIFIER", 77, 92], ["blood cells", "OBSERVATION", 96, 107], ["histiocytes", "OBSERVATION", 111, 122]]], ["But for many viruses there is no clinically approved product to serve in either approach.Therapeutic Approaches Using CytokineSince the etiology of critical pathogenic symptoms is often associated with an unbridled host inflammatory response, there have been suggestions and attempts to control the harmful effects through modulation of key inflammatory signaling (D'Elia et al. 2013 ).", [["many viruses", "PROBLEM", 8, 20], ["Therapeutic Approaches", "TREATMENT", 89, 111], ["CytokineSince", "TREATMENT", 118, 131], ["critical pathogenic symptoms", "PROBLEM", 148, 176], ["an unbridled host inflammatory response", "PROBLEM", 202, 241], ["key inflammatory signaling", "PROBLEM", 337, 363], ["viruses", "OBSERVATION", 13, 20], ["no", "UNCERTAINTY", 30, 32], ["critical", "OBSERVATION_MODIFIER", 148, 156], ["pathogenic", "OBSERVATION_MODIFIER", 157, 167], ["inflammatory", "OBSERVATION", 220, 232], ["inflammatory", "OBSERVATION_MODIFIER", 341, 353]]], ["However, a holistic approach to complete \"cure\" should probably involve investigations to provide support to both approaches simultaneously.", [["a holistic approach", "TREATMENT", 9, 28]]], ["Only ribavirin or the same combined with pegylated IFN-\u03b1 was the therapeutic strategy for controlling HCV infection, before the advent of high efficacy DAAs.", [["ribavirin", "CHEMICAL", 5, 14], ["pegylated IFN-\u03b1", "CHEMICAL", 41, 56], ["HCV infection", "DISEASE", 102, 115], ["ribavirin", "CHEMICAL", 5, 14], ["ribavirin", "SIMPLE_CHEMICAL", 5, 14], ["pegylated IFN-\u03b1", "SIMPLE_CHEMICAL", 41, 56], ["HCV", "ORGANISM", 102, 105], ["IFN", "PROTEIN", 51, 54], ["HCV", "SPECIES", 102, 105], ["ribavirin", "TREATMENT", 5, 14], ["pegylated IFN", "TREATMENT", 41, 54], ["the therapeutic strategy", "TREATMENT", 61, 85], ["controlling HCV infection", "PROBLEM", 90, 115], ["high efficacy DAAs", "PROBLEM", 138, 156], ["ribavirin", "OBSERVATION", 5, 14]]], ["Similarly IFN-\u03bb and glucocorticoids, both of which can consolidate the BBB, have been suggested as therapeutics for combating viral diseases that disrupt this barrier (Rhen and Cidlowski 2005; Daniels et al. 2014; Lazear et al. 2015; Wang et al. 2004; Blecharz et al. 2010; Fabene et al. 2008) .", [["BBB", "ANATOMY", 71, 74], ["viral diseases", "DISEASE", 126, 140], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 10, 15], ["glucocorticoids", "SIMPLE_CHEMICAL", 20, 35], ["BBB", "MULTI-TISSUE_STRUCTURE", 71, 74], ["IFN", "PROTEIN", 10, 13], ["glucocorticoids", "TREATMENT", 20, 35], ["viral diseases", "PROBLEM", 126, 140]]], ["Likewise, administration of PICs like CCL7 and IL17A has shown efficacy in increasing survival of mice experimentally infected with WNV ( Bardina et al. 2015; Acharya et al. 2016) .", [["IL17A", "CHEMICAL", 47, 52], ["CCL7", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL17A", "GENE_OR_GENE_PRODUCT", 47, 52], ["mice", "ORGANISM", 98, 102], ["WNV", "ORGANISM", 132, 135], ["PICs", "PROTEIN", 28, 32], ["CCL7", "PROTEIN", 38, 42], ["IL17A", "PROTEIN", 47, 52], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["WNV", "SPECIES", 132, 135], ["PICs like CCL7", "TREATMENT", 28, 42], ["increasing", "OBSERVATION_MODIFIER", 75, 85], ["survival", "OBSERVATION_MODIFIER", 86, 94]]], ["In dengue patients, however, meddling with either promoter or inhibitor of inflammation has been suggested as possible approaches (Tsai et al. 2013; Goh et al. 2014; Callaway et al. 2015; Ji et al. 2005; Dinarello 2011) .", [["dengue", "DISEASE", 3, 9], ["inflammation", "DISEASE", 75, 87], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["inflammation", "PROBLEM", 75, 87]]], ["Small molecules that can influence the function of the NLRP3 inflammosome have also been projected as potential therapies for CHIKV and can be tested against dengue as well (Chen et al. 2017; Coll et al. 2015; Hottz et al. 2013) .", [["CHIKV", "DISEASE", 126, 131], ["dengue", "DISEASE", 158, 164], ["NLRP3", "GENE_OR_GENE_PRODUCT", 55, 60], ["CHIKV", "ORGANISM", 126, 131], ["NLRP3 inflammosome", "PROTEIN", 55, 73], ["CHIKV", "SPECIES", 126, 131], ["dengue", "SPECIES", 158, 164], ["Small molecules", "PROBLEM", 0, 15], ["the NLRP3 inflammosome", "TREATMENT", 51, 73], ["CHIKV", "PROBLEM", 126, 131], ["dengue", "PROBLEM", 158, 164], ["molecules", "OBSERVATION", 6, 15]]], ["Alternative approaches using pharmaceuticals that indirectly mitigate the pathological effect without interfering with inflammation have also been discussed (Olmo et al. 2017; Grip and Janciauskiene 2009; Reynolds and Miller 1989; Thomas and Grossberg 2009; Giguere and Tremblay 2004; Raemer et al. 2009 ).Concluding RemarksAn ability to suppress innate immunity pathways is common among viruses that cause severe human diseases.", [["inflammation", "DISEASE", 119, 131], ["human", "ORGANISM", 414, 419], ["human", "SPECIES", 414, 419], ["human", "SPECIES", 414, 419], ["Alternative approaches", "TREATMENT", 0, 22], ["pharmaceuticals", "TREATMENT", 29, 44], ["inflammation", "PROBLEM", 119, 131], ["severe human diseases", "PROBLEM", 407, 428]]], ["Nonetheless modulating inflammation needs extreme caution, in order to reduce potential cytotoxicity of the administered therapeutic.", [["inflammation", "DISEASE", 23, 35], ["modulating inflammation", "PROBLEM", 12, 35], ["extreme caution", "TREATMENT", 42, 57], ["potential cytotoxicity", "PROBLEM", 78, 100], ["inflammation", "OBSERVATION", 23, 35]]], ["Therefore, there is a need to go beyond association studies to generate a clearer picture of the exact role that inflammation plays in viral pathology, which can then assist in developing therapeutic strategies that tinker with inflammation.Conflict of InterestThe author declares that they have no competing interests.", [["inflammation", "DISEASE", 113, 125], ["inflammation", "DISEASE", 228, 240], ["association studies", "TEST", 40, 59], ["inflammation", "PROBLEM", 113, 125], ["viral pathology", "PROBLEM", 135, 150], ["inflammation", "PROBLEM", 228, 240], ["inflammation", "OBSERVATION", 113, 125], ["inflammation", "OBSERVATION", 228, 240]]]], "PMC7162626": [["Proposed risk stratifications8bib8bibr,9bib9bibr ::: Introduction", [["8bib8bibr,9bib9bibr", "PROTEIN", 29, 48]]]], "c75a464797d5838ef56491dc33ceb913d8fd49c8": [["IntroductionThe increasing incidence of infection caused by the rapid development of microbial resistance to most of the known antibiotics is a serious health problem.", [["infection", "DISEASE", 40, 49], ["infection", "PROBLEM", 40, 49], ["microbial resistance", "PROBLEM", 85, 105], ["the known antibiotics", "TREATMENT", 117, 138], ["a serious health problem", "PROBLEM", 142, 166], ["increasing", "OBSERVATION_MODIFIER", 16, 26], ["incidence", "OBSERVATION_MODIFIER", 27, 36], ["infection", "OBSERVATION", 40, 49], ["rapid", "OBSERVATION_MODIFIER", 64, 69], ["microbial resistance", "OBSERVATION", 85, 105]]], ["There are a number of factors responsible for mutations in the microbial genomes.", [["microbial genomes", "DNA", 63, 80], ["mutations", "PROBLEM", 46, 55], ["microbial genomes", "OBSERVATION", 63, 80]]], ["As multidrugresistant microbial strains proliferate, the necessity for effective therapy has stimulated research on the design and synthesis of novel antimicrobial molecules [1] .IntroductionIn spite of nearly three decades of intensive research toward the treatment and eradication of HIV/AIDS, the disease remains a global health problem.", [["HIV/AIDS", "DISEASE", 286, 294], ["HIV", "ORGANISM", 286, 289], ["HIV", "SPECIES", 286, 289], ["HIV", "SPECIES", 286, 289], ["multidrugresistant microbial strains proliferate", "PROBLEM", 3, 51], ["effective therapy", "TREATMENT", 71, 88], ["synthesis of novel antimicrobial molecules", "TREATMENT", 131, 173], ["intensive research", "TREATMENT", 227, 245], ["the treatment", "TREATMENT", 253, 266], ["eradication", "TREATMENT", 271, 282], ["HIV", "PROBLEM", 286, 289], ["AIDS", "PROBLEM", 290, 294], ["the disease", "PROBLEM", 296, 307], ["a global health problem", "PROBLEM", 316, 339]]], ["The advent of highly active antiretroviral therapy (HAART) in the mid 1990s, which employed various combinations of reverse transcriptase and protease inhibitors, led to marked improvements of clinical outcomes.", [["reverse transcriptase", "PROTEIN", 116, 137], ["highly active antiretroviral therapy", "TREATMENT", 14, 50], ["HAART", "TREATMENT", 52, 57], ["reverse transcriptase and protease inhibitors", "TREATMENT", 116, 161], ["active", "OBSERVATION_MODIFIER", 21, 27], ["antiretroviral therapy", "OBSERVATION", 28, 50], ["marked", "OBSERVATION_MODIFIER", 170, 176], ["improvements", "OBSERVATION_MODIFIER", 177, 189]]], ["While the diversity of drugs now available to the clinician has substantially improved HIV treatment, still significant challenges remain.", [["HIV", "SPECIES", 87, 90], ["drugs", "TREATMENT", 23, 28], ["HIV treatment", "TREATMENT", 87, 100], ["improved", "OBSERVATION_MODIFIER", 78, 86], ["HIV", "OBSERVATION", 87, 90], ["significant", "OBSERVATION_MODIFIER", 108, 119], ["challenges", "OBSERVATION", 120, 130]]], ["Of particular concern are long-term treatment side effects and the emergence of drugresistant viral strains [2] .IntroductionThe heterocyclic molecule, benzimidazole, is isosteric with indole and purine nuclei, which are present in a number of fundamental cellular components and bioactive compounds which makes the benzimidazole molecule endowed with a variety of biological properties [3] .", [["nuclei", "ANATOMY", 203, 209], ["cellular", "ANATOMY", 256, 264], ["benzimidazole", "CHEMICAL", 152, 165], ["indole", "CHEMICAL", 185, 191], ["purine", "CHEMICAL", 196, 202], ["benzimidazole", "CHEMICAL", 152, 165], ["indole", "CHEMICAL", 185, 191], ["purine", "CHEMICAL", 196, 202], ["benzimidazole", "CHEMICAL", 316, 329], ["benzimidazole", "SIMPLE_CHEMICAL", 152, 165], ["indole", "SIMPLE_CHEMICAL", 185, 191], ["purine nuclei", "SIMPLE_CHEMICAL", 196, 209], ["cellular", "CELL", 256, 264], ["long-term treatment side effects", "TREATMENT", 26, 58], ["drugresistant viral strains", "PROBLEM", 80, 107], ["The heterocyclic molecule", "TREATMENT", 125, 150], ["benzimidazole", "TREATMENT", 152, 165], ["isosteric with indole and purine nuclei", "TREATMENT", 170, 209], ["bioactive compounds", "TREATMENT", 280, 299], ["the benzimidazole molecule", "TREATMENT", 312, 338], ["long-term", "OBSERVATION_MODIFIER", 26, 35], ["heterocyclic molecule", "OBSERVATION", 129, 150], ["purine nuclei", "OBSERVATION", 196, 209], ["fundamental", "OBSERVATION_MODIFIER", 244, 255], ["cellular components", "OBSERVATION", 256, 275], ["bioactive compounds", "OBSERVATION", 280, 299]]], ["The study of recent literature reveals that benzimidazole is reported to have number of biological activities viz. antiviral [4] , antifungal [5] , antihelmintic [6] , antiprotozoal [7] , psychotropic [8] , anti-HIV [9] , antitumor [10] , antioxidant [11] and anticoagulant [12] activities.IntroductionIndeed, a number of important drugs used in different therapeutic areas contain the benzimidazole ring, as proton pump inhibitors (omeprazole), antihypertensives (candesartan, telmisartan), antihistaminics (astemizole), antihelmintics (albendazole, mebendazole), as well as several other kinds of still investigational therapeutic agents, including antitumorals and antivirals [1] .IntroductionQSAR refers to a discipline in computational chemistry that addresses the modeling of biological activities or chemical reactivity based on the quantitative description for the chemical structure of molecules.", [["antitumor", "ANATOMY", 222, 231], ["benzimidazole", "CHEMICAL", 44, 57], ["omeprazole", "CHEMICAL", 433, 443], ["candesartan", "CHEMICAL", 465, 476], ["telmisartan", "CHEMICAL", 478, 489], ["astemizole", "CHEMICAL", 509, 519], ["antihelmintics", "CHEMICAL", 522, 536], ["albendazole", "CHEMICAL", 538, 549], ["mebendazole", "CHEMICAL", 551, 562], ["benzimidazole", "CHEMICAL", 44, 57], ["benzimidazole", "CHEMICAL", 386, 399], ["omeprazole", "CHEMICAL", 433, 443], ["candesartan", "CHEMICAL", 465, 476], ["telmisartan", "CHEMICAL", 478, 489], ["antihistaminics", "CHEMICAL", 492, 507], ["astemizole", "CHEMICAL", 509, 519], ["albendazole", "CHEMICAL", 538, 549], ["mebendazole", "CHEMICAL", 551, 562], ["benzimidazole", "SIMPLE_CHEMICAL", 44, 57], ["antifungal [5]", "SIMPLE_CHEMICAL", 131, 145], ["antihelmintic [6]", "SIMPLE_CHEMICAL", 148, 165], ["antiprotozoal [7]", "SIMPLE_CHEMICAL", 168, 185], ["psychotropic [8]", "SIMPLE_CHEMICAL", 188, 204], ["anti-", "SIMPLE_CHEMICAL", 207, 212], ["HIV", "ORGANISM", 212, 215], ["antitumor", "CANCER", 222, 231], ["[10]", "SIMPLE_CHEMICAL", 232, 236], ["antioxidant [11]", "SIMPLE_CHEMICAL", 239, 255], ["anticoagulant [12]", "SIMPLE_CHEMICAL", 260, 278], ["benzimidazole ring", "SIMPLE_CHEMICAL", 386, 404], ["proton pump inhibitors", "SIMPLE_CHEMICAL", 409, 431], ["omeprazole", "SIMPLE_CHEMICAL", 433, 443], ["antihypertensives", "SIMPLE_CHEMICAL", 446, 463], ["candesartan", "SIMPLE_CHEMICAL", 465, 476], ["telmisartan", "SIMPLE_CHEMICAL", 478, 489], ["antihistaminics", "SIMPLE_CHEMICAL", 492, 507], ["astemizole", "SIMPLE_CHEMICAL", 509, 519], ["antihelmintics", "SIMPLE_CHEMICAL", 522, 536], ["albendazole", "SIMPLE_CHEMICAL", 538, 549], ["mebendazole", "SIMPLE_CHEMICAL", 551, 562], ["antitumorals", "SIMPLE_CHEMICAL", 651, 663], ["HIV", "SPECIES", 212, 215], ["HIV", "SPECIES", 212, 215], ["The study", "TEST", 0, 9], ["benzimidazole", "TREATMENT", 44, 57], ["antiviral [", "TREATMENT", 115, 126], ["antifungal", "TREATMENT", 131, 141], ["antihelmintic", "TREATMENT", 148, 161], ["antiprotozoal", "TREATMENT", 168, 181], ["psychotropic", "TREATMENT", 188, 200], ["anti-HIV", "TREATMENT", 207, 215], ["antitumor", "TREATMENT", 222, 231], ["antioxidant", "TREATMENT", 239, 250], ["anticoagulant", "TREATMENT", 260, 273], ["important drugs", "TREATMENT", 322, 337], ["the benzimidazole ring", "TREATMENT", 382, 404], ["proton pump inhibitors", "TREATMENT", 409, 431], ["omeprazole)", "TREATMENT", 433, 444], ["antihypertensives", "TREATMENT", 446, 463], ["candesartan", "TREATMENT", 465, 476], ["telmisartan", "TREATMENT", 478, 489], ["antihistaminics (astemizole)", "TREATMENT", 492, 520], ["antihelmintics", "TREATMENT", 522, 536], ["albendazole", "TREATMENT", 538, 549], ["mebendazole", "TREATMENT", 551, 562], ["still investigational therapeutic agents", "TREATMENT", 599, 639], ["antitumorals", "TREATMENT", 651, 663], ["antivirals", "TREATMENT", 668, 678], ["benzimidazole ring", "OBSERVATION", 386, 404]]], ["Quantitative structureeactivity relationship (QSAR) is one of the most important areas in chemometrics, and is a valuable tool that is used extensively in drug design and medicinal chemistry.", [["medicinal chemistry", "TEST", 171, 190]]], ["Once a reliable QSAR model is established, we can predict the activities of molecules, and know which structural features play an important role in biological processes [14] .IntroductionBearing these results in mind and in continuation of our research efforts in searching novel antiviral agents [15, 16] , we hereby present the synthesis, antimicrobial and antiviral activity and QSAR modeling of 4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids.ChemistryThe synthesis of compounds 1-20 followed the general pathway elicited in Scheme 1.", [["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 399, 479], ["compounds 1-20", "CHEMICAL", 506, 520], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 399, 479], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "SIMPLE_CHEMICAL", 399, 479], ["compounds 1-20", "SIMPLE_CHEMICAL", 506, 520], ["novel antiviral agents", "TREATMENT", 274, 296], ["the synthesis", "TREATMENT", 326, 339], ["antimicrobial", "TREATMENT", 341, 354], ["antiviral activity", "TREATMENT", 359, 377], ["QSAR modeling", "TEST", 382, 395], ["substituted aryl/alkyl carbonyl)", "TREATMENT", 405, 437], ["benzoimidazol", "TREATMENT", 438, 451], ["benzenesulfonic acids", "TREATMENT", 458, 479], ["Chemistry", "TEST", 480, 489], ["The synthesis of compounds", "TEST", 489, 515]]], ["The key intermediate, 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid was prepared by the condensation of benzimidazole with aryldiazonium chloride of 4-amino-benzenesulfonic acid, which in turn prepared by the diazotization of 4-aminobenzenesulfonic acid [17] .", [["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 22, 68], ["benzimidazole", "CHEMICAL", 105, 118], ["aryldiazonium chloride", "CHEMICAL", 124, 146], ["4-amino-benzenesulfonic acid", "CHEMICAL", 150, 178], ["4-aminobenzenesulfonic acid", "CHEMICAL", 227, 254], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 22, 68], ["benzimidazole", "CHEMICAL", 105, 118], ["aryldiazonium chloride", "CHEMICAL", 124, 146], ["4-amino-benzenesulfonic acid", "CHEMICAL", 150, 178], ["4-aminobenzenesulfonic acid", "CHEMICAL", 227, 254], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 22, 68], ["benzimidazole", "SIMPLE_CHEMICAL", 105, 118], ["aryldiazonium chloride", "SIMPLE_CHEMICAL", 124, 146], ["4-amino-benzenesulfonic acid", "SIMPLE_CHEMICAL", 150, 178], ["4-aminobenzenesulfonic acid", "SIMPLE_CHEMICAL", 227, 254], ["benzoimidazol", "TREATMENT", 28, 41], ["benzenesulfonic acid", "TREATMENT", 48, 68], ["benzimidazole", "TREATMENT", 105, 118], ["aryldiazonium chloride", "TREATMENT", 124, 146], ["amino-benzenesulfonic acid", "TREATMENT", 152, 178]]], ["However, based on our experience, the application of the cupric chloride for the condensation of aryldiazonium chloride with benzimidazole as suggested by Dahiya and Pathak [18] resulted in resinous (sticky) products.", [["cupric chloride", "CHEMICAL", 57, 72], ["aryldiazonium chloride", "CHEMICAL", 97, 119], ["benzimidazole", "CHEMICAL", 125, 138], ["Dahiya", "CHEMICAL", 155, 161], ["cupric chloride", "CHEMICAL", 57, 72], ["aryldiazonium chloride", "CHEMICAL", 97, 119], ["benzimidazole", "CHEMICAL", 125, 138], ["cupric chloride", "SIMPLE_CHEMICAL", 57, 72], ["aryldiazonium chloride", "SIMPLE_CHEMICAL", 97, 119], ["benzimidazole", "SIMPLE_CHEMICAL", 125, 138], ["Dahiya", "SIMPLE_CHEMICAL", 155, 161], ["Pathak [18]", "SIMPLE_CHEMICAL", 166, 177], ["the cupric chloride", "TREATMENT", 53, 72], ["the condensation of aryldiazonium chloride", "TREATMENT", 77, 119], ["benzimidazole", "TREATMENT", 125, 138], ["resinous (sticky) products", "TREATMENT", 190, 216]]], ["Therefore, the coupling was carried out by using sodium acetate along with stirring at cold conditions for the initial 3 h followed by 48 h stirring at room temperature which resulted in a solid product.", [["sodium acetate", "CHEMICAL", 49, 63], ["sodium acetate", "CHEMICAL", 49, 63], ["sodium acetate", "SIMPLE_CHEMICAL", 49, 63], ["sodium acetate", "TREATMENT", 49, 63]]], ["For the synthesis of 4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids, the key intermediates 4-(1H-benzoimidazol-2-yl)benzenesulfonic acid has been reacted with corresponding aryl/alkyl acid chlorides which were formed by the reaction of corresponding aryl/alkyl acids with thionyl chloride.", [["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 21, 101], ["4-(1H-benzoimidazol-2-yl)benzenesulfonic acid", "CHEMICAL", 125, 170], ["aryl/alkyl acid chlorides", "CHEMICAL", 207, 232], ["aryl/alkyl acids", "CHEMICAL", 284, 300], ["thionyl chloride", "CHEMICAL", 306, 322], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 21, 101], ["4-(1H-benzoimidazol-2-yl)benzenesulfonic acid", "CHEMICAL", 125, 170], ["aryl/alkyl acid chlorides", "CHEMICAL", 207, 232], ["aryl/alkyl acids", "CHEMICAL", 284, 300], ["thionyl chloride", "CHEMICAL", 306, 322], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "SIMPLE_CHEMICAL", 21, 101], ["4-(1H-benzoimidazol-2-yl)benzenesulfonic acid", "SIMPLE_CHEMICAL", 125, 170], ["aryl/alkyl acid chlorides", "SIMPLE_CHEMICAL", 207, 232], ["aryl/alkyl acids", "SIMPLE_CHEMICAL", 284, 300], ["thionyl chloride", "SIMPLE_CHEMICAL", 306, 322], ["the synthesis", "TEST", 4, 17], ["substituted aryl/alkyl carbonyl)", "TREATMENT", 27, 59], ["benzoimidazol", "TREATMENT", 60, 73], ["benzenesulfonic acids", "TREATMENT", 80, 101], ["benzoimidazol", "TREATMENT", 131, 144], ["benzenesulfonic acid", "TREATMENT", 150, 170], ["corresponding aryl/alkyl acid chlorides", "TREATMENT", 193, 232], ["corresponding aryl/alkyl acids", "TREATMENT", 270, 300], ["thionyl chloride", "TREATMENT", 306, 322]]], ["It is important to note here that the yield of most of the synthesized benzimidazoles were below 50%.", [["benzimidazoles", "CHEMICAL", 71, 85], ["benzimidazoles", "CHEMICAL", 71, 85], ["benzimidazoles", "SIMPLE_CHEMICAL", 71, 85], ["the synthesized benzimidazoles", "TREATMENT", 55, 85]]], ["The low yield of synthetic compounds may be attributed to any one or more of the following reasons [17] : a).", [["synthetic compounds", "TREATMENT", 17, 36], ["low yield", "OBSERVATION_MODIFIER", 4, 13]]], ["The reaction may be reversible and position of equilibrium is unfavorable to the product; b).", [["The reaction", "PROBLEM", 0, 12], ["may be", "UNCERTAINTY", 13, 19], ["reversible", "OBSERVATION_MODIFIER", 20, 30]]], ["The incursion of side reactions leading to the formation of by-products; c).", [["side reactions", "PROBLEM", 17, 31]]], ["The premature work-up of the reaction before its completion; d).", [["the reaction", "PROBLEM", 25, 37]]], ["The volatilization of products during reaction or work-up; e).", [["The volatilization of products", "TREATMENT", 0, 30]]], ["The loss of product due to incomplete extraction, inefficient crystallization or other work-up procedures; f).", [["The loss of product", "PROBLEM", 0, 19], ["incomplete extraction", "TREATMENT", 27, 48], ["inefficient crystallization", "TREATMENT", 50, 77]]], ["The presence of contaminants in the reactants or reagents leading to a less efficient reaction.", [["contaminants in the reactants", "PROBLEM", 16, 45], ["a less efficient reaction", "PROBLEM", 69, 94], ["contaminants", "OBSERVATION", 16, 28]]], ["The physicochemical characteristics of the synthesized compounds are presented in Table 1 .ChemistryThe structures of compounds 1-20 were assigned by IR and 1 H NMR spectroscopic data, which are consistent with the proposed molecular structures.", [["compounds 1-20", "CHEMICAL", 118, 132], ["1 H", "CHEMICAL", 157, 160], ["compounds 1-20", "SIMPLE_CHEMICAL", 118, 132], ["the synthesized compounds", "PROBLEM", 39, 64], ["Chemistry", "TEST", 91, 100], ["1 H NMR spectroscopic data", "TEST", 157, 183], ["synthesized compounds", "OBSERVATION", 43, 64], ["consistent with", "UNCERTAINTY", 195, 210]]], ["The primary amino group in compound 1 is depicted by the presence of NH asymmetric stretch at 3481.81 cm \u00c01 .", [["NH", "CHEMICAL", 69, 71], ["amino", "CHEMICAL", 12, 17], ["NH", "CHEMICAL", 69, 71], ["amino", "AMINO_ACID", 12, 17], ["NH asymmetric stretch", "PROBLEM", 69, 90], ["amino group", "OBSERVATION", 12, 23], ["asymmetric", "OBSERVATION_MODIFIER", 72, 82], ["stretch", "OBSERVATION_MODIFIER", 83, 90]]], ["The IR bending vibration corresponding to OCH 3 of compound 8 appeared at 1425.61 cm \u00c01 .", [["OCH 3", "CHEMICAL", 42, 47], ["The IR bending vibration", "TEST", 0, 24]]], ["The presence of heterocyclic pyridine moiety in compound 15 is demonstrated by the presence of CH out of plane bending at 829.04 cm \u00c01 .", [["heterocyclic pyridine", "CHEMICAL", 16, 37], ["pyridine", "CHEMICAL", 29, 37], ["CH", "CHEMICAL", 95, 97], ["heterocyclic pyridine moiety", "SIMPLE_CHEMICAL", 16, 44], ["heterocyclic pyridine moiety", "TREATMENT", 16, 44], ["heterocyclic", "OBSERVATION", 16, 28], ["pyridine moiety", "OBSERVATION", 29, 44]]], ["The presence of an additional SeN stretch at 808.61 cm \u00c01 apart from the SO 3 asymmetric stretch in the region of 1260e1150 cm \u00c01 indicated that compound 20 contains a link between SO 2 and N 1 of benzimidazole.", [["SO 2 and N 1 of benzimidazole", "CHEMICAL", 181, 210], ["SeN", "CHEMICAL", 30, 33], ["SO 3", "CHEMICAL", 73, 77], ["SO 2", "CHEMICAL", 181, 185], ["N", "CHEMICAL", 190, 191], ["benzimidazole", "CHEMICAL", 197, 210], ["SO 2", "SIMPLE_CHEMICAL", 181, 185], ["N 1 of benzimidazole", "SIMPLE_CHEMICAL", 190, 210], ["benzimidazole", "TREATMENT", 197, 210], ["stretch", "OBSERVATION_MODIFIER", 34, 41], ["asymmetric", "OBSERVATION_MODIFIER", 78, 88], ["stretch", "OBSERVATION", 89, 96], ["region", "ANATOMY_MODIFIER", 104, 110]]], ["The appearance of C]O stretch in the range of 1630e1600 cm \u00c01 indicated the formation of tertiary amides (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) by the reaction of acid chlorides with the 4-(1H-benzoimidazol-2yl)-benzenesulfonic acid.", [["acid chlorides", "CHEMICAL", 215, 229], ["4-(1H-benzoimidazol-2yl)-benzenesulfonic acid", "CHEMICAL", 239, 284], ["C]O", "CHEMICAL", 18, 21], ["tertiary amides", "CHEMICAL", 89, 104], ["acid chlorides", "CHEMICAL", 215, 229], ["4-(1H-benzoimidazol-2yl)-benzenesulfonic acid", "CHEMICAL", 239, 284], ["tertiary amides (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20)", "SIMPLE_CHEMICAL", 89, 195], ["acid chlorides", "SIMPLE_CHEMICAL", 215, 229], ["4-(1H-benzoimidazol-2yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 239, 284], ["C]O stretch", "TEST", 18, 29], ["tertiary amides", "TEST", 89, 104], ["acid chlorides", "TREATMENT", 215, 229], ["benzoimidazol", "TREATMENT", 245, 258], ["benzenesulfonic acid", "PROBLEM", 264, 284], ["stretch", "OBSERVATION_MODIFIER", 22, 29]]], ["Formation of tertiary amide is further evidenced by the absence of IR bands at 1725e1700 cm \u00c01 and 1700e1680 cm \u00c01 corresponding to the alkyl and aryl acids, respectively.", [["alkyl", "CHEMICAL", 136, 141], ["aryl acids", "CHEMICAL", 146, 156], ["tertiary amide", "CHEMICAL", 13, 27], ["alkyl and aryl acids", "CHEMICAL", 136, 156], ["tertiary amide", "SIMPLE_CHEMICAL", 13, 27], ["alkyl", "SIMPLE_CHEMICAL", 136, 141], ["aryl acids", "SIMPLE_CHEMICAL", 146, 156], ["IR bands", "TEST", 67, 75], ["the alkyl and aryl acids", "TEST", 132, 156], ["tertiary amide", "OBSERVATION", 13, 27], ["alkyl", "ANATOMY_MODIFIER", 136, 141]]], ["The appearance of SO 3 asymmetric stretch in the region of 1260e1150 cm \u00c01 demonstrated the presence of SO 3 H group of benzenesulfonic acid attached to the 2nd position of benzimidazole.ChemistryThe appearance of singlet around 2.5 d ppm corresponds to the proton of SO 3 H in the NMR of all the compounds indicated the presence of para sulfonyl phenyl nucleus to the 2nd position of synthesized benzimidazoles (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .", [["SO 3 H", "CHEMICAL", 104, 110], ["benzenesulfonic acid", "CHEMICAL", 120, 140], ["benzimidazole", "CHEMICAL", 173, 186], ["SO 3 H", "CHEMICAL", 268, 274], ["para sulfonyl phenyl", "CHEMICAL", 333, 353], ["benzimidazoles", "CHEMICAL", 397, 411], ["SO 3", "CHEMICAL", 18, 22], ["SO 3 H", "CHEMICAL", 104, 110], ["benzenesulfonic acid", "CHEMICAL", 120, 140], ["benzimidazole", "CHEMICAL", 173, 186], ["SO 3 H", "CHEMICAL", 268, 274], ["para sulfonyl phenyl", "CHEMICAL", 333, 353], ["benzimidazoles", "CHEMICAL", 397, 411], ["SO 3 H", "SIMPLE_CHEMICAL", 104, 110], ["benzenesulfonic acid", "SIMPLE_CHEMICAL", 120, 140], ["benzimidazole", "SIMPLE_CHEMICAL", 173, 186], ["SO 3 H", "SIMPLE_CHEMICAL", 268, 274], ["para sulfonyl phenyl nucleus", "SIMPLE_CHEMICAL", 333, 361], ["benzimidazoles (11) (12) (13) (14) (15) (16) (17) (18) (19) (20)", "SIMPLE_CHEMICAL", 397, 461], ["benzenesulfonic acid", "TREATMENT", 120, 140], ["the 2nd position of benzimidazole", "TREATMENT", 153, 186], ["para sulfonyl phenyl nucleus", "PROBLEM", 333, 361], ["synthesized benzimidazoles", "TREATMENT", 385, 411], ["asymmetric", "OBSERVATION_MODIFIER", 23, 33], ["stretch", "OBSERVATION_MODIFIER", 34, 41], ["region", "ANATOMY_MODIFIER", 49, 55], ["singlet", "OBSERVATION_MODIFIER", 214, 221]]], ["Further the multiplet corresponds to 6 chloride of methacrylic acid.", [["6 chloride", "CHEMICAL", 37, 47], ["methacrylic acid", "CHEMICAL", 51, 67], ["chloride", "CHEMICAL", 39, 47], ["methacrylic acid", "CHEMICAL", 51, 67], ["6 chloride of methacrylic acid", "SIMPLE_CHEMICAL", 37, 67], ["6 chloride of methacrylic acid", "TREATMENT", 37, 67]]], ["Further the coupling constant value of 18 Hz in compound 14 indicated that the nature of the double bond in the synthesized compound 14 is of trans nature.", [["the coupling constant value", "TEST", 8, 35], ["double bond", "OBSERVATION", 93, 104]]], ["Compound 8 showed a singlet at d 3.78 ppm corresponding to a proton of the OCH 3 .", [["OCH 3", "CHEMICAL", 75, 80]]], ["This confirmed the attachment of the para methoxy benzoyl group to the N 1 position of benzimidazole.", [["methoxy benzoyl", "CHEMICAL", 42, 57], ["benzimidazole", "CHEMICAL", 87, 100], ["para methoxy benzoyl", "CHEMICAL", 37, 57], ["benzimidazole", "CHEMICAL", 87, 100], ["para methoxy benzoyl", "SIMPLE_CHEMICAL", 37, 57], ["benzimidazole", "SIMPLE_CHEMICAL", 87, 100], ["N 1 position", "PROTEIN", 71, 83], ["the para methoxy benzoyl group", "TREATMENT", 33, 63], ["the N 1 position of benzimidazole", "TREATMENT", 67, 100]]], ["The absence of a singlet at d 11 ppm in the NMR spectra of compounds 1-20 indicated the absence of the free COOH group.", [["compounds 1-20", "CHEMICAL", 59, 73], ["COOH", "CHEMICAL", 108, 112], ["COOH", "GENE_OR_GENE_PRODUCT", 108, 112], ["COOH group", "PROTEIN", 108, 118], ["a singlet at d 11 ppm", "TREATMENT", 15, 36], ["the NMR spectra of compounds", "TEST", 40, 68]]], ["This confirms that the compounds 1-20 are tertiary amides and not the physical mixture of aryl/alkyl acids and 4-(1Hbenzoimidazol-2-yl)-benzenesulfonic acid.", [["compounds 1-20", "CHEMICAL", 23, 37], ["aryl/alkyl acids", "CHEMICAL", 90, 106], ["4-(1Hbenzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 111, 156], ["tertiary amides", "CHEMICAL", 42, 57], ["aryl/alkyl acids", "CHEMICAL", 90, 106], ["4-(1Hbenzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 111, 156], ["1-20", "SIMPLE_CHEMICAL", 33, 37], ["tertiary amides", "SIMPLE_CHEMICAL", 42, 57], ["aryl/alkyl acids", "SIMPLE_CHEMICAL", 90, 106], ["4-(1Hbenzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 111, 156], ["the compounds", "TEST", 19, 32], ["tertiary amides", "TREATMENT", 42, 57], ["aryl/alkyl acids", "TREATMENT", 90, 106], ["1Hbenzoimidazol", "TEST", 114, 129], ["benzenesulfonic acid", "TREATMENT", 136, 156]]], ["Therefore, this assures the reaction of aryl/alkyl acid chlorides with the secondary nitrogen of the benzimidazole nucleus.Antimicrobial activityThe synthesized compounds were evaluated for their in vitro antimicrobial activities against two Gram-positive bacteria e Staphylococcus aureus, Bacillus subtilis; the Gram-negative bacterium e Escherichia coli and the fungal strains e Aspergillus niger and Candida albicans by tube dilution method [19] using ciprofloxacin and fluconazole as control drugs for antibacterial and antifungal activity, respectively.", [["tube", "ANATOMY", 423, 427], ["aryl/alkyl acid chlorides", "CHEMICAL", 40, 65], ["Staphylococcus aureus", "DISEASE", 267, 288], ["ciprofloxacin", "CHEMICAL", 455, 468], ["fluconazole", "CHEMICAL", 473, 484], ["aryl/alkyl acid chlorides", "CHEMICAL", 40, 65], ["nitrogen", "CHEMICAL", 85, 93], ["benzimidazole", "CHEMICAL", 101, 114], ["ciprofloxacin", "CHEMICAL", 455, 468], ["fluconazole", "CHEMICAL", 473, 484], ["aryl/alkyl acid chlorides", "SIMPLE_CHEMICAL", 40, 65], ["Gram", "GENE_OR_GENE_PRODUCT", 242, 246], ["Staphylococcus aureus", "ORGANISM", 267, 288], ["Bacillus subtilis", "ORGANISM", 290, 307], ["Escherichia coli", "ORGANISM", 339, 355], ["Aspergillus niger", "ORGANISM", 381, 398], ["Candida albicans", "ORGANISM", 403, 419], ["tube", "TISSUE", 423, 427], ["ciprofloxacin", "SIMPLE_CHEMICAL", 455, 468], ["fluconazole", "SIMPLE_CHEMICAL", 473, 484], ["Staphylococcus aureus", "SPECIES", 267, 288], ["Bacillus subtilis", "SPECIES", 290, 307], ["Escherichia coli", "SPECIES", 339, 355], ["Aspergillus niger", "SPECIES", 381, 398], ["Candida albicans", "SPECIES", 403, 419], ["Staphylococcus aureus", "SPECIES", 267, 288], ["Bacillus subtilis", "SPECIES", 290, 307], ["Escherichia coli", "SPECIES", 339, 355], ["Aspergillus niger", "SPECIES", 381, 398], ["Candida albicans", "SPECIES", 403, 419], ["aryl/alkyl acid chlorides", "TREATMENT", 40, 65], ["the secondary nitrogen of the benzimidazole nucleus", "TREATMENT", 71, 122], ["Antimicrobial activity", "TREATMENT", 123, 145], ["two Gram", "TEST", 238, 246], ["positive bacteria e Staphylococcus aureus", "PROBLEM", 247, 288], ["Bacillus subtilis", "PROBLEM", 290, 307], ["the Gram-negative bacterium e Escherichia coli", "PROBLEM", 309, 355], ["the fungal strains", "TEST", 360, 378], ["e Aspergillus niger", "TREATMENT", 379, 398], ["Candida albicans", "TREATMENT", 403, 419], ["tube dilution method", "TREATMENT", 423, 443], ["ciprofloxacin", "TREATMENT", 455, 468], ["fluconazole", "TREATMENT", 473, 484], ["drugs", "TREATMENT", 496, 501], ["antibacterial and antifungal activity", "TREATMENT", 506, 543], ["benzimidazole nucleus", "OBSERVATION", 101, 122], ["positive bacteria", "OBSERVATION_MODIFIER", 247, 264], ["Staphylococcus aureus", "OBSERVATION", 267, 288], ["Escherichia coli", "OBSERVATION", 339, 355]]], ["The results of the antimicrobial studies are presented in Table 2 .", [["the antimicrobial studies", "TEST", 15, 40]]], ["In general the compounds showed an improved antibacterial activity when compared to their antifungal activity.", [["improved", "OBSERVATION_MODIFIER", 35, 43], ["antibacterial activity", "OBSERVATION", 44, 66]]], ["The deduced patterns of antimicrobial activity of the synthesized benzimidazoles are in the following order: Antibacterial activity > antifungal activity.Antimicrobial activityThe compound 9 is the most effective compound against S. aureus with pMICsa value of 2.43 (Table 2) , respectively.", [["benzimidazoles", "CHEMICAL", 66, 80], ["compound 9", "CHEMICAL", 180, 190], ["benzimidazoles", "CHEMICAL", 66, 80], ["benzimidazoles", "SIMPLE_CHEMICAL", 66, 80], ["S. aureus", "ORGANISM", 230, 239], ["S. aureus", "SPECIES", 230, 239], ["S. aureus", "SPECIES", 230, 239], ["the synthesized benzimidazoles", "TREATMENT", 50, 80], ["Antibacterial activity", "TREATMENT", 109, 131], ["Antimicrobial activity", "TREATMENT", 154, 176], ["S. aureus", "PROBLEM", 230, 239], ["pMICsa value", "TEST", 245, 257], ["antimicrobial activity", "OBSERVATION", 24, 46], ["most effective", "OBSERVATION_MODIFIER", 198, 212], ["aureus", "OBSERVATION", 233, 239]]], ["For activity against B. subtilis the compounds 7 and 9 yielded better activity ( (Table 2) respectively.", [["B. subtilis", "ORGANISM", 21, 32], ["B. subtilis", "SPECIES", 21, 32], ["B. subtilis", "SPECIES", 21, 32]]], ["From the above discussion it is evident that compound 9 emerged as the most active antibacterial benzimidazole.", [["compound 9", "CHEMICAL", 45, 55], ["benzimidazole", "CHEMICAL", 97, 110], ["benzimidazole", "CHEMICAL", 97, 110], ["antibacterial benzimidazole", "SIMPLE_CHEMICAL", 83, 110], ["the most active antibacterial benzimidazole", "TREATMENT", 67, 110], ["antibacterial benzimidazole", "OBSERVATION", 83, 110]]], ["Compounds 9 and 18 emerged as the most effective antifungal agents against C. albicans whereas compound 18 was most active against A. niger (Table 2 ).", [["Compounds 9 and 18", "CHEMICAL", 0, 18], ["compound 18", "CHEMICAL", 95, 106], ["C. albicans", "ORGANISM", 75, 86], ["A. niger", "ORGANISM", 131, 139], ["C. albicans", "SPECIES", 75, 86], ["A. niger", "SPECIES", 131, 139], ["C. albicans", "SPECIES", 75, 86], ["A. niger", "SPECIES", 131, 139], ["antifungal agents", "TREATMENT", 49, 66], ["C. albicans", "PROBLEM", 75, 86]]], ["From the above discussion it is evident that compound 18 emerged as the most effective antifungal benzimidazole.Antimicrobial activityThe minimum bactericidal concentration/minimum fungicidal concentration (MBC/MFC) ( Table 3 ) determination results revealed that the synthesized compounds were fungistatic against both fungi and bacteriostatic against S. aureus, B. subtilis but bacteriocidal against E. coli.", [["benzimidazole", "CHEMICAL", 98, 111], ["MBC", "CHEMICAL", 207, 210], ["benzimidazole", "CHEMICAL", 98, 111], ["antifungal benzimidazole", "SIMPLE_CHEMICAL", 87, 111], ["S. aureus", "ORGANISM", 353, 362], ["B. subtilis", "ORGANISM", 364, 375], ["E. coli", "ORGANISM", 402, 409], ["S. aureus", "SPECIES", 353, 362], ["B. subtilis", "SPECIES", 364, 375], ["E. coli", "SPECIES", 402, 409], ["S. aureus", "SPECIES", 353, 362], ["B. subtilis", "SPECIES", 364, 375], ["E. coli", "SPECIES", 402, 409], ["the most effective antifungal benzimidazole", "TREATMENT", 68, 111], ["Antimicrobial activity", "TREATMENT", 112, 134], ["The minimum bactericidal concentration", "TREATMENT", 134, 172], ["minimum fungicidal concentration", "TEST", 173, 205], ["MBC/MFC", "TEST", 207, 214], ["the synthesized compounds", "PROBLEM", 264, 289], ["fungistatic", "PROBLEM", 295, 306], ["both fungi", "PROBLEM", 315, 325], ["S. aureus", "PROBLEM", 353, 362], ["B. subtilis", "PROBLEM", 364, 375], ["bacteriocidal", "PROBLEM", 380, 393], ["E. coli", "PROBLEM", 402, 409], ["aureus", "OBSERVATION", 356, 362], ["coli", "OBSERVATION", 405, 409]]], ["In general, the MBC and MFC of synthesized benzimidazole derivatives were 3-fold higher than their MIC values, which indicated that they were bacteriostatic and fungistatic in action except for E. coli (a drug is considered to be bacteriosatic/fungistatic when its MBC and MFC values are 3-fold higher than its MIC values) [20] .", [["MBC", "CHEMICAL", 16, 19], ["benzimidazole", "CHEMICAL", 43, 56], ["MBC", "CHEMICAL", 265, 268], ["benzimidazole", "CHEMICAL", 43, 56], ["MBC", "SIMPLE_CHEMICAL", 16, 19], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 43, 68], ["E. coli", "ORGANISM", 194, 201], ["MBC", "SIMPLE_CHEMICAL", 265, 268], ["E. coli", "SPECIES", 194, 201], ["E. coli", "SPECIES", 194, 201], ["the MBC", "TEST", 12, 19], ["synthesized benzimidazole derivatives", "TREATMENT", 31, 68], ["their MIC values", "TEST", 93, 109], ["bacteriostatic", "PROBLEM", 142, 156], ["fungistatic", "PROBLEM", 161, 172], ["E. coli", "PROBLEM", 194, 201], ["bacteriosatic", "PROBLEM", 230, 243], ["fungistatic", "PROBLEM", 244, 255], ["its MBC", "TEST", 261, 268], ["MFC values", "TEST", 273, 283], ["bacteriostatic", "OBSERVATION_MODIFIER", 142, 156]]], ["In the case of S. aureus compounds 10 and 17 and for Bacillus subtitlis compounds 11 and 17 were found to be active bacteriocidal agents.Development of one-target QSAR modelIn order to understand the experimental antimicrobial data on a theoretical basis, we established a quantitative structure activity relationship (QSAR) between the in vitro antimicrobial activity of synthesized benzimidazole derivatives and descriptors coding for lipophilic, electronic, steric and topological properties of the molecules under consideration using the linear free energy relationship model (LFER) described by Hansch and Fujita [21] .", [["benzimidazole", "CHEMICAL", 384, 397], ["benzimidazole", "CHEMICAL", 384, 397], ["S. aureus", "ORGANISM", 15, 24], ["Bacillus subtitlis", "ORGANISM", 53, 71], ["bacteriocidal agents", "SIMPLE_CHEMICAL", 116, 136], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 384, 409], ["S. aureus", "SPECIES", 15, 24], ["Bacillus subtitlis", "SPECIES", 53, 71], ["S. aureus", "SPECIES", 15, 24], ["Bacillus subtitlis", "SPECIES", 53, 71], ["S. aureus compounds", "PROBLEM", 15, 34], ["Bacillus subtitlis compounds", "TEST", 53, 81], ["active bacteriocidal agents", "TREATMENT", 109, 136], ["the in vitro antimicrobial activity", "TREATMENT", 333, 368], ["synthesized benzimidazole derivatives", "TREATMENT", 372, 409], ["lipophilic, electronic, steric and topological properties", "PROBLEM", 437, 494], ["aureus", "OBSERVATION", 18, 24], ["active", "OBSERVATION", 109, 115]]], ["Biological activity data determined as MIC values were first transformed into pMIC values and used as dependent variables in a QSAR study.", [["Biological activity data", "TEST", 0, 24], ["MIC values", "TEST", 39, 49], ["a QSAR study", "TEST", 125, 137]]], ["The different molecular descriptors (independent variables) like log of octanol-water partition coefficient (log P), molar refractivity (MR), Kier's molecular connectivity ( 0 c, 0 c v , 1 c, 1 c v , 2 c, 2 c v ) and shape (k 1, ka 1 ) topological indices, Randic topological index (R), Balaban topological index (J), Wiener topological index (W), Total energy (Te), energies of highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO), dipole moment (m), electronic energy (Ele.E), nuclear energy (Nu.E) and molecular surface area (SA) calculated for of 4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids are used as independent variables and are presented in Table 4 [22e27].Development of one-target QSAR modelIn the present study, a data set of 20 benzimidazole derivatives was subjected to linear free energy regression analysis for model generation.", [["octanol", "CHEMICAL", 72, 79], ["benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 626, 667], ["benzimidazole", "CHEMICAL", 814, 827], ["octanol", "CHEMICAL", 72, 79], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 587, 667], ["benzimidazole", "CHEMICAL", 814, 827], ["octanol", "SIMPLE_CHEMICAL", 72, 79], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "SIMPLE_CHEMICAL", 587, 667], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 814, 839], ["MR", "PROTEIN", 137, 139], ["MR", "TEST", 137, 139], ["Kier's molecular connectivity", "TEST", 142, 171], ["shape", "TEST", 217, 222], ["k", "TEST", 224, 225], ["topological indices", "TEST", 236, 255], ["Randic topological index", "TEST", 257, 281], ["Balaban topological index", "TEST", 287, 312], ["Wiener topological index", "TEST", 318, 342], ["nuclear energy", "TEST", 515, 529], ["substituted aryl/alkyl carbonyl", "TREATMENT", 593, 624], ["benzoimidazol", "TREATMENT", 626, 639], ["benzenesulfonic acids", "TREATMENT", 646, 667], ["20 benzimidazole derivatives", "TREATMENT", 811, 839], ["model generation", "PROBLEM", 900, 916], ["molecular orbital", "ANATOMY", 396, 413], ["orbital", "ANATOMY", 453, 460], ["surface", "ANATOMY_MODIFIER", 551, 558]]], ["The reference drugs were not included in model development as they belong to different structural series.", [["The reference drugs", "TREATMENT", 0, 19]]], ["Preliminary analysis was carried out in terms of correlation analysis.", [["Preliminary analysis", "TEST", 0, 20], ["correlation analysis", "TEST", 49, 69]]], ["A correlation matrix constructed for antibacterial activity against S. aureus is presented in Table 5 .", [["S. aureus", "ORGANISM", 68, 77], ["S. aureus", "SPECIES", 68, 77], ["S. aureus", "SPECIES", 68, 77], ["A correlation matrix", "TREATMENT", 0, 20], ["antibacterial activity", "PROBLEM", 37, 59], ["S. aureus", "PROBLEM", 68, 77], ["aureus", "OBSERVATION", 71, 77]]], ["The correlations of different molecular descriptors with antimicrobial activity are presented in Table 6 .", [["antimicrobial activity", "TREATMENT", 57, 79], ["antimicrobial activity", "OBSERVATION", 57, 79]]], ["In general, high colinearity (r > 0.8) was observed between different parameters.", [["high colinearity", "OBSERVATION", 12, 28]]], ["The high interrelationship was observed between Te and Nu.E (r \u00bc 0.990) and low interrelationship was observed between 2 c v and LUMO (r \u00bc 0.001).Development of one-target QSAR modelCorrelation matrix (Table 5 ) indicated the importance of the topological parameter, Balaban index (J) in describing antibacterial activity of synthesized benzimidazole derivatives against S. aureusDevelopment of one-target QSAR modelot-QSAR model for antibacterial activity against S. aureusDevelopment of one-target QSAR modelHere and thereafter, n e number of data points, r e correlation coefficient, q 2 e cross validated r 2 obtained by leave one out method, s e standard error of the estimate and F e Fischer statistics.Development of one-target QSAR modelAs the coefficient of J in Eq.", [["benzimidazole", "CHEMICAL", 337, 350], ["benzimidazole", "CHEMICAL", 337, 350], ["c v", "GENE_OR_GENE_PRODUCT", 121, 124], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 337, 362], ["S. aureus", "ORGANISM", 371, 380], ["S. aureus", "ORGANISM", 465, 474], ["S. aureus", "SPECIES", 371, 380], ["S. aureus", "SPECIES", 465, 474], ["S. aureus", "SPECIES", 371, 380], ["S. aureus", "SPECIES", 465, 474], ["LUMO", "TEST", 129, 133], ["the topological parameter", "TREATMENT", 240, 265], ["Balaban index (J)", "TREATMENT", 267, 284], ["antibacterial activity of synthesized benzimidazole derivatives", "TREATMENT", 299, 362], ["S. aureus", "PROBLEM", 371, 380], ["QSAR model", "TREATMENT", 419, 429], ["antibacterial activity", "TREATMENT", 434, 456], ["S. aureus", "PROBLEM", 465, 474], ["aureus", "OBSERVATION", 374, 380], ["aureus", "OBSERVATION", 468, 474]]], ["(1) is negative, therefore the antibacterial activity against S. aureus will increase with a decrease in value of J. This is clearly evident from Table 4 (Table 4) , has minimum antibacterial activity against S. aureus.Development of one-target QSAR modelThe addition of electronic parameter, the energy of lowest unoccupied molecular orbital (LUMO) to Balaban index [Eq.", [["S. aureus", "ORGANISM", 62, 71], ["S. aureus", "ORGANISM", 209, 218], ["S. aureus", "SPECIES", 62, 71], ["S. aureus", "SPECIES", 209, 218], ["S. aureus", "SPECIES", 62, 71], ["S. aureus", "SPECIES", 209, 218], ["the antibacterial activity", "TREATMENT", 27, 53], ["S. aureus", "PROBLEM", 62, 71], ["S. aureus", "PROBLEM", 209, 218], ["electronic parameter", "TEST", 271, 291], ["Balaban index", "TEST", 353, 366], ["negative", "OBSERVATION", 7, 15], ["aureus", "OBSERVATION", 65, 71], ["decrease", "OBSERVATION_MODIFIER", 93, 101], ["antibacterial activity", "OBSERVATION_MODIFIER", 178, 200], ["aureus", "OBSERVATION", 212, 218], ["molecular orbital", "ANATOMY", 325, 342]]], ["(2)). ot-QSAR model for antibacterial activity against S. aureusDevelopment of one-target QSAR modelThe above results indicated that the antibacterial activity of synthesized benzimidazole derivatives are determined mainly by the topological parameter, Balaban index (J) followed by the electronic parameter, LUMO and topological parameter, valence second order molecular connectivity index ( 2 c v ).Development of one-target QSAR modelThe QSAR model expressed by Eq.", [["benzimidazole", "CHEMICAL", 175, 188], ["benzimidazole", "CHEMICAL", 175, 188], ["S. aureus", "ORGANISM", 55, 64], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 175, 200], ["S. aureus", "SPECIES", 55, 64], ["S. aureus", "SPECIES", 55, 64], ["QSAR model", "TREATMENT", 9, 19], ["antibacterial activity", "TREATMENT", 24, 46], ["S. aureus", "PROBLEM", 55, 64], ["the antibacterial activity of synthesized benzimidazole derivatives", "TREATMENT", 133, 200], ["Balaban index (J)", "TREATMENT", 253, 270], ["aureus", "OBSERVATION", 58, 64]]], ["The value of q 2 greater than 0.5 is the basic requirement for qualifying a QSAR model to be valid one.", [["The value", "TEST", 0, 9], ["a QSAR model", "TREATMENT", 74, 86]]], ["It can be seen from the results that the observed and predicted antimicrobial activities lie close to each other as evidenced by their low residual values.", [["their low residual values", "PROBLEM", 129, 154], ["low residual", "OBSERVATION_MODIFIER", 135, 147]]], ["The plot of predicted pMICsa against observed pMIC sa (Fig. 1 ) also favors the model expressed by Eq.", [["pMICsa", "GENE_OR_GENE_PRODUCT", 22, 28], ["pMICsa", "DNA", 22, 28]]], ["Further, the plot of observed pMIC sa vs residual pMIC sa (Fig. 2) indicated that there was no systemic error in model development as the propagation of residuals was observed on both positive and negative sides [28] .Development of one-target QSAR modelThe MLR Eqs.", [["pMIC", "DNA", 30, 34], ["observed pMIC sa", "PROBLEM", 21, 37], ["residual pMIC sa", "PROBLEM", 41, 57], ["systemic error", "PROBLEM", 95, 109], ["the propagation of residuals", "PROBLEM", 134, 162], ["no", "UNCERTAINTY", 92, 94], ["systemic error", "OBSERVATION", 95, 109]]], ["(4)e (7) were developed to predict the antimicrobial activity of benzimidazole derivatives against B. subtilis, E. coli, C. albicans and A. niger. ot-QSAR model for antibacterial activity against B. subtilisDevelopment of one-target QSAR model95 ot-QSAR model for antibacterial activity against E. coli pMIC ec \u00bc \u00c00:230 2 c v \u00c0 2:747 J \u00c0 0:496 LUMO \u00fe 7:092Development of one-target QSAR modelot-QSAR model for antifungal activity against C. albicansDevelopment of one-target QSAR modelQSAR model for antifungal activity against A. niger pMIC an \u00bc \u00c00:087 log P \u00fe 0:00004 NE \u00fe 0:285Development of one-target QSAR modelAs in case of S. aureus, the MLR equations derived for B. subtilis and E. coli also indicated the importance of the topological parameter, Balaban index (J) followed by the electronic parameter, LUMO and topological parameter, valence second order molecular connectivity index ( 2 c v ) in describing antibacterial activity against B. subtilis and E. coli and antifungal activity against C. albicans.", [["benzimidazole", "CHEMICAL", 65, 78], ["benzimidazole", "CHEMICAL", 65, 78], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 65, 90], ["B. subtilis", "ORGANISM", 99, 110], ["E. coli", "ORGANISM", 112, 119], ["C. albicans", "ORGANISM", 121, 132], ["A. niger", "ORGANISM", 137, 145], ["B. subtilis", "ORGANISM", 196, 207], ["E. coli", "ORGANISM", 295, 302], ["C. albicans", "ORGANISM", 438, 449], ["A. niger pMIC", "ORGANISM", 528, 541], ["S. aureus", "ORGANISM", 630, 639], ["B. subtilis", "ORGANISM", 671, 682], ["E. coli", "ORGANISM", 687, 694], ["B. subtilis", "ORGANISM", 948, 959], ["E. coli", "ORGANISM", 964, 971], ["C. albicans", "ORGANISM", 1004, 1015], ["B. subtilis", "SPECIES", 99, 110], ["E. coli", "SPECIES", 112, 119], ["C. albicans", "SPECIES", 121, 132], ["A. niger", "SPECIES", 137, 145], ["B. subtilis", "SPECIES", 196, 207], ["E. coli", "SPECIES", 295, 302], ["C. albicans", "SPECIES", 438, 449], ["A. niger", "SPECIES", 528, 536], ["S. aureus", "SPECIES", 630, 639], ["B. subtilis", "SPECIES", 671, 682], ["E. coli", "SPECIES", 687, 694], ["B. subtilis", "SPECIES", 948, 959], ["E. coli", "SPECIES", 964, 971], ["C. albicans", "SPECIES", 1004, 1015], ["B. subtilis", "SPECIES", 99, 110], ["E. coli", "SPECIES", 112, 119], ["C. albicans", "SPECIES", 121, 132], ["A. niger", "SPECIES", 137, 145], ["B. subtilis", "SPECIES", 196, 207], ["E. coli", "SPECIES", 295, 302], ["C. albicans", "SPECIES", 438, 449], ["A. niger", "SPECIES", 528, 536], ["S. aureus", "SPECIES", 630, 639], ["B. subtilis", "SPECIES", 671, 682], ["E. coli", "SPECIES", 687, 694], ["B. subtilis", "SPECIES", 948, 959], ["E. coli", "SPECIES", 964, 971], ["C. albicans", "SPECIES", 1004, 1015], ["benzimidazole derivatives", "TREATMENT", 65, 90], ["B. subtilis", "PROBLEM", 99, 110], ["E. coli", "PROBLEM", 112, 119], ["QSAR model", "TREATMENT", 150, 160], ["antibacterial activity", "TREATMENT", 165, 187], ["target QSAR", "TEST", 226, 237], ["QSAR model", "TEST", 249, 259], ["antibacterial activity", "TEST", 264, 286], ["E. coli", "TEST", 295, 302], ["LUMO", "TEST", 344, 348], ["antifungal activity", "TREATMENT", 410, 429], ["antifungal activity", "TREATMENT", 500, 519], ["S. aureus", "PROBLEM", 630, 639], ["the MLR equations", "TEST", 641, 658], ["B. subtilis", "PROBLEM", 671, 682], ["E. coli", "PROBLEM", 687, 694], ["Balaban index (J)", "TREATMENT", 755, 772], ["antibacterial activity", "TREATMENT", 917, 939], ["B. subtilis", "TREATMENT", 948, 959], ["E. coli", "TREATMENT", 964, 971], ["antifungal activity", "TREATMENT", 976, 995], ["C. albicans", "PROBLEM", 1004, 1015], ["E. coli", "OBSERVATION_MODIFIER", 112, 119], ["aureus", "OBSERVATION", 633, 639]]], ["But in case of antifungal activity of benzimidazole derivatives against A. niger the MLR equation indicated importance of the lipophilic parameter, log of octanolewater partition coefficient log P and the electronic parameter, nuclear energy (Nu.", [["nuclear", "ANATOMY", 227, 234], ["benzimidazole", "CHEMICAL", 38, 51], ["benzimidazole", "CHEMICAL", 38, 51], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 38, 63], ["A. niger", "ORGANISM", 72, 80], ["octanolewater", "SIMPLE_CHEMICAL", 155, 168], ["A. niger", "SPECIES", 72, 80], ["A. niger", "SPECIES", 72, 80], ["antifungal activity", "TREATMENT", 15, 34], ["benzimidazole derivatives", "TREATMENT", 38, 63], ["the MLR equation", "TEST", 81, 97], ["the lipophilic parameter", "TEST", 122, 146]]], ["4e7 against respective microorganisms is supported by the low residual activity values (Table 7) .", [["4e7", "CHEMICAL", 0, 3], ["4e7", "SIMPLE_CHEMICAL", 0, 3], ["the low residual activity values", "PROBLEM", 54, 86], ["microorganisms", "OBSERVATION", 23, 37], ["low", "OBSERVATION_MODIFIER", 58, 61], ["residual activity", "OBSERVATION", 62, 79]]], ["Further the high q 2 values observed also supports the suitability of the QSAR models (q 2 > 0.5) described by Eqs.", [["the QSAR models", "TEST", 70, 85]]], ["In case of the MLR models derived for A. niger, the q 2 value is less than 0.5, which shows that the developed models are invalid one.", [["A. niger", "ORGANISM", 38, 46], ["A. niger", "SPECIES", 38, 46], ["A. niger", "SPECIES", 38, 46], ["the MLR models", "TEST", 11, 25], ["the q 2 value", "TEST", 48, 61]]], ["Generally for QSAR studies, the biological activities of compounds should span 2e3 orders of magnitude.", [["QSAR studies", "TEST", 14, 26]]], ["But it is important to note that the predictability of the QSAR models developed in the present study is highly evidenced by the low residual values.", [["the QSAR models", "PROBLEM", 55, 70], ["the present study", "TEST", 84, 101], ["the low residual values", "PROBLEM", 125, 148], ["low residual", "OBSERVATION_MODIFIER", 129, 141]]], ["This is in accordance with results suggested by Bajaj et al. [30] , who stated that the reliability of the QSAR model lies in its predictive ability even though the activity data are in the narrow range.", [["the activity data", "TEST", 161, 178]]], ["When biological activity data lies in the narrow range, the presence of minimum standard deviation of the biological activity justifies its use in QSAR studies [34, 35] .", [["biological activity data", "TEST", 5, 29], ["QSAR studies", "TEST", 147, 159], ["narrow range", "OBSERVATION_MODIFIER", 42, 54]]], ["The minimum standard deviation (Table 2 ) observed in the antimicrobial activity data justifies its use in QSAR studies.Development of multi-target QSAR modelAccording to the above ot-QSAR models one should use five different equations to predict the activity of a new compound against the five microbial species.", [["The minimum standard deviation (Table 2 )", "PROBLEM", 0, 41], ["the antimicrobial activity data", "TEST", 54, 85], ["QSAR studies", "TEST", 107, 119], ["multi-target QSAR modelAccording", "TREATMENT", 135, 167], ["minimum", "OBSERVATION_MODIFIER", 4, 11], ["standard deviation", "OBSERVATION", 12, 30], ["multi-target QSAR", "OBSERVATION", 135, 152]]], ["The ot-QSAR models, which are almost in all the literature, become unpractical or complicated to use when we have to predict each compound results for more than one-target.", [["The ot-QSAR models", "TEST", 0, 18]]], ["However, very recently the interest has been increased in development of multi-target QSAR (mt-QSAR) models.", [["multi-target QSAR", "TEST", 73, 90], ["increased", "OBSERVATION_MODIFIER", 45, 54]]], ["In opposition to ot-QSAR, the mt-QSAR model is a single equation that considers the nature of molecular descriptors which are common and essential for describing the antimicrobial activity [36e40].Development of multi-target QSAR modelIn the present study we have attempted to develop three different types of mt-QSAR models viz. mt-QSAR model for describing antibacterial activity of synthesized compounds against S. aureus, B. subtilis and E. coli, mt-QSAR model for describing antifungal activity of synthesized compounds against C. albicans Table 7 Comparison of observed and predicted antibacterial and antifungal activity obtained by ot-QSAR model.Development of multi-target QSAR modelComp. pMICsa (Eq.", [["S. aureus", "ORGANISM", 415, 424], ["B. subtilis", "ORGANISM", 426, 437], ["E. coli", "ORGANISM", 442, 449], ["S. aureus", "SPECIES", 415, 424], ["B. subtilis", "SPECIES", 426, 437], ["E. coli", "SPECIES", 442, 449], ["C. albicans", "SPECIES", 533, 544], ["S. aureus", "SPECIES", 415, 424], ["B. subtilis", "SPECIES", 426, 437], ["E. coli", "SPECIES", 442, 449], ["C. albicans", "SPECIES", 533, 544], ["multi-target QSAR model", "TREATMENT", 212, 235], ["the present study", "TEST", 238, 255], ["QSAR model", "TEST", 333, 343], ["antibacterial activity of synthesized compounds", "TREATMENT", 359, 406], ["S. aureus", "PROBLEM", 415, 424], ["B. subtilis", "PROBLEM", 426, 437], ["E. coli", "PROBLEM", 442, 449], ["QSAR model", "TEST", 454, 464], ["antifungal activity of synthesized compounds", "TREATMENT", 480, 524], ["antibacterial", "TREATMENT", 590, 603], ["antifungal activity", "TEST", 608, 627], ["multi-target QSAR model", "OBSERVATION", 212, 235], ["aureus", "OBSERVATION", 418, 424], ["E. coli", "OBSERVATION_MODIFIER", 442, 449], ["multi-target QSAR modelComp", "OBSERVATION", 669, 696]]], ["(3)) pMICbs (Eq.", [["pMICbs", "PROTEIN", 5, 11]]], ["(7) and A. niger as well a common mt-QSAR model for describing the antimicrobial activity of synthesized benzimidazole derivatives against all the above mentioned microorganisms.Development of multi-target QSAR modelIn order to develop mt-QSAR models, we have calculated the average antibacterial activity [pMIC b \u00bc (pMIC sa \u00fe pMICbs \u00fe pMICec)/ 3], antifungal activity [pMIC f \u00bc (pMIC ca \u00fe pMIC an )/2] and antimicrobial activity values [pMIC am \u00bc (pMIC sa \u00fe pMICbs \u00fe pMIC ec \u00fe pMIC ca \u00fe pMIC an )/5] of benzimidazole derivatives which are presented in Table 2 .", [["benzimidazole", "CHEMICAL", 105, 118], ["benzimidazole", "CHEMICAL", 504, 517], ["benzimidazole", "CHEMICAL", 105, 118], ["benzimidazole", "CHEMICAL", 504, 517], ["A. niger", "ORGANISM", 8, 16], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 105, 130], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 504, 529], ["pMICbs", "PROTEIN", 459, 465], ["A. niger", "SPECIES", 8, 16], ["A. niger", "SPECIES", 8, 16], ["the antimicrobial activity of synthesized benzimidazole derivatives", "TREATMENT", 63, 130], ["multi-target QSAR model", "TREATMENT", 193, 216], ["the average antibacterial activity", "TREATMENT", 271, 305], ["pMIC b \u00bc (pMIC sa \u00fe pMICbs", "TREATMENT", 307, 333], ["antifungal activity", "TREATMENT", 349, 368], ["pMIC f \u00bc (pMIC ca \u00fe pMIC an )", "TREATMENT", 370, 399], ["antimicrobial activity values", "TREATMENT", 407, 436], ["pMIC sa \u00fe pMICbs", "TREATMENT", 449, 465], ["pMIC", "TREATMENT", 468, 472], ["pMIC ca", "TREATMENT", 478, 485], ["benzimidazole derivatives", "TREATMENT", 504, 529], ["multi-target QSAR model", "OBSERVATION", 193, 216]]], ["These average activity values were also correlated with the molecular descriptors of synthesized compounds ( Table 6 ).Development of multi-target QSAR modelThe predictability of Eqs.", [["multi-target QSAR model", "TREATMENT", 134, 157], ["multi-target QSAR model", "OBSERVATION", 134, 157], ["predictability", "OBSERVATION_MODIFIER", 161, 175]]], ["(11)e(13) was verified by calculating the antibacterial, antifungal and antimicrobial activities for substituted benzimidazoles respectively and the low residual activity values indicated the high predictability of above mentioned equations (Table 8 ).", [["benzimidazoles", "CHEMICAL", 113, 127], ["benzimidazoles", "CHEMICAL", 113, 127], ["(11)e(13)", "SIMPLE_CHEMICAL", 0, 9], ["benzimidazoles", "SIMPLE_CHEMICAL", 113, 127], ["the antibacterial", "TREATMENT", 38, 55], ["antifungal", "TREATMENT", 57, 67], ["antimicrobial activities", "TREATMENT", 72, 96], ["substituted benzimidazoles", "TREATMENT", 101, 127], ["the low residual activity values", "PROBLEM", 145, 177], ["high predictability", "OBSERVATION_MODIFIER", 192, 211]]], ["Further the plot of observed pMICam and predicted pMICam (Fig. 3 ) also in favor of the mt-QSAR target model for antimicrobial activity.", [["pMICam", "GENE_OR_GENE_PRODUCT", 29, 35], ["pMICam", "PROTEIN", 29, 35], ["antimicrobial activity", "TREATMENT", 113, 135]]], ["The propagation of activity values on both sides of zero, in the plot of observed pMICam against residual pMICam, indicated that there was no systemic error in the development of mt-QSAR model (Fig. 4) .", [["pMICam", "PROTEIN", 82, 88], ["pMICam", "PROTEIN", 106, 112], ["activity values", "TEST", 19, 34], ["residual pMICam", "PROBLEM", 97, 112], ["systemic error", "PROBLEM", 142, 156], ["propagation", "OBSERVATION_MODIFIER", 4, 15], ["activity", "OBSERVATION_MODIFIER", 19, 27], ["no", "UNCERTAINTY", 139, 141], ["systemic error", "OBSERVATION", 142, 156]]], ["The other statistically significant ot-QSAR and mt-QSAR models derived are presented in Table 9 .Development of multi-target QSAR modelThe Balaban index J is a variant of connectivity index and represents extended connectivity.", [["multi-target QSAR model", "TREATMENT", 112, 135], ["multi-target QSAR model", "OBSERVATION", 112, 135], ["extended connectivity", "OBSERVATION", 205, 226]]], ["It is a good descriptor for the shape of molecules and is one of the widely used topological indices for QSAR and QSPR studies.", [["QSAR and QSPR studies", "TEST", 105, 126]]], ["The Balaban index of a connected (molecular) graph G is defined as [41] :Development of multi-target QSAR modelwhere, m is the number of edges, m is the cyclomatic number, D u is the sum of distances between vertex u and all other vertices of G, and the summation goes over all edges from the edge set E (G electronic parameter LUMO, which denotes the energy of lowest unoccupied molecular orbital directly relates to the electron affinity and characterizes the sensibility of the molecule towards an attack by necleophile.", [["electron", "SIMPLE_CHEMICAL", 422, 430], ["The Balaban index", "TEST", 0, 17], ["edge", "OBSERVATION_MODIFIER", 293, 297], ["molecular orbital", "ANATOMY", 380, 397]]], ["The contribution of LUMO in describing antimicrobial activity may be attributed to the interaction of benzimidazole derivatives with nucleophilic amino acid residue like cysteine of microorganisms [42] .", [["benzimidazole", "CHEMICAL", 102, 115], ["amino acid", "CHEMICAL", 146, 156], ["cysteine", "CHEMICAL", 170, 178], ["benzimidazole", "CHEMICAL", 102, 115], ["amino acid", "CHEMICAL", 146, 156], ["cysteine", "CHEMICAL", 170, 178], ["LUMO", "SIMPLE_CHEMICAL", 20, 24], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 102, 127], ["nucleophilic amino acid", "SIMPLE_CHEMICAL", 133, 156], ["cysteine", "AMINO_ACID", 170, 178], ["benzimidazole derivatives", "TREATMENT", 102, 127], ["nucleophilic amino acid residue", "TREATMENT", 133, 164], ["cysteine of microorganisms", "PROBLEM", 170, 196], ["LUMO", "OBSERVATION", 20, 24]]], ["The topological descriptor, i.e. the valence second order molecular connectivity index encodes information related to the degree of stargraph likeness and takes a large value for more linear molecule [43] .", [["stargraph likeness", "PROBLEM", 132, 150], ["stargraph likeness", "OBSERVATION", 132, 150]]], ["(13) indicated that higher the values of J, LUMO and 2 c v lower will be the antimicrobial activity of benzimidazole derivatives.Development of multi-target QSAR modelThe residual activity values in the case of mt-QSAR model for antimicrobial activity are less when compared to the residuals of one-target models (Table 7) as well the multi-target models for antibacterial and antifungal activities (Table 8 ).", [["benzimidazole", "CHEMICAL", 103, 116], ["benzimidazole", "CHEMICAL", 103, 116], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 103, 128], ["J, LUMO and 2 c v", "TREATMENT", 41, 58], ["the antimicrobial activity", "TREATMENT", 73, 99], ["benzimidazole derivatives", "TREATMENT", 103, 128], ["multi-target QSAR model", "TREATMENT", 144, 167], ["The residual activity values", "PROBLEM", 167, 195], ["antimicrobial activity", "TREATMENT", 229, 251], ["the residuals", "TEST", 278, 291], ["antibacterial and antifungal activities", "TREATMENT", 359, 398], ["multi-target QSAR model", "OBSERVATION", 144, 167], ["residual", "OBSERVATION_MODIFIER", 171, 179], ["activity", "OBSERVATION_MODIFIER", 180, 188], ["values", "OBSERVATION_MODIFIER", 189, 195]]], ["This mt-QSAR equation (Eq.", [["QSAR equation", "TEST", 8, 21]]], ["(13)) can be used to predict the activity of substituted benzimidazoles against different microbial species.Development of multi-target QSAR modelFurthermore, the topological parameter, Balaban index (J) followed by the electronic parameter, LUMO and topological parameter, valence second order molecular connectivity index ( 2 c v ) is describing the antimicrobial activity of 4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .Development of multi-target QSAR modelIt is important to mention here that the development of multi-QSAR target models exhibited the following advantages over onetarget QSAR models: (a).", [["benzimidazoles", "CHEMICAL", 57, 71], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 378, 458], ["benzimidazoles", "CHEMICAL", 57, 71], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 378, 458], ["benzimidazoles", "SIMPLE_CHEMICAL", 57, 71], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20)", "SIMPLE_CHEMICAL", 378, 549], ["substituted benzimidazoles", "TREATMENT", 45, 71], ["different microbial species", "PROBLEM", 80, 107], ["the topological parameter", "TEST", 159, 184], ["Balaban index (J)", "TREATMENT", 186, 203], ["the antimicrobial activity", "TEST", 348, 374], ["substituted aryl/alkyl carbonyl)", "TREATMENT", 384, 416], ["benzoimidazol", "TREATMENT", 417, 430], ["benzenesulfonic acids", "TREATMENT", 437, 458], ["multi-target QSAR model", "TREATMENT", 566, 589], ["multi-QSAR target models", "PROBLEM", 645, 669], ["microbial species", "OBSERVATION", 90, 107], ["multi-target QSAR", "OBSERVATION", 123, 140], ["multi-target QSAR model", "OBSERVATION", 566, 589]]], ["There is an improvement in statistical parameters when compared to one-target models (improvement in r, q2, etc. cf. Eq.", [["statistical parameters", "TEST", 27, 49], ["improvement", "OBSERVATION_MODIFIER", 12, 23], ["improvement", "OBSERVATION_MODIFIER", 86, 97]]], ["No change in the trend of molecular descriptors has been observed, i.e. all the three parameters, i.e. J, LUMO and 2 c v showed the same negative correlation with antimicrobial activity as observed in the case of onetarget models. (c).", [["c v", "GENE_OR_GENE_PRODUCT", 117, 120], ["J, LUMO and 2 c v", "TEST", 103, 120], ["antimicrobial activity", "TREATMENT", 163, 185], ["change", "OBSERVATION_MODIFIER", 3, 9]]], ["There was a significant decrease in residual values when compared to the residual values observed in onetarget QSAR models, i.e. mt-QSAR model has better predictability than the ot-QSAR model.Table 9Regression analysis and quality of correlation for modeling antibacterial and antifungal activity of synthesized Benzimidazole derivatives.Antiviral activityA broad antiviral screening of the 4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) was performed against a variety of DNA and RNA viruses (Tables 10e14).", [["Benzimidazole", "CHEMICAL", 312, 325], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 391, 471], ["Benzimidazole", "CHEMICAL", 312, 325], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 391, 471], ["Benzimidazole derivatives", "SIMPLE_CHEMICAL", 312, 337], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19)", "SIMPLE_CHEMICAL", 391, 557], ["DNA", "CELLULAR_COMPONENT", 598, 601], ["a significant decrease in residual values", "PROBLEM", 10, 51], ["the residual values", "TEST", 69, 88], ["mt-QSAR model", "TEST", 129, 142], ["Table 9Regression analysis", "TEST", 192, 218], ["modeling antibacterial", "TREATMENT", 250, 272], ["antifungal activity of synthesized Benzimidazole derivatives", "TREATMENT", 277, 337], ["Antiviral activityA", "TREATMENT", 338, 357], ["antiviral screening", "TEST", 364, 383], ["substituted aryl/alkyl carbonyl)", "TREATMENT", 397, 429], ["benzoimidazol", "TREATMENT", 430, 443], ["benzenesulfonic acids", "TREATMENT", 450, 471], ["DNA and RNA viruses", "TREATMENT", 598, 617], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["decrease", "OBSERVATION_MODIFIER", 24, 32], ["residual values", "OBSERVATION", 36, 51]]], ["None of the compounds were inhibitory to the virus-induced cytopathicity at subtoxic concentrations.Structure activity relationshipFrom the results of antimicrobial and antiviral activities, the following structure activity relationship can be drawn:Structure activity relationship1.", [["subtoxic", "CHEMICAL", 76, 84], ["Structure activity relationship1", "PROTEIN", 250, 282], ["the virus", "PROBLEM", 41, 50], ["cytopathicity at subtoxic concentrations", "PROBLEM", 59, 99], ["antimicrobial and antiviral activities", "TREATMENT", 151, 189], ["subtoxic concentrations", "OBSERVATION", 76, 99]]], ["The results of antibacterial activity indicated that compound 9, 4-[1-(4-Nitrobenzoyl)-1H-benzoimidazol-2-yl]-benzenesulfonic acid was effective against all the three bacterial species under test.", [["compound 9", "CHEMICAL", 53, 63], ["4-[1-(4-Nitrobenzoyl)-1H-benzoimidazol-2-yl]-benzenesulfonic acid", "CHEMICAL", 65, 130], ["4-[1-(4-Nitrobenzoyl)-1H-benzoimidazol-2-yl]-benzenesulfonic acid", "CHEMICAL", 65, 130], ["4-[1-(4-Nitrobenzoyl)-1H-benzoimidazol-2-yl]-benzenesulfonic acid", "SIMPLE_CHEMICAL", 65, 130], ["antibacterial activity", "TEST", 15, 37], ["4-Nitrobenzoyl)", "TREATMENT", 71, 86], ["benzoimidazol", "TREATMENT", 90, 103], ["benzenesulfonic acid", "TREATMENT", 110, 130]]], ["It may be due to the presence of the electron withdrawing nitro group.", [["nitro", "CHEMICAL", 58, 63], ["nitro", "CHEMICAL", 58, 63], ["electron", "SIMPLE_CHEMICAL", 37, 45], ["nitro group", "TREATMENT", 58, 69], ["may be due to", "UNCERTAINTY", 3, 16]]], ["The role of electron withdrawing group in increasing the antimicrobial activity is similar to the results of Sharma et al. [44] .", [["electron", "SIMPLE_CHEMICAL", 12, 20], ["antimicrobial activity", "OBSERVATION", 57, 79]]], ["The results of antifungal activity indicated that compound 18, 4-(1-octadec-9-enoyl-1H-benzoimidazol-2-yl)-benzenesulfonic acid was effective against both tested fungal strains.", [["compound 18, 4-(1-octadec-9-enoyl-1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 50, 127], ["4-(1-octadec-9-enoyl-1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 63, 127], ["4-(1-octadec-9-enoyl-1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 63, 127], ["antifungal activity", "TEST", 15, 34], ["compound", "TEST", 50, 58], ["octadec", "TEST", 68, 75], ["enoyl", "TEST", 78, 83], ["benzoimidazol", "TREATMENT", 87, 100], ["benzenesulfonic acid", "TREATMENT", 107, 127], ["both tested fungal strains", "PROBLEM", 150, 176], ["fungal strains", "OBSERVATION", 162, 176]]], ["The comparison of most effective antibacterial and antifungal compound gave information that the aromatic acid substitution at N 1 of benzimidazole is required for antibacterial activity and aliphatic acid substitution at N 1 of benzimidazole is required for antifungal activity.", [["aromatic acid", "CHEMICAL", 97, 110], ["N 1 of benzimidazole", "CHEMICAL", 127, 147], ["aliphatic acid", "CHEMICAL", 191, 205], ["N 1 of benzimidazole", "CHEMICAL", 222, 242], ["aromatic acid", "CHEMICAL", 97, 110], ["benzimidazole", "CHEMICAL", 134, 147], ["aliphatic acid", "CHEMICAL", 191, 205], ["benzimidazole", "CHEMICAL", 229, 242], ["aromatic acid", "SIMPLE_CHEMICAL", 97, 110], ["benzimidazole", "SIMPLE_CHEMICAL", 134, 147], ["aliphatic acid", "SIMPLE_CHEMICAL", 191, 205], ["N 1 of benzimidazole", "SIMPLE_CHEMICAL", 222, 242], ["most effective antibacterial", "TREATMENT", 18, 46], ["antifungal compound", "TREATMENT", 51, 70], ["the aromatic acid substitution", "TREATMENT", 93, 123], ["benzimidazole", "TREATMENT", 134, 147], ["antibacterial activity", "TREATMENT", 164, 186], ["aliphatic acid substitution", "TREATMENT", 191, 218], ["benzimidazole", "TREATMENT", 229, 242], ["antifungal activity", "TREATMENT", 259, 278]]], ["This indicated that different structural requirements are essential for binding of drug to bacterial or fungal targets respectively [45] .", [["different structural requirements", "PROBLEM", 20, 53], ["bacterial or fungal targets", "PROBLEM", 91, 118]]], ["None of the compounds were endowed with antiviral activity at subtoxic concentrations.ConclusionA series of 4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids (1-e20), was synthesized by the reaction of 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid with corresponding aryl/alkyl acid chlorides.", [["subtoxic", "CHEMICAL", 62, 70], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 108, 188], ["1-e20", "CHEMICAL", 190, 195], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 233, 279], ["aryl/alkyl acid chlorides", "CHEMICAL", 299, 324], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 108, 188], ["1-e20", "CHEMICAL", 190, 195], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 233, 279], ["aryl/alkyl acid chlorides", "CHEMICAL", 299, 324], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "SIMPLE_CHEMICAL", 108, 188], ["1-e20", "SIMPLE_CHEMICAL", 190, 195], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 233, 279], ["aryl/alkyl acid chlorides", "SIMPLE_CHEMICAL", 299, 324], ["antiviral activity at subtoxic concentrations", "TREATMENT", 40, 85], ["ConclusionA series", "TEST", 86, 104], ["substituted aryl/alkyl carbonyl)", "TREATMENT", 114, 146], ["benzoimidazol", "TREATMENT", 147, 160], ["benzenesulfonic acids", "TREATMENT", 167, 188], ["benzoimidazol", "TREATMENT", 239, 252], ["benzenesulfonic acid", "TREATMENT", 259, 279], ["corresponding aryl/alkyl acid chlorides", "TREATMENT", 285, 324]]], ["The synthesized compounds were characterized by physicochemical and spectral means and the IR and NMR spectral data are found in agreement with the assigned molecular structures.", [["the IR", "TEST", 87, 93], ["NMR spectral data", "TEST", 98, 115]]], ["Further, the synthesized compounds were evaluated for their in vitro antimicrobial activities against the bacterial strains S. aureus, B. subtilis; E. coli and fungal strains e A. niger and C. albicans by tube dilution method.", [["tube", "ANATOMY", 205, 209], ["S. aureus", "ORGANISM", 124, 133], ["B. subtilis", "ORGANISM", 135, 146], ["E. coli", "ORGANISM", 148, 155], ["fungal strains", "ORGANISM", 160, 174], ["A. niger", "ORGANISM", 177, 185], ["C. albicans", "ORGANISM", 190, 201], ["tube", "TISSUE", 205, 209], ["S. aureus", "SPECIES", 124, 133], ["B. subtilis", "SPECIES", 135, 146], ["E. coli", "SPECIES", 148, 155], ["A. niger", "SPECIES", 177, 185], ["C. albicans", "SPECIES", 190, 201], ["S. aureus", "SPECIES", 124, 133], ["B. subtilis", "SPECIES", 135, 146], ["E. coli", "SPECIES", 148, 155], ["A. niger", "SPECIES", 177, 185], ["C. albicans", "SPECIES", 190, 201], ["the bacterial strains S. aureus", "PROBLEM", 102, 133], ["B. subtilis", "PROBLEM", 135, 146], ["E. coli", "PROBLEM", 148, 155], ["fungal strains", "PROBLEM", 160, 174], ["C. albicans", "TREATMENT", 190, 201], ["tube dilution method", "TREATMENT", 205, 225], ["aureus", "OBSERVATION", 127, 133]]], ["The antimicrobial screening results indicated that compounds 4-[1-(4-Nitrobenzoyl)-1H-benzoimidazol-2-yl]-benzenesulfonic acid (9) and 4-(1-octadec-9-enoyl-1H-benzoimidazol-2-yl)-benzenesulfonic acid (18) were the most active ones.", [["4-[1-(4-Nitrobenzoyl)-1H-benzoimidazol-2-yl]-benzenesulfonic acid", "CHEMICAL", 61, 126], ["9", "CHEMICAL", 128, 129], ["4-(1-octadec-9-enoyl-1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 135, 199], ["4-[1-(4-Nitrobenzoyl)-1H-benzoimidazol-2-yl]-benzenesulfonic acid", "CHEMICAL", 61, 126], ["4-(1-octadec-9-enoyl-1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 135, 199], ["4-[1-(4-Nitrobenzoyl)-1H-benzoimidazol-2-yl]-benzenesulfonic acid", "SIMPLE_CHEMICAL", 61, 126], ["4-(1-octadec-9-enoyl-1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 135, 199], ["The antimicrobial screening", "TEST", 0, 27], ["compounds", "TEST", 51, 60], ["Nitrobenzoyl)", "TREATMENT", 69, 82], ["benzoimidazol", "TREATMENT", 86, 99], ["benzenesulfonic acid", "TREATMENT", 106, 126], ["octadec", "TEST", 140, 147], ["enoyl", "TREATMENT", 150, 155], ["benzoimidazol", "TREATMENT", 159, 172], ["benzenesulfonic acid", "TREATMENT", 179, 199]]], ["The antiviral evaluations revealed no specific antiviral activity for the test compounds.", [["The antiviral evaluations", "TEST", 0, 25], ["the test compounds", "TEST", 70, 88], ["antiviral activity", "OBSERVATION", 47, 65]]], ["The QSAR study carried out to find the relationship between physicochemical parameters and antimicrobial activity of benzimidazole derivatives indicated the importance of the topological parameter, Balaban index (1) 4-Amino-benzenesulfonic acid (0.13 mol) in hydrochloric acid/ water mixture (1:1) was diazotized using solution of sodium nitrite at 0e10 C. To the diazotized mixture, benzimidazole (0.004 mol) was added with vigorous shaking.", [["benzimidazole", "CHEMICAL", 117, 130], ["4-Amino-benzenesulfonic acid", "CHEMICAL", 216, 244], ["hydrochloric acid", "CHEMICAL", 259, 276], ["sodium nitrite", "CHEMICAL", 331, 345], ["benzimidazole", "CHEMICAL", 384, 397], ["benzimidazole", "CHEMICAL", 117, 130], ["4-Amino-benzenesulfonic acid", "CHEMICAL", 216, 244], ["hydrochloric acid", "CHEMICAL", 259, 276], ["sodium nitrite", "CHEMICAL", 331, 345], ["benzimidazole", "CHEMICAL", 384, 397], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 117, 142], ["4-Amino-benzenesulfonic acid", "SIMPLE_CHEMICAL", 216, 244], ["hydrochloric acid", "SIMPLE_CHEMICAL", 259, 276], ["sodium nitrite", "SIMPLE_CHEMICAL", 331, 345], ["benzimidazole", "SIMPLE_CHEMICAL", 384, 397], ["The QSAR study", "TEST", 0, 14], ["antimicrobial activity of benzimidazole derivatives", "TREATMENT", 91, 142], ["the topological parameter", "TEST", 171, 196], ["Balaban index", "TEST", 198, 211], ["Amino-benzenesulfonic acid", "TREATMENT", 218, 244], ["hydrochloric acid/ water mixture", "TREATMENT", 259, 291], ["sodium nitrite", "TREATMENT", 331, 345], ["the diazotized mixture", "TREATMENT", 360, 382], ["benzimidazole", "TREATMENT", 384, 397], ["vigorous shaking", "PROBLEM", 425, 441]]], ["A solution of sodium acetate (40 g in 100 ml) was added drop wise to the above mixture by maintaining temperature at 5e10 C. The above solution was stirred initially for 3 h at cold condition followed by continuation of stirring at room temperature for 48 h.", [["sodium acetate", "CHEMICAL", 14, 28], ["sodium acetate", "CHEMICAL", 14, 28], ["sodium acetate", "SIMPLE_CHEMICAL", 14, 28], ["A solution of sodium acetate", "TREATMENT", 0, 28], ["The above solution", "TREATMENT", 125, 143]]], ["The product, 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid obtained was filtered, dried and recrystallized using alcohol.ConclusionA solution of 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid (0.002 mol) in diethyl ether (50 ml) was added with a solution of acid chloride of anthranilic acid (0.002 mol) in diethyl ether (50 ml).", [["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 13, 59], ["alcohol", "CHEMICAL", 114, 121], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 146, 192], ["diethyl ether", "CHEMICAL", 208, 221], ["acid chloride", "CHEMICAL", 259, 272], ["anthranilic acid", "CHEMICAL", 276, 292], ["diethyl ether", "CHEMICAL", 308, 321], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 13, 59], ["alcohol", "CHEMICAL", 114, 121], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 146, 192], ["diethyl ether", "CHEMICAL", 208, 221], ["chloride", "CHEMICAL", 264, 272], ["anthranilic acid", "CHEMICAL", 276, 292], ["diethyl ether", "CHEMICAL", 308, 321], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 13, 59], ["alcohol", "SIMPLE_CHEMICAL", 114, 121], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 146, 192], ["diethyl ether", "SIMPLE_CHEMICAL", 208, 221], ["chloride", "SIMPLE_CHEMICAL", 264, 272], ["anthranilic acid", "SIMPLE_CHEMICAL", 276, 292], ["diethyl ether", "SIMPLE_CHEMICAL", 308, 321], ["benzoimidazol", "TREATMENT", 19, 32], ["benzenesulfonic acid", "TREATMENT", 39, 59], ["ConclusionA solution", "TREATMENT", 122, 142], ["benzoimidazol", "TREATMENT", 152, 165], ["benzenesulfonic acid", "TREATMENT", 172, 192], ["a solution of acid chloride of anthranilic acid", "TREATMENT", 245, 292]]], ["The resultant product, 4-[1-(2-amino-benzoyl-1H-benzoimidazol-2-yl]-benzenesulfonic acid was isolated by evaporation of ether and purified by recrystallisation with methanol.ConclusionThe compounds 2-20 are synthesized by the similar procedure followed for compound 1 using corresponding aryl/alkyl acid chlorides with 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid.QSAR studiesThe structures of substituted benzimidazole derivatives are first pre-optimized with the Molecular Mechanics Force Field (MM\u00fe) procedure included in Hyperchem 6.03 [48] and the resulting geometries are further refined by means of the semiempirical method PM3 (parametric Method-3).", [["4-[1-(2-amino-benzoyl-1H-benzoimidazol-2-yl]-benzenesulfonic acid", "CHEMICAL", 23, 88], ["methanol", "CHEMICAL", 165, 173], ["compounds 2-20", "CHEMICAL", 188, 202], ["aryl/alkyl acid chlorides", "CHEMICAL", 288, 313], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 319, 365], ["benzimidazole", "CHEMICAL", 408, 421], ["4-[1-(2-amino-benzoyl-1H-benzoimidazol-2-yl]-benzenesulfonic acid", "CHEMICAL", 23, 88], ["ether", "CHEMICAL", 120, 125], ["methanol", "CHEMICAL", 165, 173], ["aryl/alkyl acid chlorides", "CHEMICAL", 288, 313], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 319, 365], ["benzimidazole", "CHEMICAL", 408, 421], ["4-[1-(2-amino-benzoyl-1H-benzoimidazol-2-yl]-benzenesulfonic acid", "SIMPLE_CHEMICAL", 23, 88], ["ether", "SIMPLE_CHEMICAL", 120, 125], ["methanol", "SIMPLE_CHEMICAL", 165, 173], ["2-20", "SIMPLE_CHEMICAL", 198, 202], ["aryl/alkyl acid chlorides", "SIMPLE_CHEMICAL", 288, 313], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 319, 365], ["substituted benzimidazole derivatives", "SIMPLE_CHEMICAL", 396, 433], ["The resultant product", "TREATMENT", 0, 21], ["amino", "TREATMENT", 31, 36], ["benzoyl", "TREATMENT", 37, 44], ["benzoimidazol", "TREATMENT", 48, 61], ["benzenesulfonic acid", "TREATMENT", 68, 88], ["methanol", "TREATMENT", 165, 173], ["the similar procedure", "TREATMENT", 222, 243], ["corresponding aryl/alkyl acid chlorides", "TREATMENT", 274, 313], ["benzoimidazol", "TREATMENT", 325, 338], ["benzenesulfonic acid", "TREATMENT", 345, 365], ["QSAR studies", "TEST", 366, 378], ["substituted benzimidazole derivatives", "TREATMENT", 396, 433], ["the Molecular Mechanics Force Field (MM\u00fe) procedure", "TREATMENT", 463, 514], ["Hyperchem", "TEST", 527, 536], ["benzimidazole derivatives", "OBSERVATION", 408, 433]]], ["We chose a gradient norm limit of 0.01 kcal/A for the geometry optimization.", [["the geometry optimization", "TREATMENT", 50, 75]]], ["The lowest energy structure was used for each molecule to calculate physicochemical properties using TSAR 3.3 software for Windows [49] .", [["TSAR", "TEST", 101, 105]]], ["Further, the regression analysis was performed using the SPSS software package [50] .QSAR studiesThe predictive powers of the equations were validated by leave one out (LOO) cross validation method, where a model is built with N-1 compounds and Nth compound is predicted.", [["N-1 compounds", "CHEMICAL", 227, 240], ["Nth", "CHEMICAL", 245, 248], ["Nth", "CHEMICAL", 245, 248], ["N-1 compounds", "SIMPLE_CHEMICAL", 227, 240], ["Nth compound", "SIMPLE_CHEMICAL", 245, 257], ["the regression analysis", "TEST", 9, 32], ["QSAR studies", "TEST", 85, 97]]], ["Each compound is left out of the model derivation and predicted in turn.", [["the model derivation", "TREATMENT", 29, 49], ["left", "ANATOMY_MODIFIER", 17, 21], ["model derivation", "OBSERVATION", 33, 49]]], ["S (Y predicted \u00c0 Y actual ) 2 is predictive residual error sum of squares [51] . ) and HIV-2(ROD) in MT-4 cell cultures and the results were expressed as the 50% effective concentration (EC 50 ) or drug concentration required to inhibit virus-induced cytopathicity by 50%.", [["MT-4 cell cultures", "ANATOMY", 101, 119], ["cytopathicity", "DISEASE", 251, 264], ["MT-4 cell cultures", "CELL", 101, 119], ["MT-4 cell cultures", "CELL_LINE", 101, 119], ["HIV", "TEST", 87, 90], ["cell cultures", "TEST", 106, 119], ["drug concentration", "PROBLEM", 198, 216], ["virus", "PROBLEM", 237, 242], ["induced cytopathicity", "PROBLEM", 243, 264]]], ["Read-out was through microscopical inspection or the MTS viability staining method.", [["microscopical inspection", "TEST", 21, 45]]], ["Cells, grown in 96-well plates, were infected with 100 CCID 50 of virus, one CCID 50 being the 50% cell culture infective dose in the presence of serial dilutions of the compounds.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 99, 103], ["Cells", "CELL", 0, 5], ["cell", "CELL", 99, 103], ["Cells", "TEST", 0, 5], ["virus", "TREATMENT", 66, 71]]], ["The cultures were further incubated at 37 C for several (2e4) days, until complete cytopathicity was observed in the infected and untreated virus control.Cytotoxic assaysThe cytotoxicity of the compounds was evaluated in parallel with their antiviral activity in uninfected cell cultures, and is expressed as the minimum cytotoxic concentration (MCC) that causes a microscopically detectable alteration of normal cell morphology (HEL, HeLa, CRFK, MDCK and Vero cells).", [["cultures", "ANATOMY", 4, 12], ["cell cultures", "ANATOMY", 274, 287], ["cell", "ANATOMY", 413, 417], ["HEL", "ANATOMY", 430, 433], ["HeLa", "ANATOMY", 435, 439], ["CRFK", "ANATOMY", 441, 445], ["MDCK", "ANATOMY", 447, 451], ["Vero cells", "ANATOMY", 456, 466], ["cell cultures", "CELL", 274, 287], ["cell", "CELL", 413, 417], ["HEL", "CELL", 430, 433], ["HeLa", "CELL", 435, 439], ["CRFK", "CELL", 441, 445], ["MDCK", "CELL", 447, 451], ["Vero cells", "CELL", 456, 466], ["uninfected cell cultures", "CELL_LINE", 263, 287], ["HEL", "CELL_LINE", 430, 433], ["HeLa", "CELL_LINE", 435, 439], ["CRFK", "CELL_LINE", 441, 445], ["MDCK", "CELL_LINE", 447, 451], ["Vero cells", "CELL_LINE", 456, 466], ["The cultures", "TEST", 0, 12], ["complete cytopathicity", "PROBLEM", 74, 96], ["untreated virus control", "TREATMENT", 130, 153], ["Cytotoxic assays", "TEST", 154, 170], ["The cytotoxicity of the compounds", "PROBLEM", 170, 203], ["uninfected cell cultures", "TEST", 263, 287], ["a microscopically detectable alteration of normal cell morphology", "PROBLEM", 363, 428], ["HEL", "TEST", 430, 433], ["HeLa", "TEST", 435, 439], ["CRFK", "TEST", 441, 445], ["infected", "OBSERVATION", 117, 125], ["untreated virus", "OBSERVATION", 130, 145], ["cytotoxicity", "OBSERVATION_MODIFIER", 174, 186], ["compounds", "OBSERVATION_MODIFIER", 194, 203], ["antiviral activity", "OBSERVATION", 241, 259], ["uninfected cell cultures", "OBSERVATION", 263, 287], ["microscopically", "OBSERVATION_MODIFIER", 365, 380], ["detectable", "OBSERVATION_MODIFIER", 381, 391], ["alteration", "OBSERVATION_MODIFIER", 392, 402], ["normal cell morphology", "OBSERVATION", 406, 428], ["Vero cells", "OBSERVATION", 456, 466]]]], "813aa3cdf6ea385c5741d4e71d31e75656e8a895": [["InterpretationTalcum powder, a petrolatum-lanolin mixture, and a coconut oil-cocoa butter-beeswax mixture showed excellent long-lasting low friction.", [["petrolatum-lanolin", "CHEMICAL", 31, 49], ["coconut oil-cocoa butter-beeswax", "CHEMICAL", 65, 97], ["petrolatum-lanolin", "CHEMICAL", 31, 49], ["petrolatum-lanolin", "SIMPLE_CHEMICAL", 31, 49], ["InterpretationTalcum powder", "TREATMENT", 0, 27], ["a petrolatum-lanolin mixture", "TREATMENT", 29, 57], ["a coconut oil", "TREATMENT", 63, 76], ["excellent", "OBSERVATION_MODIFIER", 113, 122], ["low friction", "OBSERVATION_MODIFIER", 136, 148]]], ["Moisturising the skin results in excessive friction, and the use of products that are aimed at 'moisturising without leaving a non-greasyCovid-19, PPE and skin injuryPersonal Protective Equipment (PPE) such as goggles, visors and respiratory protective equipment are a critical component in the defence against infectious diseases for frontline medical personnel.", [["skin", "ANATOMY", 17, 21], ["skin", "ANATOMY", 155, 159], ["skin injury", "DISEASE", 155, 166], ["infectious diseases", "DISEASE", 311, 330], ["skin", "ORGAN", 17, 21], ["skin", "ORGAN", 155, 159], ["excessive friction", "PROBLEM", 33, 51], ["products", "TREATMENT", 68, 76], ["a non-greasyCovid", "TREATMENT", 125, 142], ["skin injury", "PROBLEM", 155, 166], ["Personal Protective Equipment (PPE)", "TREATMENT", 166, 201], ["visors", "TREATMENT", 219, 225], ["respiratory protective equipment", "TREATMENT", 230, 262], ["skin", "ANATOMY", 17, 21], ["excessive friction", "OBSERVATION", 33, 51], ["skin", "ANATOMY", 155, 159], ["injury", "OBSERVATION", 160, 166]]], ["During the COVID-19 pandemic, the use of facial PPE is essential to limit the infection rate as the SARS-CoV-2 virus enters and infects human cells through respiratory, oral and ocular mucosal membranes via airborne transmission of contaminated droplets [1, 2] .", [["facial", "ANATOMY", 41, 47], ["cells", "ANATOMY", 142, 147], ["respiratory", "ANATOMY", 156, 167], ["oral", "ANATOMY", 169, 173], ["ocular mucosal membranes", "ANATOMY", 178, 202], ["infection", "DISEASE", 78, 87], ["SARS", "DISEASE", 100, 104], ["PPE", "GENE_OR_GENE_PRODUCT", 48, 51], ["SARS-CoV-2 virus", "ORGANISM", 100, 116], ["human", "ORGANISM", 136, 141], ["cells", "CELL", 142, 147], ["oral", "ORGANISM_SUBDIVISION", 169, 173], ["ocular mucosal membranes", "MULTI-TISSUE_STRUCTURE", 178, 202], ["human cells", "CELL_TYPE", 136, 147], ["CoV-2 virus", "SPECIES", 105, 116], ["human", "SPECIES", 136, 141], ["SARS-CoV-2 virus", "SPECIES", 100, 116], ["human", "SPECIES", 136, 141], ["the COVID", "TEST", 7, 16], ["facial PPE", "TREATMENT", 41, 51], ["the infection rate", "PROBLEM", 74, 92], ["the SARS", "TEST", 96, 104], ["CoV", "TEST", 105, 108], ["facial", "ANATOMY", 41, 47], ["ocular mucosal", "ANATOMY", 178, 192]]], ["Refreshment of PPE poses increased virus exposure risk and as such, medical staff wear their facial PPE for much longer than recommended.", [["facial", "ANATOMY", 93, 99], ["PPE", "CHEMICAL", 15, 18], ["PPE", "GENE_OR_GENE_PRODUCT", 15, 18], ["PPE", "TREATMENT", 15, 18], ["increased virus exposure risk", "PROBLEM", 25, 54], ["their facial PPE", "TREATMENT", 87, 103]]], ["The recent global COVID-19 pandemic has highlighted that prolonged use of facial PPE can cause a range of skin issues, including irritation and injuries such as skin tears, pressure injuries and urticaria [3] .", [["facial", "ANATOMY", 74, 80], ["skin", "ANATOMY", 106, 110], ["skin", "ANATOMY", 161, 165], ["PPE", "CHEMICAL", 81, 84], ["injuries", "DISEASE", 144, 152], ["skin tears", "DISEASE", 161, 171], ["pressure injuries", "DISEASE", 173, 190], ["urticaria", "DISEASE", 195, 204], ["skin", "ORGAN", 106, 110], ["skin", "ORGAN", 161, 165], ["The recent global COVID", "TEST", 0, 23], ["facial PPE", "TREATMENT", 74, 84], ["skin issues", "PROBLEM", 106, 117], ["irritation", "PROBLEM", 129, 139], ["injuries", "PROBLEM", 144, 152], ["skin tears", "PROBLEM", 161, 171], ["pressure injuries", "PROBLEM", 173, 190], ["urticaria", "PROBLEM", 195, 204], ["skin", "ANATOMY", 106, 110], ["skin", "ANATOMY", 161, 165], ["tears", "OBSERVATION", 166, 171], ["pressure injuries", "OBSERVATION", 173, 190], ["urticaria", "OBSERVATION", 195, 204]]], ["Maintaining skin health and preventing injury whilst using PPE has become an important aspect of advice to medical staff [4] .", [["skin", "ANATOMY", 12, 16], ["PPE", "CHEMICAL", 59, 62], ["skin", "ORGAN", 12, 16], ["injury", "PROBLEM", 39, 45], ["skin", "ANATOMY", 12, 16], ["injury", "OBSERVATION", 39, 45]]], ["Preventing skin injury has become increasingly critical as recent findings show that there also is a dermal pathway to COVID-19 infection [5] .", [["skin", "ANATOMY", 11, 15], ["dermal", "ANATOMY", 101, 107], ["skin injury", "DISEASE", 11, 22], ["COVID-19", "CHEMICAL", 119, 127], ["infection", "DISEASE", 128, 137], ["COVID-19", "CHEMICAL", 119, 127], ["skin", "ORGAN", 11, 15], ["dermal", "TISSUE", 101, 107], ["COVID-19", "GENE_OR_GENE_PRODUCT", 119, 127], ["skin injury", "PROBLEM", 11, 22], ["a dermal pathway", "PROBLEM", 99, 115], ["COVID", "TEST", 119, 124], ["infection", "PROBLEM", 128, 137], ["skin", "ANATOMY", 11, 15], ["injury", "OBSERVATION", 16, 22]]], ["In a survey by Jiang et al. on skin injuries incurred by medical staff during the COVID-19 pandemic, respondents included the nasion, cheek bones and the forehead amongst the main affected anatomical sites [6] .", [["skin", "ANATOMY", 31, 35], ["cheek bones", "ANATOMY", 134, 145], ["forehead", "ANATOMY", 154, 162], ["skin injuries", "DISEASE", 31, 44], ["skin", "ORGAN", 31, 35], ["cheek bones", "MULTI-TISSUE_STRUCTURE", 134, 145], ["forehead", "ORGANISM_SUBDIVISION", 154, 162], ["skin injuries", "PROBLEM", 31, 44], ["the COVID", "TEST", 78, 87], ["the nasion, cheek bones and the forehead", "PROBLEM", 122, 162], ["skin", "ANATOMY", 31, 35], ["injuries", "OBSERVATION", 36, 44], ["cheek bones", "ANATOMY", 134, 145], ["forehead", "ANATOMY", 154, 162], ["main", "OBSERVATION_MODIFIER", 175, 179]]], ["Elevated shear strains are observed at bony prominences, explaining why PPE-induced facial skin injury is often found at these sites [7] .", [["bony prominences", "ANATOMY", 39, 55], ["facial skin", "ANATOMY", 84, 95], ["PPE", "CHEMICAL", 72, 75], ["skin injury", "DISEASE", 91, 102], ["bony prominences", "PATHOLOGICAL_FORMATION", 39, 55], ["PPE", "GENE_OR_GENE_PRODUCT", 72, 75], ["skin", "ORGAN", 91, 95], ["Elevated shear strains", "PROBLEM", 0, 22], ["PPE", "PROBLEM", 72, 75], ["facial skin injury", "PROBLEM", 84, 102], ["shear strains", "OBSERVATION", 9, 22], ["bony", "ANATOMY", 39, 43], ["prominences", "OBSERVATION", 44, 55], ["facial", "ANATOMY_MODIFIER", 84, 90], ["skin", "ANATOMY", 91, 95], ["injury", "OBSERVATION", 96, 102]]], ["They concluded that heavy sweating, increased duration of PPE use, the application of higher-grade PPE, and being of the male gender were significant risk indicators for skin injury to occur.", [["skin", "ANATOMY", 170, 174], ["heavy sweating", "DISEASE", 20, 34], ["skin injury", "DISEASE", 170, 181], ["skin", "ORGAN", 170, 174], ["heavy sweating", "PROBLEM", 20, 34], ["higher-grade PPE", "TREATMENT", 86, 102], ["skin injury", "PROBLEM", 170, 181], ["heavy", "OBSERVATION_MODIFIER", 20, 25], ["sweating", "OBSERVATION", 26, 34], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["skin", "ANATOMY", 170, 174], ["injury", "OBSERVATION", 175, 181]]], ["Heavy and airtight PPE inhibits perspiration to volatilise, thus changing the microclimate and decreasing the tolerance of skin to injury [8, 9] .", [["skin", "ANATOMY", 123, 127], ["skin", "ORGAN", 123, 127], ["Heavy and airtight PPE", "PROBLEM", 0, 22], ["perspiration", "PROBLEM", 32, 44], ["volatilise", "TREATMENT", 48, 58], ["injury", "PROBLEM", 131, 137], ["airtight", "OBSERVATION_MODIFIER", 10, 18], ["PPE", "OBSERVATION", 19, 22], ["skin", "ANATOMY", 123, 127], ["injury", "OBSERVATION", 131, 137]]], ["Foo et al. reported high rates of detrimental skin reactions amongst N95 face mask users and concluded a need to investigate alternate means to prevent injury [10] .Relating the clinical issues to biomechanicsThe negative effects of shear forces acting on the skin have long been established, Reichel demonstrated in 1958 that skin injury develops at lower pressures when a shear force is applied to the skin [11] .", [["skin", "ANATOMY", 46, 50], ["skin", "ANATOMY", 260, 264], ["skin", "ANATOMY", 327, 331], ["skin", "ANATOMY", 404, 408], ["skin injury", "DISEASE", 327, 338], ["skin", "ORGAN", 46, 50], ["skin", "ORGAN", 260, 264], ["skin", "ORGAN", 327, 331], ["skin", "ORGAN", 404, 408], ["detrimental skin reactions", "PROBLEM", 34, 60], ["N95 face mask", "TREATMENT", 69, 82], ["injury", "PROBLEM", 152, 158], ["shear forces", "TREATMENT", 233, 245], ["skin injury", "PROBLEM", 327, 338], ["a shear force", "TREATMENT", 372, 385], ["skin", "ANATOMY", 46, 50], ["negative", "OBSERVATION", 213, 221], ["shear forces", "OBSERVATION", 233, 245], ["skin", "ANATOMY", 260, 264], ["skin", "ANATOMY", 327, 331], ["injury", "OBSERVATION", 332, 338], ["lower pressures", "OBSERVATION_MODIFIER", 351, 366], ["skin", "ANATOMY", 404, 408]]], ["In addition, excessive shear can affect the integrity of skin and the combination of high shear stresses and weakened structure of the skin will result in substantial tissue deformation and cellular distortion [12] .", [["skin", "ANATOMY", 57, 61], ["skin", "ANATOMY", 135, 139], ["tissue", "ANATOMY", 167, 173], ["cellular", "ANATOMY", 190, 198], ["skin", "ORGAN", 57, 61], ["skin", "ORGAN", 135, 139], ["tissue", "TISSUE", 167, 173], ["cellular", "CELL", 190, 198], ["excessive shear", "PROBLEM", 13, 28], ["high shear stresses", "PROBLEM", 85, 104], ["weakened structure of the skin", "PROBLEM", 109, 139], ["substantial tissue deformation", "PROBLEM", 155, 185], ["cellular distortion", "PROBLEM", 190, 209], ["excessive shear", "OBSERVATION", 13, 28], ["skin", "ANATOMY", 57, 61], ["high shear stresses", "OBSERVATION", 85, 104], ["weakened", "OBSERVATION", 109, 117], ["skin", "ANATOMY", 135, 139], ["substantial tissue deformation", "OBSERVATION", 155, 185], ["cellular distortion", "OBSERVATION", 190, 209]]], ["Shear loading decreases blood perfusion and transcutaneous oxygen level in skin, making it more prone to injury [13] .", [["blood", "ANATOMY", 24, 29], ["transcutaneous", "ANATOMY", 44, 58], ["skin", "ANATOMY", 75, 79], ["oxygen", "CHEMICAL", 59, 65], ["oxygen", "CHEMICAL", 59, 65], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["oxygen", "SIMPLE_CHEMICAL", 59, 65], ["skin", "ORGAN", 75, 79], ["Shear loading", "TREATMENT", 0, 13], ["blood perfusion", "TEST", 24, 39], ["transcutaneous oxygen level", "TEST", 44, 71], ["injury", "PROBLEM", 105, 111], ["skin", "ANATOMY", 75, 79]]], ["These findings, as schematically summarised in Fig 1B, mean that controlling the level of shear in the skin-PPE interface is critical to the prevention of injury.", [["skin", "ANATOMY", 103, 107], ["skin", "ORGAN", 103, 107], ["injury", "PROBLEM", 155, 161], ["shear", "OBSERVATION_MODIFIER", 90, 95], ["skin", "ANATOMY", 103, 107], ["PPE interface", "OBSERVATION", 108, 121], ["injury", "OBSERVATION", 155, 161]]], ["Shear stresses occur at the skin-PPE interface due to three primary mechanisms: (i) expansion of the PPE material in the direction perpendicular to loading; (ii) sticking of the contacting bodies due to static friction that prevents initial sliding, and to a lesser extent (iii) dynamic friction due to macroscopic sliding of the contacting bodies.", [["skin", "ANATOMY", 28, 32], ["skin", "ORGAN", 28, 32], ["Shear stresses", "PROBLEM", 0, 14], ["expansion of the PPE material", "PROBLEM", 84, 113], ["static friction", "PROBLEM", 203, 218], ["initial sliding", "TREATMENT", 233, 248], ["dynamic friction", "PROBLEM", 279, 295], ["stresses", "OBSERVATION", 6, 14], ["skin", "ANATOMY", 28, 32], ["static friction", "OBSERVATION", 203, 218], ["lesser extent", "OBSERVATION_MODIFIER", 259, 272], ["dynamic friction", "OBSERVATION", 279, 295], ["macroscopic sliding", "OBSERVATION", 303, 322]]], ["These three mechanisms may occur due to motion of facial features and adjustments of the PPE.", [["facial", "ANATOMY", 50, 56], ["motion of facial features", "PROBLEM", 40, 65], ["the PPE", "TREATMENT", 85, 92], ["facial", "ANATOMY", 50, 56]]], ["This is also recognised in recent literature and advice to medical staff, which include halfhourly application of a lubricant or a moisturiser to the skin [4, 14] .PLOS ONEEvaluating lubricant performance to reduce COVID-19 PPE-related skin injury PLOS ONE | https://doi.org/10.1371/journal.pone.0239363 September 24, 2020 2 / 13PLOS ONEFunding: The authors thank the Imperial College COVID-19 response fund for funding this study.Competing interests:The authors declare no conflict of interest.", [["skin", "ANATOMY", 150, 154], ["skin", "ANATOMY", 236, 240], ["skin injury", "DISEASE", 236, 247], ["skin", "ORGAN", 150, 154], ["skin", "ORGAN", 236, 240], ["a lubricant", "TREATMENT", 114, 125], ["COVID", "TEST", 215, 220], ["skin injury", "PROBLEM", 236, 247], ["funding this study", "TEST", 412, 430], ["skin", "ANATOMY", 150, 154], ["skin", "ANATOMY", 236, 240], ["injury", "OBSERVATION", 241, 247]]], ["All substances tested were obtained through normal commercial channels, except for some dressings, where the supplier provided a free trial version on their website, and one of the waxes, which was only available in the USA and was delivered to the investigators upon request.", [["All substances", "TEST", 0, 14], ["some dressings", "TREATMENT", 83, 97], ["a free trial version", "TREATMENT", 127, 147]]], ["The corresponding author had full access to data in the study and had final responsibility for the decision to submit for publication.", [["the study", "TEST", 52, 61]]], ["This does not alter our adherence to PLOS ONE policies on sharing data and materials.Competing interests:It can be concluded that understanding the interaction between skin and PPE is essential to prevent injury [15] .", [["skin", "ANATOMY", 168, 172], ["skin", "ORGAN", 168, 172], ["skin and PPE", "TREATMENT", 168, 180], ["injury", "PROBLEM", 205, 211], ["skin", "ANATOMY", 168, 172]]], ["In this work we present our investigation into the shear loads caused by static friction in a skin-polydimethylsiloxane (PDMS) interface under conditions replicating that of a PPE-skin contact.", [["skin", "ANATOMY", 94, 98], ["skin", "ANATOMY", 180, 184], ["skin-polydimethylsiloxane", "CHEMICAL", 94, 119], ["PDMS", "CHEMICAL", 121, 125], ["polydimethylsiloxane", "CHEMICAL", 99, 119], ["PDMS", "CHEMICAL", 121, 125], ["skin", "ORGAN", 94, 98], ["skin", "ORGAN", 180, 184], ["a skin-polydimethylsiloxane (PDMS)", "TREATMENT", 92, 126], ["static friction", "OBSERVATION", 73, 88], ["skin", "ANATOMY", 94, 98], ["skin", "ANATOMY", 180, 184]]], ["PDMS was chosen as it is commonly used in PPE as the compliant material that interfaces with skin.", [["skin", "ANATOMY", 93, 97], ["PDMS", "CHEMICAL", 0, 4], ["PDMS", "CHEMICAL", 0, 4], ["skin", "ORGAN", 93, 97], ["PDMS", "TREATMENT", 0, 4], ["skin", "ANATOMY", 93, 97]]], ["The objective is to provide hospital staff with advice and practical solutions when they are required to wear facial PPE for prolonged periods of time.Competing interests:This study provides evidence that the application of a commercially available, inexpensive, and dermatologically safe lubricant at the skin-PPE interface results in lower shear stresses over extended periods of time and could therefore relieve skin injuries caused by PPE (Fig 1C) .Methods and materialsThe study was approved by the Imperial College London Science, Engineering and Technology Research Ethics Committee (SETREC), reference 20IC5999.TribometerA portable tribometer with a wheel-shaped probe is used in this work (Fig 2A) [16] .", [["facial", "ANATOMY", 110, 116], ["skin", "ANATOMY", 306, 310], ["skin", "ANATOMY", 415, 419], ["skin injuries", "DISEASE", 415, 428], ["20IC5999", "CHEMICAL", 610, 618], ["skin", "ORGAN", 306, 310], ["skin", "ORGAN", 415, 419], ["wheel-shaped probe", "DNA", 658, 676], ["practical solutions", "TREATMENT", 59, 78], ["facial PPE", "TREATMENT", 110, 120], ["This study", "TEST", 171, 181], ["lower shear stresses", "PROBLEM", 336, 356], ["skin injuries", "PROBLEM", 415, 428], ["The study", "TEST", 474, 483], ["a wheel-shaped probe", "TREATMENT", 656, 676], ["skin", "ANATOMY", 306, 310], ["lower shear", "OBSERVATION_MODIFIER", 336, 347], ["skin", "ANATOMY", 415, 419], ["injuries", "OBSERVATION", 420, 428]]], ["The motorised wheel is placed against the skin, creating a shear force upon rotation.", [["skin", "ANATOMY", 42, 46], ["skin", "ORGAN", 42, 46], ["a shear force upon rotation", "TREATMENT", 57, 84], ["skin", "ANATOMY", 42, 46]]], ["The motor is connected to two perpendicularly mounted force transducers that measure the applied normal load and the resulting shear forces in the contact.", [["two perpendicularly mounted force transducers", "TREATMENT", 26, 71], ["normal", "OBSERVATION", 97, 103], ["shear", "OBSERVATION_MODIFIER", 127, 132], ["forces", "OBSERVATION_MODIFIER", 133, 139]]], ["The system is free to move vertically through sliding bearings whilst horizontal motion is restricted.", [["free", "OBSERVATION_MODIFIER", 14, 18], ["sliding bearings", "OBSERVATION", 46, 62]]], ["The load on the skin-probe contact is applied through dead-weight loading and, when the device is used upright, equals the combined weight of the probe, motor, force transducers and the slider.", [["skin", "ANATOMY", 16, 20], ["skin", "ORGAN", 16, 20], ["dead-weight loading", "TREATMENT", 54, 73], ["the device", "TREATMENT", 84, 94], ["skin", "ANATOMY", 16, 20]]], ["The probe has a width of 10 mm and a diameter of 33 mm.", [["width", "OBSERVATION_MODIFIER", 16, 21], ["10 mm", "OBSERVATION_MODIFIER", 25, 30], ["diameter", "OBSERVATION_MODIFIER", 37, 45], ["33 mm", "OBSERVATION_MODIFIER", 49, 54]]], ["It comprises a 25 mm aluminium core, covered with a 2 mm adhesive tape and a 2 mm platinum cured PDMS layer (Silex, Hampshire, UK).", [["aluminium", "CHEMICAL", 21, 30], ["platinum", "CHEMICAL", 82, 90], ["aluminium", "CHEMICAL", 21, 30], ["platinum", "CHEMICAL", 82, 90], ["PDMS", "CHEMICAL", 97, 101], ["a 25 mm aluminium core", "TREATMENT", 13, 35], ["a 2 mm adhesive tape", "TREATMENT", 50, 70], ["a 2 mm platinum cured PDMS layer", "TREATMENT", 75, 107], ["25 mm", "OBSERVATION_MODIFIER", 15, 20], ["layer", "OBSERVATION_MODIFIER", 102, 107]]], ["The rotational velocity of the probe is 10\ufffd6 rpm, resulting in a sliding speed of 18\ufffd4 mm s -1 at the skin interface.TribometerBrill et al. state that contact pressures for ventilation masks range between 8 and 30 kPa [17] .", [["skin", "ANATOMY", 102, 106], ["skin", "ORGAN", 102, 106], ["The rotational velocity", "TEST", 0, 23], ["a sliding speed", "TEST", 63, 78], ["contact pressures", "TEST", 151, 168], ["ventilation masks", "TREATMENT", 173, 190], ["rotational", "OBSERVATION_MODIFIER", 4, 14], ["velocity", "OBSERVATION_MODIFIER", 15, 23], ["10\ufffd6 rpm", "OBSERVATION", 40, 48], ["skin", "ANATOMY", 102, 106], ["interface", "ANATOMY_MODIFIER", 107, 116]]], ["Kuilenburg suggests an effective modulus of elasticity of 50 kPa for skin at this length scale [18] .", [["skin", "ANATOMY", 69, 73], ["skin", "ORGAN", 69, 73], ["effective", "OBSERVATION_MODIFIER", 23, 32], ["modulus", "OBSERVATION", 33, 40], ["50 kPa", "OBSERVATION_MODIFIER", 58, 64], ["skin", "ANATOMY", 69, 73]]], ["A load of 1\ufffd1 N in combination with the dimensions and properties of the probe results in a mean contact pressure of 20 kPa.", [["1\ufffd1 N", "CHEMICAL", 10, 15], ["A load of 1\ufffd1 N", "TREATMENT", 0, 15], ["a mean contact pressure", "TEST", 90, 113]]], ["Experiments were performed on the skin of the left (non-dominant) arm, with the sliding direction of the wheel from the radial to the ulnar side.", [["skin", "ANATOMY", 34, 38], ["left", "ANATOMY", 46, 50], ["radial", "ANATOMY", 120, 126], ["ulnar", "ANATOMY", 134, 139], ["skin", "ORGAN", 34, 38], ["ulnar side", "MULTI-TISSUE_STRUCTURE", 134, 144], ["skin", "ANATOMY", 34, 38], ["left", "ANATOMY_MODIFIER", 46, 50], ["arm", "ANATOMY", 66, 69], ["radial", "ANATOMY_MODIFIER", 120, 126], ["ulnar", "ANATOMY", 134, 139]]], ["The normal and shear forces during the experiments were measured and a resulting coefficient of friction was calculated.", [["the experiments", "TEST", 35, 50], ["normal", "OBSERVATION", 4, 10], ["shear", "OBSERVATION_MODIFIER", 15, 20], ["forces", "OBSERVATION_MODIFIER", 21, 27]]], ["Fig 2C shows two typical curves for a dry (blue) and a lubricated (orange) contact.", [["a dry (blue", "TREATMENT", 36, 47], ["a lubricated (orange", "TREATMENT", 53, 73]]], ["The maximum coefficient of friction during the initial stage of sliding, representing the transition from static to dynamic friction, was reported ( Fig 2D) .", [["sliding", "TREATMENT", 64, 71], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["coefficient", "OBSERVATION_MODIFIER", 12, 23], ["friction", "OBSERVATION_MODIFIER", 27, 35], ["dynamic friction", "OBSERVATION", 116, 132]]], ["Each experiment was performed three times, and in the results (Fig 3) the standard deviation is shown using error bars.ParticipantsDue to COVID-19 restrictions, performing in vivo tests was limited to a single participant.", [["participant", "SPECIES", 210, 221], ["vivo tests", "TEST", 175, 185]]], ["The participant, Caucasian male, healthy, age 44 years, mass 80 kg, height 1.84 m, gave informed consent.", [["participant", "SPECIES", 4, 15], ["mass", "PROBLEM", 56, 60]]], ["Our previous work has shown large interpersonal differences in friction for unlubricated skin, which are related to variations in sebum, hydration and mechanical properties [16, 19] .", [["skin", "ANATOMY", 89, 93], ["sebum", "ANATOMY", 130, 135], ["skin", "ORGAN", 89, 93], ["sebum", "TISSUE", 130, 135], ["unlubricated skin", "PROBLEM", 76, 93], ["variations in sebum", "PROBLEM", 116, 135], ["hydration and mechanical properties", "TREATMENT", 137, 172], ["large", "OBSERVATION_MODIFIER", 28, 33], ["interpersonal", "OBSERVATION_MODIFIER", 34, 47], ["differences", "OBSERVATION_MODIFIER", 48, 59], ["friction", "OBSERVATION_MODIFIER", 63, 71], ["skin", "ANATOMY", 89, 93], ["sebum", "ANATOMY", 130, 135]]], ["Although exact values may vary between people, Derler et al. demonstrated that the observed trends in friction are repeatable for variations of the lubrication and skin hydration [20] .", [["skin", "ANATOMY", 164, 168], ["people", "ORGANISM", 39, 45], ["skin", "ORGAN", 164, 168], ["people", "SPECIES", 39, 45], ["the lubrication and skin hydration", "TREATMENT", 144, 178], ["skin", "ANATOMY", 164, 168]]], ["Additionally, Veijgen et al. and Falloon et al. found that age was not a major parameter affecting friction [16, 21] .", [["Falloon et al", "TREATMENT", 33, 46]]], ["The experimental programme was performed over a one month period, from mid-May to mid-June 2020.Friction reducing agentsCriteria for products to be included in this investigation were (i) commercial availability, and (ii) safe for topical application.", [["Friction reducing agents", "TREATMENT", 96, 120], ["topical application", "TREATMENT", 231, 250]]], ["A longlist of commercially available creams, balms, powders, and ointments with a wide range of ingredients was composed, from which a shortlist was compiled based on direct availability and minimisation of duplication of main ingredients.", [["balms", "SIMPLE_CHEMICAL", 45, 50], ["commercially available creams", "TREATMENT", 14, 43], ["balms", "TREATMENT", 45, 50], ["powders", "TREATMENT", 52, 59], ["ointments", "TREATMENT", 65, 74], ["a wide range of ingredients", "TREATMENT", 80, 107], ["duplication of main ingredients", "TREATMENT", 207, 238], ["main", "OBSERVATION_MODIFIER", 222, 226]]], ["The resulting shortlist of products was categorised into four groups depending on their appearance: \"creams and grease-like lubricants\", \"wax-like lubricants\", \"powders\", and \"dressings and thin solid films\".", [["creams", "TREATMENT", 101, 107], ["\"dressings and thin solid films", "TREATMENT", 175, 206]]], ["Protocol Experiments were performed on the left (non-dominant) volar forearm, which is commonly used as a test site [19] [20] [21] [22] [23] .", [["volar forearm", "ANATOMY", 63, 76], ["[19] [20] [21] [22] [23]", "CHEMICAL", 116, 140], ["volar forearm", "MULTI-TISSUE_STRUCTURE", 63, 76], ["[19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 116, 140], ["a test site", "TEST", 104, 115], ["left", "ANATOMY_MODIFIER", 43, 47], ["volar forearm", "ANATOMY", 63, 76]]], ["Hendriks et al. reported no significant difference in friction values measured on the forearm and the cheek for a range of materials and conditions [22] .", [["forearm", "ANATOMY", 86, 93], ["cheek", "ANATOMY", 102, 107], ["forearm", "ORGANISM_SUBDIVISION", 86, 93], ["cheek", "ORGAN", 102, 107], ["friction values", "TEST", 54, 69], ["no", "UNCERTAINTY", 25, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["difference", "OBSERVATION_MODIFIER", 40, 50], ["friction values", "OBSERVATION", 54, 69], ["forearm", "ANATOMY", 86, 93], ["cheek", "ANATOMY", 102, 107]]], ["The forearm was placed in a relaxed position onto a solid horizontal surface, schematically illustrated in Fig 2B.", [["forearm", "ANATOMY", 4, 11], ["surface", "ANATOMY", 69, 76], ["forearm", "ORGAN", 4, 11], ["a solid horizontal surface", "TREATMENT", 50, 76], ["forearm", "ANATOMY", 4, 11], ["Fig 2B", "OBSERVATION", 107, 113]]], ["The casing of the tribometer was placed onto the forearm, also initiating contact between the probe and the skin test-site.", [["forearm", "ANATOMY", 49, 56], ["skin", "ANATOMY", 108, 112], ["forearm", "ORGANISM_SUBDIVISION", 49, 56], ["skin", "ORGAN", 108, 112], ["skin test-site", "DNA", 108, 122], ["the tribometer", "TREATMENT", 14, 28], ["the skin test", "TEST", 104, 117], ["forearm", "ANATOMY", 49, 56], ["skin", "ANATOMY", 108, 112]]], ["After a waiting period of 2\ufffd5 s, rotation of the probe was initiated, creating a sliding interface between the probe and the skin surface.Friction reducing agents48 hours before commencing the experimental programme, hair was removed from the skin by strip waxing.", [["skin surface", "ANATOMY", 125, 137], ["hair", "ANATOMY", 217, 221], ["skin", "ANATOMY", 243, 247], ["skin", "ORGAN", 125, 129], ["hair", "ORGAN", 217, 221], ["skin", "ORGAN", 243, 247], ["rotation of the probe", "TREATMENT", 33, 54], ["a sliding interface between the probe", "TREATMENT", 79, 116], ["the experimental programme", "TREATMENT", 189, 215], ["sliding interface", "OBSERVATION", 81, 98], ["skin", "ANATOMY", 125, 129], ["surface", "ANATOMY_MODIFIER", 130, 137], ["skin", "ANATOMY", 243, 247]]], ["This procedure was repeated every five days to keep the skin clear of hair, after which no experiments were performed for 12 hours.", [["skin", "ANATOMY", 56, 60], ["hair", "ANATOMY", 70, 74], ["skin", "ORGAN", 56, 60], ["hair", "ORGAN", 70, 74], ["This procedure", "TREATMENT", 0, 14], ["skin", "ANATOMY", 56, 60], ["clear", "OBSERVATION", 61, 66]]], ["At least one hour prior to an experiment, the skin was cleaned using water and a non-soap body wash (Aveeno Daily Moisturising, Johnson & Johnson, USA), rinsed and dried using a cloth towel.", [["skin", "ANATOMY", 46, 50], ["body", "ANATOMY", 90, 94], ["skin", "ORGAN", 46, 50], ["body", "ORGANISM_SUBDIVISION", 90, 94], ["water", "TREATMENT", 69, 74], ["a non-soap body wash (Aveeno", "TREATMENT", 79, 107], ["a cloth towel", "TREATMENT", 176, 189], ["skin", "ANATOMY", 46, 50]]], ["No further skin care regimen was followed.", [["skin", "ANATOMY", 11, 15], ["skin", "ORGAN", 11, 15], ["further skin care regimen", "TREATMENT", 3, 28], ["skin", "ANATOMY", 11, 15]]], ["The substance under investigation was applied to the skin as specified in the product information leaflet that was supplied with most products.", [["skin", "ANATOMY", 53, 57], ["skin", "ORGAN", 53, 57], ["skin", "ANATOMY", 53, 57]]], ["For most liquid substances, and for the cases where the amount to be applied was not specified clearly, this means that approximately 0\ufffd05 ml was applied at a location two-thirds of the distance from the wrist to the elbow.", [["wrist", "ANATOMY", 204, 209], ["elbow", "ANATOMY", 217, 222], ["wrist", "ORGANISM_SUBDIVISION", 204, 209], ["elbow", "ORGANISM_SUBDIVISION", 217, 222], ["most liquid substances", "TREATMENT", 4, 26], ["wrist", "ANATOMY", 204, 209], ["elbow", "ANATOMY", 217, 222]]], ["The substance was distributed and rubbed in using the index finger of the other hand over a 4 x 6 cm 2 area marked with a permanent marker, resulting in a coverage of approximately 2 mg/cm 2 .", [["hand", "ANATOMY", 80, 84], ["a permanent marker", "TREATMENT", 120, 138], ["rubbed", "OBSERVATION_MODIFIER", 34, 40], ["4 x 6 cm", "OBSERVATION_MODIFIER", 92, 100], ["permanent marker", "OBSERVATION_MODIFIER", 122, 138]]], ["For petrolatum to be effective, it has been suggested that a thick layer should be applied 14 .", [["petrolatum", "CHEMICAL", 4, 14], ["petrolatum", "CHEMICAL", 4, 14], ["petrolatum", "SIMPLE_CHEMICAL", 4, 14], ["petrolatum", "TREATMENT", 4, 14], ["a thick layer", "TREATMENT", 59, 72]]], ["This advice was also followed by applying about 0\ufffd5 ml to the skin.", [["skin", "ANATOMY", 62, 66], ["skin", "ORGAN", 62, 66], ["skin", "ANATOMY", 62, 66]]], ["Powders were deposited liberally onto the skin, rubbed in with the index finger of the other hand for 5 s and any excess powder was removed by briefly blowing onto the surface of the skin.PLOS ONEEvaluating lubricant performance to reduce COVID-19 PPE-related skin injury If a test provided a much-elevated friction compared to other products in the same category, then further tests using this product were not conducted.", [["skin", "ANATOMY", 42, 46], ["hand", "ANATOMY", 93, 97], ["surface", "ANATOMY", 168, 175], ["skin", "ANATOMY", 183, 187], ["skin", "ANATOMY", 260, 264], ["COVID-19 PPE", "CHEMICAL", 239, 251], ["skin injury", "DISEASE", 260, 271], ["skin", "ORGAN", 42, 46], ["finger", "ORGANISM_SUBDIVISION", 73, 79], ["hand", "ORGANISM_SUBDIVISION", 93, 97], ["surface", "CELLULAR_COMPONENT", 168, 175], ["skin", "ORGAN", 183, 187], ["skin", "ORGAN", 260, 264], ["Powders", "TREATMENT", 0, 7], ["any excess powder", "TREATMENT", 110, 127], ["COVID", "TEST", 239, 244], ["PPE", "PROBLEM", 248, 251], ["skin injury", "PROBLEM", 260, 271], ["a test", "TEST", 275, 281], ["a much-elevated friction", "PROBLEM", 291, 315], ["further tests", "TEST", 370, 383], ["this product", "TREATMENT", 390, 402], ["skin", "ANATOMY", 42, 46], ["rubbed", "OBSERVATION_MODIFIER", 48, 54], ["index finger", "ANATOMY", 67, 79], ["surface", "ANATOMY_MODIFIER", 168, 175], ["skin", "ANATOMY", 183, 187], ["skin", "ANATOMY", 260, 264], ["injury", "OBSERVATION", 265, 271]]], ["Additionally, if a test showed a strong increase of friction with time, no further measurements at other time-intervals were performed.", [["a test", "TEST", 17, 23], ["friction", "OBSERVATION_MODIFIER", 52, 60]]], ["After each experiment, the product was removed from the skin using a gentle wipe with a paper tissue and the skin was cleaned using water and non-soap body wash, followed by a recovery period of at least 3 h before another experiment was commenced.", [["skin", "ANATOMY", 56, 60], ["tissue", "ANATOMY", 94, 100], ["skin", "ANATOMY", 109, 113], ["body", "ANATOMY", 151, 155], ["skin", "ORGAN", 56, 60], ["tissue", "TISSUE", 94, 100], ["skin", "ORGAN", 109, 113], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["a gentle wipe", "TREATMENT", 67, 80], ["a paper tissue", "TREATMENT", 86, 100], ["water", "TREATMENT", 132, 137], ["non-soap body wash", "TREATMENT", 142, 160], ["skin", "ANATOMY", 56, 60], ["skin", "ANATOMY", 109, 113]]], ["A friction measurements on untreated, or 'dry' skin was performed at the start of every test day and, although dry friction results are inherently somewhat more variable than lubricated experiments asPLOS ONEEvaluating lubricant performance to reduce COVID-19 PPE-related skin injury evidenced by the error bars in Fig 3, no deviating trends were observed.", [["skin", "ANATOMY", 47, 51], ["skin", "ANATOMY", 272, 276], ["COVID-19 PPE", "CHEMICAL", 251, 263], ["skin injury", "DISEASE", 272, 283], ["skin", "ORGAN", 47, 51], ["skin", "ORGAN", 272, 276], ["A friction measurements", "TEST", 0, 23], ["'dry' skin", "PROBLEM", 41, 51], ["dry friction results", "PROBLEM", 111, 131], ["COVID", "TEST", 251, 256], ["PPE", "PROBLEM", 260, 263], ["skin injury", "PROBLEM", 272, 283], ["deviating trends", "PROBLEM", 325, 341], ["friction", "OBSERVATION_MODIFIER", 2, 10], ["skin", "ANATOMY", 47, 51], ["skin", "ANATOMY", 272, 276], ["injury", "OBSERVATION", 277, 283]]], ["This indicates that there was no significant change in the friction behaviour of the skin during the course of the experimental programme.", [["skin", "ANATOMY", 85, 89], ["skin", "ORGAN", 85, 89], ["significant change in the friction behaviour of the skin", "PROBLEM", 33, 89], ["no", "UNCERTAINTY", 30, 32], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["change", "OBSERVATION_MODIFIER", 45, 51], ["friction behaviour", "OBSERVATION", 59, 77], ["skin", "ANATOMY", 85, 89]]], ["In this contribution, we aim to provide a solution that will reduce PPE-skin shear forces over the duration of an extended shift of four hours.", [["skin", "ANATOMY", 72, 76], ["skin", "ORGAN", 72, 76], ["a solution", "TREATMENT", 40, 50], ["PPE", "TREATMENT", 68, 71], ["skin shear forces", "TREATMENT", 72, 89], ["skin", "ANATOMY", 72, 76], ["shear", "OBSERVATION", 77, 82]]], ["All lubricants listed in Table 1 were tested and, based on their friction performance directly upon application and after 5-10 minutes, a selection was made for testing over a fourhour period.", [["All lubricants", "TREATMENT", 0, 14], ["testing", "TEST", 161, 168]]], ["In between tests the skin with the applied product was covered by a piece of PDMS which was held in place using four fabric plasters.Role of the funding sourceThe research funder did not play a role in the research.", [["skin", "ANATOMY", 21, 25], ["skin", "ORGAN", 21, 25], ["the applied product", "TREATMENT", 31, 50], ["a piece of PDMS", "TREATMENT", 66, 81], ["skin", "ANATOMY", 21, 25]]], ["Fig 3 shows the measured coefficient of friction for the various products, alongside the value for unlubricated skin in the topmost red coloured bar.", [["skin", "ANATOMY", 112, 116], ["skin", "ORGAN", 112, 116], ["the various products", "TREATMENT", 53, 73], ["unlubricated skin", "PROBLEM", 99, 116], ["skin", "ANATOMY", 112, 116], ["coloured bar", "OBSERVATION", 136, 148]]], ["Results are grouped by product category: 'creams and grease-like products', 'wax-like products', 'powders' and 'dressings and thin solid films'.", [["creams", "TREATMENT", 42, 48], ["grease-like products", "TREATMENT", 53, 73], ["'powders'", "TREATMENT", 97, 106], ["'dressings", "TREATMENT", 111, 121], ["thin solid films", "TEST", 126, 142]]], ["The reported coefficient of friction for each product was measured directly upon application, and 1, 2 and 4 hours after application.ResultsMost products provide a low friction directly upon application and a reduction in friction to 20% of the unlubricated situation is observed.", [["a low friction", "TREATMENT", 162, 176], ["a reduction in friction", "TREATMENT", 207, 230], ["coefficient", "OBSERVATION_MODIFIER", 13, 24], ["friction", "OBSERVATION_MODIFIER", 28, 36], ["low friction", "OBSERVATION_MODIFIER", 164, 176], ["reduction", "OBSERVATION_MODIFIER", 209, 218], ["friction", "OBSERVATION_MODIFIER", 222, 230]]], ["For some products, this low initial friction is followed by a rapid increase over time, examples include 'silicone-based' and 'water and glycerine-based' products, for which the measured friction exceeds the original dry friction by 1% and 29%, respectively.", [["glycerine", "CHEMICAL", 137, 146], ["glycerine", "CHEMICAL", 137, 146], ["water", "SIMPLE_CHEMICAL", 127, 132], ["glycerine", "SIMPLE_CHEMICAL", 137, 146], ["'silicone-based' and 'water and glycerine", "TREATMENT", 105, 146], ["friction", "OBSERVATION_MODIFIER", 36, 44], ["rapid", "OBSERVATION_MODIFIER", 62, 67], ["increase", "OBSERVATION_MODIFIER", 68, 76]]], ["Other products, such as petrolatum show a more gradual increase over time, providing an initial friction reduction to 47% of the dry value, which increases again towards to dry value after approximately four hours.", [["petrolatum", "CHEMICAL", 24, 34], ["petrolatum", "SIMPLE_CHEMICAL", 24, 34], ["petrolatum", "TREATMENT", 24, 34], ["an initial friction reduction", "TREATMENT", 85, 114], ["the dry value", "TEST", 125, 138], ["gradual", "OBSERVATION_MODIFIER", 47, 54], ["increase", "OBSERVATION_MODIFIER", 55, 63]]], ["Powders with a liquid carrier generally show low instantaneous friction of approximately 50% of the dry friction, followed by an increase over time once the carrier has evaporated.", [["Powders", "TREATMENT", 0, 7], ["a liquid carrier", "TREATMENT", 13, 29], ["low instantaneous friction", "PROBLEM", 45, 71], ["the dry friction", "PROBLEM", 96, 112], ["low instantaneous", "OBSERVATION_MODIFIER", 45, 62], ["friction", "OBSERVATION_MODIFIER", 63, 71], ["dry friction", "OBSERVATION", 100, 112], ["increase", "OBSERVATION_MODIFIER", 129, 137]]], ["Most dry powder products did not provide sufficiently low values to warrant investigating their longer-term performance, except talcum powder which provides consistently low friction, rising from 49% of the dry friction value directly after application to 59% at 4 hours after application.", [["Most dry powder products", "TREATMENT", 0, 24], ["talcum powder", "TREATMENT", 128, 141], ["consistently low friction", "PROBLEM", 157, 182], ["the dry friction value", "PROBLEM", 203, 225], ["low friction", "OBSERVATION_MODIFIER", 170, 182], ["dry friction", "OBSERVATION_MODIFIER", 207, 219]]], ["The various dressings tested showed moderately reduced levels of friction, with levels at approximately 60% of the value for dry friction.", [["The various dressings", "TEST", 0, 21], ["moderately reduced levels of friction", "PROBLEM", 36, 73], ["levels", "TEST", 80, 86], ["dry friction", "PROBLEM", 125, 137], ["moderately", "OBSERVATION_MODIFIER", 36, 46], ["reduced", "OBSERVATION_MODIFIER", 47, 54], ["levels", "OBSERVATION_MODIFIER", 55, 61], ["friction", "OBSERVATION_MODIFIER", 65, 73], ["dry friction", "OBSERVATION", 125, 137]]], ["Overall, persistent low friction was obtained for the duration of the entire fourhour test for talcum powder (49%-59%), the petrolatum-lanolin mixture (30%) and the coconut oil-cocoa butter-beeswax mixture (31%-53%).DiscussionThese observations described above are in line with literature [19] [20] [21] [22] [23] .", [["petrolatum-lanolin", "CHEMICAL", 124, 142], ["coconut oil-cocoa butter-beeswax", "CHEMICAL", 165, 197], ["petrolatum", "CHEMICAL", 124, 134], ["lanolin", "CHEMICAL", 135, 142], ["petrolatum-lanolin", "SIMPLE_CHEMICAL", 124, 142], ["[19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 289, 313], ["persistent low friction", "PROBLEM", 9, 32], ["the entire fourhour test", "TEST", 66, 90], ["talcum powder", "TEST", 95, 108], ["the petrolatum-lanolin mixture", "TEST", 120, 150], ["the coconut oil", "TEST", 161, 176], ["persistent", "OBSERVATION_MODIFIER", 9, 19], ["low friction", "OBSERVATION", 20, 32], ["petrolatum", "ANATOMY", 124, 134], ["cocoa butter", "OBSERVATION", 177, 189]]], ["It is worth noting that friction is a system property that not only depends on the lubricant, but also on the materials in contact, the applied pressure, and the environmental conditions.", [["friction", "OBSERVATION", 24, 32]]], ["PPE that interfaces with skin often uses a compliant \"rubber-like\" material such as PDMS or a thermoplastic elastomer to reduce discomfort due to normal loading.", [["skin", "ANATOMY", 25, 29], ["PDMS", "CHEMICAL", 84, 88], ["skin", "ORGAN", 25, 29], ["a thermoplastic elastomer", "TREATMENT", 92, 117], ["discomfort", "PROBLEM", 128, 138], ["skin", "ANATOMY", 25, 29], ["normal", "OBSERVATION", 146, 152]]], ["However, most published work into contact mechanics and friction investigates hard specimens such as steel, glass or engineering plastics and focuses on the sliding or dynamic friction [19] [20] [21] [22] [23] .", [["specimens", "ANATOMY", 83, 92], ["[19] [20] [21] [22] [23]", "CHEMICAL", 185, 209], ["20] [21] [22] [23]", "SIMPLE_CHEMICAL", 191, 209], ["engineering plastics", "TREATMENT", 117, 137]]], ["Therefore, the applicability of existing tribological knowledge to PPE-skin interactions is limited.DiscussionIn the presented results, long-lasting low friction was observed for talcum powder, the coconut oil-cocoa butter-beeswax mixture and the petrolatum-lanolin mixture, whilst a range of products with almost similar composition demonstrated only brief-lasting low friction.", [["skin", "ANATOMY", 71, 75], ["coconut oil-cocoa butter-beeswax", "CHEMICAL", 198, 230], ["petrolatum-lanolin", "CHEMICAL", 247, 265], ["petrolatum", "CHEMICAL", 247, 257], ["lanolin", "CHEMICAL", 258, 265], ["skin", "ORGAN", 71, 75], ["beeswax", "SIMPLE_CHEMICAL", 223, 230], ["petrolatum-lanolin", "SIMPLE_CHEMICAL", 247, 265], ["butter", "SPECIES", 216, 222], ["talcum powder", "TREATMENT", 179, 192], ["the coconut oil", "TREATMENT", 194, 209], ["the petrolatum-lanolin mixture", "TREATMENT", 243, 273], ["skin", "ANATOMY", 71, 75], ["petrolatum", "ANATOMY", 247, 257], ["low friction", "OBSERVATION_MODIFIER", 366, 378]]], ["The friction in the skin-PPE contact depends on the interplay between the lubricant, the skin and the PPE material and includes the persistence of the product in the interface as well as the adsorption into the stratum corneum.", [["skin", "ANATOMY", 20, 24], ["skin", "ANATOMY", 89, 93], ["stratum corneum", "ANATOMY", 211, 226], ["skin", "ORGAN", 20, 24], ["skin", "ORGAN", 89, 93], ["stratum corneum", "TISSUE", 211, 226], ["the lubricant", "TREATMENT", 70, 83], ["the PPE material", "TREATMENT", 98, 114], ["friction", "OBSERVATION_MODIFIER", 4, 12], ["skin", "ANATOMY", 20, 24], ["PPE", "OBSERVATION", 25, 28], ["skin", "ANATOMY", 89, 93], ["stratum corneum", "ANATOMY", 211, 226]]], ["The total friction response is the combination of the forces related to viscoelastic deformation of the bulk material, F bulk , and the forces related to breaking of intermolecular bonds on the interface between the two material, F int , as shown in Eq (1).", [["The total friction response", "TREATMENT", 0, 27], ["the forces", "PROBLEM", 50, 60], ["viscoelastic deformation of the bulk material", "PROBLEM", 72, 117], ["breaking of intermolecular bonds", "PROBLEM", 154, 186], ["total", "OBSERVATION_MODIFIER", 4, 9], ["friction response", "OBSERVATION", 10, 27], ["forces", "OBSERVATION", 54, 60], ["viscoelastic deformation", "OBSERVATION", 72, 96], ["bulk material", "OBSERVATION", 104, 117], ["F bulk", "OBSERVATION_MODIFIER", 119, 125], ["intermolecular bonds", "OBSERVATION", 166, 186]]], ["Adams et al. demonstrated that for contacts between skin and other surfaces the interfacial friction dominates the total frictional effects, whilst viscoelastic effects may be ignored: [23]DiscussionThe interfacial friction force, Eq (2), is the product of the area of contact A between the two surfaces and the shear strength of the interface \u03c4:DiscussionWhilst this appears to be a straightforward relationship, i.e. lubricants directly affect \u03c4 thus causing low friction, the complexity is that with time the lubrication effect may decrease, whilst adding a substance to the skin may also have a pronounced effect on the contact area through various mechanisms, as illustrated in Fig 4A-4F .Creams and grease-like lubricantsCompared to the unlubricated situation of Fig 4A, applying a cream or grease-like product to the skin results in an instantaneous low friction, because of the reduced interfacial shear strength, as illustrated in Fig 4B.", [["skin", "ANATOMY", 52, 56], ["skin", "ANATOMY", 578, 582], ["skin", "ANATOMY", 824, 828], ["skin", "ORGAN", 52, 56], ["skin", "ORGAN", 578, 582], ["4A-4F", "GENE_OR_GENE_PRODUCT", 687, 692], ["skin", "ORGAN", 824, 828], ["contacts between skin and other surfaces the interfacial friction", "PROBLEM", 35, 100], ["the total frictional effects", "PROBLEM", 111, 139], ["The interfacial friction force", "TEST", 199, 229], ["low friction", "PROBLEM", 461, 473], ["the lubrication effect", "TREATMENT", 508, 530], ["Creams", "TREATMENT", 694, 700], ["grease-like lubricants", "TREATMENT", 705, 727], ["Fig 4A", "TREATMENT", 769, 775], ["a cream", "TREATMENT", 786, 793], ["an instantaneous low friction", "TREATMENT", 840, 869], ["the reduced interfacial shear strength", "TREATMENT", 882, 920], ["skin", "ANATOMY", 52, 56], ["interfacial friction", "OBSERVATION", 80, 100], ["total", "OBSERVATION_MODIFIER", 115, 120], ["frictional effects", "OBSERVATION", 121, 139], ["low friction", "OBSERVATION_MODIFIER", 461, 473], ["skin", "ANATOMY", 578, 582], ["pronounced", "OBSERVATION_MODIFIER", 599, 609], ["grease-like lubricants", "OBSERVATION_MODIFIER", 705, 727], ["skin", "ANATOMY", 824, 828], ["instantaneous", "OBSERVATION_MODIFIER", 843, 856], ["low friction", "OBSERVATION", 857, 869], ["interfacial shear strength", "OBSERVATION", 894, 920]]], ["A gradual increase in coefficient of friction is seen for petrolatum, whilst the silicone and glycerine-water demonstrate a rapid increase.", [["petrolatum", "CHEMICAL", 58, 68], ["glycerine", "CHEMICAL", 94, 103], ["petrolatum", "CHEMICAL", 58, 68], ["glycerine", "CHEMICAL", 94, 103], ["petrolatum", "SIMPLE_CHEMICAL", 58, 68], ["glycerine", "SIMPLE_CHEMICAL", 94, 103], ["A gradual increase in coefficient of friction", "PROBLEM", 0, 45], ["petrolatum", "TREATMENT", 58, 68], ["the silicone and glycerine", "TREATMENT", 77, 103], ["a rapid increase", "PROBLEM", 122, 138], ["gradual", "OBSERVATION_MODIFIER", 2, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["coefficient", "OBSERVATION_MODIFIER", 22, 33], ["friction", "OBSERVATION_MODIFIER", 37, 45], ["rapid", "OBSERVATION_MODIFIER", 124, 129], ["increase", "OBSERVATION_MODIFIER", 130, 138]]], ["The longer-term response depends on the interaction of the product and skin.", [["skin", "ANATOMY", 71, 75], ["skin", "ORGAN", 71, 75], ["longer-term response", "OBSERVATION_MODIFIER", 4, 24], ["skin", "ANATOMY", 71, 75]]], ["Dimethicone and petrolatum are highly efficient skin occlusives that prevent transepidermal water loss (TEWL) within 30 minutes of application [24, 25] .", [["skin", "ANATOMY", 48, 52], ["transepidermal", "ANATOMY", 77, 91], ["Dimethicone", "CHEMICAL", 0, 11], ["petrolatum", "CHEMICAL", 16, 26], ["transepidermal water loss", "DISEASE", 77, 102], ["Dimethicone", "CHEMICAL", 0, 11], ["petrolatum", "CHEMICAL", 16, 26], ["Dimethicone", "SIMPLE_CHEMICAL", 0, 11], ["petrolatum", "SIMPLE_CHEMICAL", 16, 26], ["skin", "ORGAN", 48, 52], ["Dimethicone", "TREATMENT", 0, 11], ["petrolatum", "TREATMENT", 16, 26], ["transepidermal water loss", "PROBLEM", 77, 102], ["petrolatum", "ANATOMY", 16, 26], ["water loss", "OBSERVATION", 92, 102]]], ["The entrapped water reduces the stiffness of the skin, whilst epidermal uptake of petrolatum or dimethicone is minimal, resulting in the situation described in Fig 4C [ 26] .", [["skin", "ANATOMY", 49, 53], ["epidermal", "ANATOMY", 62, 71], ["petrolatum", "CHEMICAL", 82, 92], ["dimethicone", "CHEMICAL", 96, 107], ["petrolatum", "CHEMICAL", 82, 92], ["dimethicone", "CHEMICAL", 96, 107], ["water", "SIMPLE_CHEMICAL", 14, 19], ["skin", "ORGAN", 49, 53], ["epidermal", "MULTI-TISSUE_STRUCTURE", 62, 71], ["petrolatum", "SIMPLE_CHEMICAL", 82, 92], ["dimethicone", "SIMPLE_CHEMICAL", 96, 107], ["The entrapped water", "TREATMENT", 0, 19], ["the stiffness of the skin", "PROBLEM", 28, 53], ["petrolatum", "TREATMENT", 82, 92], ["dimethicone", "TREATMENT", 96, 107], ["entrapped", "OBSERVATION_MODIFIER", 4, 13], ["water reduces", "OBSERVATION", 14, 27], ["stiffness", "OBSERVATION_MODIFIER", 32, 41], ["skin", "ANATOMY", 49, 53], ["minimal", "OBSERVATION_MODIFIER", 111, 118]]], ["Petrolatum is quite persistent on the skin surface, represented by Fig 4C, whilst dimethicone is more easily rubbed off, resulting in Fig 4D.", [["skin surface", "ANATOMY", 38, 50], ["Petrolatum", "CHEMICAL", 0, 10], ["dimethicone", "CHEMICAL", 82, 93], ["dimethicone", "CHEMICAL", 82, 93], ["Petrolatum", "SIMPLE_CHEMICAL", 0, 10], ["skin", "ORGAN", 38, 42], ["dimethicone", "SIMPLE_CHEMICAL", 82, 93], ["Petrolatum", "TREATMENT", 0, 10], ["quite", "OBSERVATION_MODIFIER", 14, 19], ["persistent", "OBSERVATION", 20, 30], ["skin", "ANATOMY", 38, 42], ["surface", "ANATOMY_MODIFIER", 43, 50]]], ["Comparing results obtained for petrolatum and the petrolatum-lanolin mixture suggests that the initial lubricating function of these two products is similar.", [["petrolatum", "CHEMICAL", 31, 41], ["petrolatum-lanolin", "CHEMICAL", 50, 68], ["petrolatum", "CHEMICAL", 31, 41], ["petrolatum-lanolin", "CHEMICAL", 50, 68], ["petrolatum", "SIMPLE_CHEMICAL", 31, 41], ["petrolatum-lanolin", "SIMPLE_CHEMICAL", 50, 68], ["petrolatum and the petrolatum-lanolin mixture", "TREATMENT", 31, 76], ["petrolatum", "ANATOMY", 50, 60], ["similar", "OBSERVATION_MODIFIER", 149, 156]]], ["Lanolin is an emollient that resembles natural skin lipids and is linked to lubricity [27] .", [["skin", "ANATOMY", 47, 51], ["Lanolin", "CHEMICAL", 0, 7], ["Lanolin", "CHEMICAL", 0, 7], ["Lanolin", "GENE_OR_GENE_PRODUCT", 0, 7], ["skin", "ORGAN", 47, 51], ["lipids", "ORGANISM_SUBSTANCE", 52, 58], ["Lanolin", "TREATMENT", 0, 7], ["an emollient", "TREATMENT", 11, 23], ["natural skin lipids", "TREATMENT", 39, 58]]], ["The obtained results suggest that compared to neat petrolatum, the addition of lanolin provides more enduring lubrication, whilst is still being highly occlusive, as evidenced by the friction traces shown in Fig 4B.", [["petrolatum", "CHEMICAL", 51, 61], ["lanolin", "CHEMICAL", 79, 86], ["lanolin", "CHEMICAL", 79, 86], ["lanolin", "SIMPLE_CHEMICAL", 79, 86], ["lanolin", "TREATMENT", 79, 86], ["the friction traces", "TEST", 179, 198], ["occlusive", "OBSERVATION", 152, 161], ["friction", "OBSERVATION", 183, 191]]], ["A third lubricant that shows constant results is the liquid paraffin and zinc oxide containing cream.", [["zinc oxide", "CHEMICAL", 73, 83], ["paraffin", "CHEMICAL", 60, 68], ["zinc oxide", "CHEMICAL", 73, 83], ["zinc oxide", "SIMPLE_CHEMICAL", 73, 83], ["cream", "SIMPLE_CHEMICAL", 95, 100], ["A third lubricant", "TREATMENT", 0, 17], ["the liquid paraffin and zinc oxide containing cream", "TREATMENT", 49, 100]]], ["Similar to the wax, described later in Fig 5C, it appears to be non-occlusive and forms a nonabsorbing and lubricating white film on the surface, a situation illustrated by Fig 4B.", [["surface", "ANATOMY", 137, 144], ["surface", "CELLULAR_COMPONENT", 137, 144], ["a nonabsorbing and lubricating white film", "PROBLEM", 88, 129], ["appears to be", "UNCERTAINTY", 50, 63], ["non-occlusive", "OBSERVATION", 64, 77]]], ["Humectants attract water to the stratum corneum and the epidermis from the dermis, softening the skin within 15 minutes upon application [28, 29] .", [["stratum corneum", "ANATOMY", 32, 47], ["epidermis", "ANATOMY", 56, 65], ["dermis", "ANATOMY", 75, 81], ["skin", "ANATOMY", 97, 101], ["Humectants", "SIMPLE_CHEMICAL", 0, 10], ["stratum corneum", "TISSUE", 32, 47], ["epidermis", "TISSUE", 56, 65], ["dermis", "TISSUE", 75, 81], ["skin", "ORGAN", 97, 101], ["Humectants", "TREATMENT", 0, 10], ["stratum corneum", "ANATOMY", 32, 47], ["epidermis", "ANATOMY", 56, 65], ["dermis", "ANATOMY", 75, 81], ["softening", "OBSERVATION_MODIFIER", 83, 92], ["skin", "ANATOMY", 97, 101]]], ["Commercial moisturising creams are often designed to not leave a greasy residue.", [["Commercial moisturising creams", "TREATMENT", 0, 30], ["a greasy residue", "PROBLEM", 63, 79]]], ["This leads to a situation which, in terms of reducing shear, is a highly undesirable combination of no lubrication, and thus a high value of \u03c4 and the skin being plasticised and soft, resulting in a large contact area A. This combination causes excessively high shear forces in the skin-PPE interface as schematically illustrated in Fig 4D.", [["skin", "ANATOMY", 151, 155], ["skin", "ANATOMY", 282, 286], ["skin", "ORGAN", 151, 155], ["skin", "ORGAN", 282, 286], ["A.", "SPECIES", 218, 220], ["lubrication", "TREATMENT", 103, 114], ["a high value of \u03c4", "PROBLEM", 125, 142], ["excessively high shear forces", "PROBLEM", 245, 274], ["no", "UNCERTAINTY", 100, 102], ["lubrication", "OBSERVATION", 103, 114], ["skin", "ANATOMY", 151, 155], ["soft", "OBSERVATION", 178, 182], ["large", "OBSERVATION_MODIFIER", 199, 204], ["contact", "OBSERVATION", 205, 212], ["excessively", "OBSERVATION_MODIFIER", 245, 256], ["high shear", "OBSERVATION_MODIFIER", 257, 267], ["forces", "OBSERVATION_MODIFIER", 268, 274], ["skin", "ANATOMY", 282, 286], ["PPE interface", "OBSERVATION", 287, 300]]], ["A typical friction profile measured for a moisturising cream (Nivea men creme, Beiersdorf, Germany) is shown in Fig 5A.", [["men", "SPECIES", 68, 71], ["A typical friction profile", "PROBLEM", 0, 26], ["a moisturising cream", "TREATMENT", 40, 60], ["friction profile", "OBSERVATION", 10, 26]]], ["Upon application friction is low, but 10 minutes after application a very high static friction peak can be observed.Wax-like substancesWax-like substances generally demonstrate low friction with excellent longevity.", [["a very high static friction peak", "PROBLEM", 67, 99], ["Wax", "TEST", 116, 119], ["low friction", "PROBLEM", 177, 189], ["friction", "OBSERVATION_MODIFIER", 17, 25], ["low", "OBSERVATION_MODIFIER", 29, 32], ["low friction", "OBSERVATION_MODIFIER", 177, 189]]], ["These products comprise triglycerides, fats and lipids.", [["triglycerides", "CHEMICAL", 24, 37], ["triglycerides", "SIMPLE_CHEMICAL", 24, 37], ["fats", "SIMPLE_CHEMICAL", 39, 43], ["lipids", "SIMPLE_CHEMICAL", 48, 54], ["triglycerides", "TEST", 24, 37], ["lipids", "TREATMENT", 48, 54]]], ["Low friction was observed for a mixture of coconut oil, cocoa seed butter and beeswax.", [["oil", "ANATOMY", 51, 54], ["coconut oil, cocoa seed butter", "CHEMICAL", 43, 73], ["coconut oil", "SIMPLE_CHEMICAL", 43, 54], ["cocoa", "ORGANISM_SUBDIVISION", 56, 61], ["butter", "ORGANISM_SUBDIVISION", 67, 73], ["beeswax", "SIMPLE_CHEMICAL", 78, 85], ["cocoa", "SPECIES", 56, 61], ["Low friction", "PROBLEM", 0, 12], ["a mixture of coconut oil", "TREATMENT", 30, 54], ["friction", "OBSERVATION", 4, 12], ["seed butter", "OBSERVATION", 62, 73]]], ["Fig 5C shows friction traces before and 30 minutes after application of this wax, as well as two minutes after subsequent removal of the remaining wax In the unlubricated situation the friction mainly arises mainly from lipids on the skin surface.", [["skin surface", "ANATOMY", 234, 246], ["lipids", "SIMPLE_CHEMICAL", 220, 226], ["skin surface", "MULTI-TISSUE_STRUCTURE", 234, 246], ["this wax", "TREATMENT", 72, 80], ["subsequent removal of the remaining wax", "TREATMENT", 111, 150], ["friction", "OBSERVATION_MODIFIER", 13, 21], ["wax", "OBSERVATION_MODIFIER", 147, 150], ["friction", "OBSERVATION", 185, 193], ["skin", "ANATOMY", 234, 238], ["surface", "ANATOMY_MODIFIER", 239, 246]]], ["The exact value varies strongly between people, but in general the coefficient of friction is close to 1.", [["people", "ORGANISM", 40, 46], ["people", "SPECIES", 40, 46]]], ["B: Lubricants are highly effective at reducing the shear strength of the interface, resulting in much reduced friction.", [["Lubricants", "TREATMENT", 3, 13], ["much reduced friction", "PROBLEM", 97, 118], ["reduced friction", "OBSERVATION", 102, 118]]], ["C: If the lubricating substance occludes the skin, transepidermal water loss is prevented.", [["skin", "ANATOMY", 45, 49], ["transepidermal", "ANATOMY", 51, 65], ["transepidermal water loss", "DISEASE", 51, 76], ["skin", "ORGAN", 45, 49], ["the lubricating substance", "TREATMENT", 6, 31], ["transepidermal water loss", "PROBLEM", 51, 76], ["skin", "ANATOMY", 45, 49], ["transepidermal", "OBSERVATION", 51, 65], ["water loss", "OBSERVATION", 66, 76]]], ["This hydrates the epidermis from the inside, reducing the stiffness and increasing the contact area thus increasing the coefficient of friction.", [["epidermis", "ANATOMY", 18, 27], ["epidermis", "TISSUE", 18, 27], ["This hydrates the epidermis", "PROBLEM", 0, 27], ["the stiffness", "PROBLEM", 54, 67], ["increasing the contact area", "PROBLEM", 72, 99], ["epidermis", "OBSERVATION_MODIFIER", 18, 27], ["stiffness", "OBSERVATION_MODIFIER", 58, 67], ["increasing", "OBSERVATION_MODIFIER", 72, 82]]], ["D: The lubricant may not persist due to absorption, evaporation and/or wear.", [["The lubricant", "TREATMENT", 3, 16], ["evaporation", "TREATMENT", 52, 63]]], ["Lubricant absorbed into the stratum corneum still affects swelling and stiffness, causing the friction to increase.", [["stratum corneum", "ANATOMY", 28, 43], ["swelling", "DISEASE", 58, 66], ["stiffness", "DISEASE", 71, 80], ["stratum corneum", "TISSUE", 28, 43], ["Lubricant", "TREATMENT", 0, 9], ["swelling", "PROBLEM", 58, 66], ["stiffness", "PROBLEM", 71, 80], ["the friction", "PROBLEM", 90, 102], ["stratum corneum", "ANATOMY", 28, 43], ["swelling", "OBSERVATION", 58, 66], ["stiffness", "OBSERVATION", 71, 80], ["friction", "OBSERVATION_MODIFIER", 94, 102], ["increase", "OBSERVATION_MODIFIER", 106, 114]]], ["E: The lubricant may absorb into the skin, swelling and plasticising the stratum corneum (SC).", [["skin", "ANATOMY", 37, 41], ["stratum corneum", "ANATOMY", 73, 88], ["SC", "ANATOMY", 90, 92], ["swelling", "DISEASE", 43, 51], ["skin", "ORGAN", 37, 41], ["stratum corneum", "TISSUE", 73, 88], ["SC", "MULTI-TISSUE_STRUCTURE", 90, 92], ["The lubricant", "TREATMENT", 3, 16], ["swelling", "PROBLEM", 43, 51], ["skin", "ANATOMY", 37, 41], ["swelling", "OBSERVATION", 43, 51], ["stratum corneum", "ANATOMY", 73, 88]]], ["This will reduce the stiffness and increase the contact area.", [["the stiffness", "PROBLEM", 17, 30], ["stiffness", "OBSERVATION", 21, 30], ["increase", "OBSERVATION_MODIFIER", 35, 43]]], ["The coefficient of friction will increase with time.", [["friction", "OBSERVATION_MODIFIER", 19, 27]]], ["F: Particulates may reduce the coefficient of friction: a lamellar structure provides low shear strength whilst round particles act as rollers.", [["a lamellar structure", "TREATMENT", 56, 76], ["low shear", "OBSERVATION_MODIFIER", 86, 95]]], ["Some particles absorb moisture, increasing the stiffness of the stratum corneum.", [["stratum corneum", "ANATOMY", 64, 79], ["stratum corneum", "TISSUE", 64, 79], ["Some particles absorb moisture", "PROBLEM", 0, 30], ["particles", "OBSERVATION_MODIFIER", 5, 14], ["absorb", "OBSERVATION_MODIFIER", 15, 21], ["moisture", "OBSERVATION_MODIFIER", 22, 30], ["increasing", "OBSERVATION_MODIFIER", 32, 42], ["stiffness", "OBSERVATION_MODIFIER", 47, 56], ["stratum", "ANATOMY_MODIFIER", 64, 71], ["corneum", "ANATOMY", 72, 79]]], ["The combination of these effects may lead to a strong reduction of the coefficient of friction.Wax-like substanceshttps://doi.org/10.1371/journal.pone.0239363.g004 using an alcohol wipe.", [["alcohol", "CHEMICAL", 173, 180], ["alcohol", "CHEMICAL", 173, 180], ["alcohol", "SIMPLE_CHEMICAL", 173, 180], ["strong", "OBSERVATION_MODIFIER", 47, 53], ["reduction", "OBSERVATION_MODIFIER", 54, 63]]], ["If occlusion had occurred, this would have resulted in a much-higher friction curve, compare e.g. with the green curve in Fig 5B.", [["occlusion", "PROBLEM", 3, 12], ["a much-higher friction curve", "PROBLEM", 55, 83], ["the green curve", "TEST", 103, 118], ["occlusion", "OBSERVATION", 3, 12]]], ["Because the friction response returns to its initial 'dry' value, it is concluded that occlusion did not occur and the mechanism behind the friction response is a durable low-shear layer (Fig 4B) .", [["the friction response", "PROBLEM", 8, 29], ["occlusion", "PROBLEM", 87, 96], ["the friction response", "TEST", 136, 157], ["friction response", "OBSERVATION", 12, 29], ["occlusion", "OBSERVATION", 87, 96], ["friction response", "OBSERVATION", 140, 157]]], ["It is noteworthy that the best performing wax appears to have a melting temperature just below skin temperature, meaning the deposited layer is in the liquid state.PowdersNo obvious trends were found for the various powders, which were all selected for their moisture absorbent capabilities.", [["skin", "ANATOMY", 95, 99], ["skin", "ORGAN", 95, 99], ["a melting temperature", "PROBLEM", 62, 83], ["skin temperature", "PROBLEM", 95, 111], ["Powders", "TREATMENT", 164, 171], ["obvious trends", "PROBLEM", 174, 188], ["the various powders", "TREATMENT", 204, 223], ["their moisture absorbent capabilities", "TREATMENT", 253, 290], ["skin", "ANATOMY", 95, 99], ["temperature", "OBSERVATION_MODIFIER", 100, 111], ["layer", "OBSERVATION_MODIFIER", 135, 140]]], ["Talcum powder showed low friction, in contrast to starch, zinc oxide and titanium dioxide.", [["starch, zinc oxide", "CHEMICAL", 50, 68], ["titanium dioxide", "CHEMICAL", 73, 89], ["zinc oxide", "CHEMICAL", 58, 68], ["titanium dioxide", "CHEMICAL", 73, 89], ["starch", "SIMPLE_CHEMICAL", 50, 56], ["zinc oxide", "SIMPLE_CHEMICAL", 58, 68], ["titanium dioxide", "SIMPLE_CHEMICAL", 73, 89], ["Talcum powder", "TREATMENT", 0, 13], ["low friction", "PROBLEM", 21, 33], ["zinc oxide", "TREATMENT", 58, 68], ["titanium dioxide", "TREATMENT", 73, 89], ["low friction", "OBSERVATION", 21, 33]]], ["Therefore, the effect of absorption of moisture from the stratum corneum appears negligible.", [["stratum corneum", "ANATOMY", 57, 72], ["stratum corneum", "TISSUE", 57, 72], ["moisture from the stratum corneum", "TEST", 39, 72], ["moisture", "OBSERVATION", 39, 47], ["stratum corneum", "ANATOMY", 57, 72], ["negligible", "OBSERVATION", 81, 91]]], ["Deacon et al. related the low friction of talc to its lamellar structure, which is similar to solid lubricants like graphite and molybdenum disulphide [30] .", [["talc", "CHEMICAL", 42, 46], ["graphite", "CHEMICAL", 116, 124], ["molybdenum disulphide", "CHEMICAL", 129, 150], ["talc", "CHEMICAL", 42, 46], ["graphite", "CHEMICAL", 116, 124], ["molybdenum disulphide", "CHEMICAL", 129, 150], ["graphite", "SIMPLE_CHEMICAL", 116, 124], ["molybdenum disulphide [30]", "SIMPLE_CHEMICAL", 129, 155], ["the low friction of talc", "PROBLEM", 22, 46], ["solid lubricants", "TREATMENT", 94, 110], ["graphite and molybdenum disulphide", "TREATMENT", 116, 150], ["low", "OBSERVATION_MODIFIER", 26, 29], ["friction", "OBSERVATION_MODIFIER", 30, 38], ["talc", "OBSERVATION", 42, 46], ["lamellar structure", "OBSERVATION", 54, 72]]], ["The conclusion is that the friction behaviour for powder-lubricated skin-PPE contact is determined by the powder's capacity to reduce \u03c4 as illustrated in Fig 4F.Dressings & spraysMost tested dressings demonstrated a relatively high friction against the PDMS probe.", [["skin", "ANATOMY", 68, 72], ["skin", "ORGAN", 68, 72], ["\u03c4", "PROTEIN", 134, 135], ["the friction behaviour", "TREATMENT", 23, 45], ["powder-lubricated skin", "TREATMENT", 50, 72], ["Dressings & sprays", "TREATMENT", 161, 179], ["Most tested dressings", "TREATMENT", 179, 200], ["the PDMS probe", "TREATMENT", 249, 263], ["skin", "ANATOMY", 68, 72], ["dressings", "OBSERVATION", 191, 200], ["relatively", "OBSERVATION_MODIFIER", 216, 226], ["high friction", "OBSERVATION", 227, 240], ["PDMS probe", "OBSERVATION", 253, 263]]], ["However, dressings provide protection either by functioning as a thick, compliant layer absorbing shear loading through deformation, or as a stiff layer distributing stresses over an extended area.", [["dressings", "TREATMENT", 9, 18], ["protection", "TREATMENT", 27, 37], ["shear loading through deformation", "TREATMENT", 98, 131], ["a stiff layer distributing stresses", "PROBLEM", 139, 174], ["stiff", "OBSERVATION_MODIFIER", 141, 146], ["layer", "OBSERVATION_MODIFIER", 147, 152], ["distributing", "OBSERVATION_MODIFIER", 153, 165], ["stresses", "OBSERVATION", 166, 174]]], ["Dressings may therefore be a simple and efficient method to reduce the shear loading on the skin.", [["skin", "ANATOMY", 92, 96], ["skin", "ORGAN", 92, 96], ["Dressings", "TREATMENT", 0, 9], ["a simple and efficient method", "TREATMENT", 27, 56], ["the shear loading on the skin", "PROBLEM", 67, 96], ["shear loading", "OBSERVATION", 71, 84], ["skin", "ANATOMY", 92, 96]]], ["It needs noting that in that case any mask fit testing should be redone with the dressings in place.", [["any mask fit testing", "TEST", 34, 54], ["the dressings", "TREATMENT", 77, 90], ["dressings", "OBSERVATION", 81, 90]]], ["None of the tested spray-on films had sufficient thickness or stiffness to provide protection from shear forces and most tested products had a tacky appearance, resulting in a high friction situation resembling Fig 4E.Limitations of this researchThe in vivo experimental programme was performed on a simulated PPE-skin tribo-system, using only one subject.", [["skin", "ANATOMY", 314, 318], ["skin", "ORGAN", 314, 318], ["the tested spray-on films", "TEST", 8, 33], ["sufficient thickness", "PROBLEM", 38, 58], ["stiffness", "PROBLEM", 62, 71], ["protection from shear forces", "TREATMENT", 83, 111], ["a high friction situation", "PROBLEM", 174, 199], ["this research", "TEST", 233, 246], ["a simulated PPE", "TREATMENT", 298, 313], ["stiffness", "OBSERVATION", 62, 71], ["high friction", "OBSERVATION", 176, 189], ["Fig 4E", "OBSERVATION", 211, 217], ["skin", "ANATOMY", 314, 318]]], ["Whilst quantitative results vary between people, literature shows that qualitative trends in friction are repeatable [16, 20, 21] .", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47]]], ["The mechanical aspects of the tested system match those in a skin-PPE interface, one silicone material was used to represent the wide variety of PPE available.", [["skin", "ANATOMY", 61, 65], ["skin", "ORGAN", 61, 65], ["a skin-PPE interface", "TREATMENT", 59, 79], ["one silicone material", "TREATMENT", 81, 102], ["mechanical", "OBSERVATION_MODIFIER", 4, 14], ["skin", "ANATOMY", 61, 65], ["PPE interface", "OBSERVATION", 66, 79], ["silicone material", "OBSERVATION", 85, 102]]], ["The volar forearm was used as a surrogate for facial skin, and it should be noted that there are differences between the two sites in terms of topology, composition, and lipids.", [["volar forearm", "ANATOMY", 4, 17], ["facial skin", "ANATOMY", 46, 57], ["volar forearm", "MULTI-TISSUE_STRUCTURE", 4, 17], ["skin", "ORGAN", 53, 57], ["lipids", "SIMPLE_CHEMICAL", 170, 176], ["lipids", "TREATMENT", 170, 176], ["volar forearm", "ANATOMY", 4, 17], ["skin", "ANATOMY", 53, 57]]], ["Perspiration was not taken into account as there is a large variation between people.", [["people", "ORGANISM", 78, 84], ["people", "SPECIES", 78, 84], ["Perspiration", "TEST", 0, 12], ["a large variation between people", "PROBLEM", 52, 84], ["large", "OBSERVATION_MODIFIER", 54, 59], ["variation", "OBSERVATION_MODIFIER", 60, 69]]], ["Finally, care should be taken that the use of lubricant does not affect the functionality and sealing capacity of the PPE.", [["lubricant", "TREATMENT", 46, 55]]], ["The main contribution of the presented work is in the observed qualitative trends, which serve to inform on methods to reduce shear-induced injury by adapting the skin care regime.ConclusionsReduced shear stresses acting on the skin are critical to ensure the comfortable and injury free use of PPE.", [["skin", "ANATOMY", 163, 167], ["skin", "ANATOMY", 228, 232], ["skin", "ORGAN", 163, 167], ["skin", "ORGAN", 228, 232], ["shear-induced injury", "PROBLEM", 126, 146], ["the skin care regime", "TREATMENT", 159, 179], ["Reduced shear stresses", "PROBLEM", 191, 213], ["PPE", "TREATMENT", 295, 298], ["main", "OBSERVATION_MODIFIER", 4, 8], ["injury", "OBSERVATION", 140, 146], ["skin", "ANATOMY", 163, 167], ["Reduced", "OBSERVATION_MODIFIER", 191, 198], ["shear stresses", "OBSERVATION", 199, 213], ["skin", "ANATOMY", 228, 232]]], ["A range of commercially available lubricating substances were investigated for their application as a shear reducing agent in skin-PPE contacts.", [["skin", "ANATOMY", 126, 130], ["skin", "ORGAN", 126, 130], ["lubricating substances", "TREATMENT", 34, 56], ["a shear reducing agent", "TREATMENT", 100, 122], ["skin", "ANATOMY", 126, 130]]], ["Results indicate that the use of emollients and moisturising creams is to be discouraged when wearing PPE for long durations as they may result in excessive shear forces acting on the skin.", [["skin", "ANATOMY", 184, 188], ["skin", "ORGAN", 184, 188], ["emollients", "TREATMENT", 33, 43], ["moisturising creams", "TREATMENT", 48, 67], ["excessive shear forces", "TREATMENT", 147, 169], ["shear forces", "OBSERVATION", 157, 169], ["skin", "ANATOMY", 184, 188]]], ["Talcum powder, a lanolin containing petrolatum, and a coconut oil-cocoa butter-beeswax mixture provide excellent long-lasting lubrication.ConclusionsSupporting information S1 File.", [["lanolin", "CHEMICAL", 17, 24], ["petrolatum", "CHEMICAL", 36, 46], ["coconut oil-cocoa butter-beeswax", "CHEMICAL", 54, 86], ["lanolin", "CHEMICAL", 17, 24], ["petrolatum", "CHEMICAL", 36, 46], ["lanolin", "SIMPLE_CHEMICAL", 17, 24], ["petrolatum", "SIMPLE_CHEMICAL", 36, 46], ["butter", "SPECIES", 72, 78], ["Talcum powder", "TREATMENT", 0, 13], ["a lanolin containing petrolatum", "TREATMENT", 15, 46], ["a coconut oil", "TREATMENT", 52, 65], ["cocoa butter", "TREATMENT", 66, 78], ["beeswax mixture", "TREATMENT", 79, 94]]]], "b9c612ba3de7dcbcad6924400e49538171f56b6a": [["In Italy, first cases are reported from February 2020 and since then the virus has spread quickly in all regions.", [["the virus", "PROBLEM", 69, 78], ["virus", "OBSERVATION", 73, 78], ["spread", "OBSERVATION_MODIFIER", 83, 89], ["quickly", "OBSERVATION_MODIFIER", 90, 97]]], ["On 11th March, World Health Organization has declared Coronavirus disease 2019 (COVID-19) outbreak.", [["Coronavirus disease", "DISEASE", 54, 73], ["Coronavirus disease", "PROBLEM", 54, 73], ["COVID", "TEST", 80, 85], ["outbreak", "PROBLEM", 90, 98], ["Coronavirus disease", "OBSERVATION", 54, 73]]], ["Coronavirus belongs to the Coronaviridae family, Nidovirales order, and the 2019-nCoV belongs to the \u03b2-coronavirus genus.", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 27, 40], ["2019-nCoV", "ORGANISM", 76, 85], ["\u03b2-coronavirus genus", "ORGANISM", 101, 120], ["2019-nCoV", "DNA", 76, 85]]], ["1 Nowadays the elderly and those with underlying chronic diseases are more likely to become severe cases.", [["chronic diseases", "DISEASE", 49, 65], ["underlying chronic diseases", "PROBLEM", 38, 65], ["severe cases", "PROBLEM", 92, 104], ["chronic", "OBSERVATION_MODIFIER", 49, 56], ["diseases", "OBSERVATION", 57, 65], ["more likely", "UNCERTAINTY", 70, 81]]], ["Thus far, all pediatric cases in China with laboratory-confirmed 2019-nCoV infection were mild cases, and no deaths had been reported.", [["infection", "DISEASE", 75, 84], ["deaths", "DISEASE", 109, 115], ["nCoV infection", "PROBLEM", 70, 84], ["mild cases", "PROBLEM", 90, 100], ["deaths", "PROBLEM", 109, 115], ["infection", "OBSERVATION", 75, 84], ["mild", "OBSERVATION_MODIFIER", 90, 94]]], ["2 The transmission of the 2019-nCov infection happened through the respiratory droplets by infected patients, but coronavirus can also be transmitted by contact with contaminated objects, such as phones, toys and doorknobs 3 ; however, also asymptomatic cases play a critical role in the transmission process.", [["respiratory droplets", "ANATOMY", 67, 87], ["infection", "DISEASE", 36, 45], ["patients", "ORGANISM", 100, 108], ["coronavirus", "ORGANISM", 114, 125], ["patients", "SPECIES", 100, 108], ["Cov infection", "PROBLEM", 32, 45], ["the respiratory droplets", "PROBLEM", 63, 87], ["coronavirus", "PROBLEM", 114, 125], ["infection", "OBSERVATION", 36, 45], ["respiratory droplets", "OBSERVATION", 67, 87], ["infected", "OBSERVATION", 91, 99]]]], "6377508d4fa2860213bdac9e0bc70fa0341fa79c": [["IntroductionIV Alteplase is administered in ischemic stroke patients who are eligible for thrombolysis.", [["Alteplase", "CHEMICAL", 15, 24], ["ischemic stroke", "DISEASE", 44, 59], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["IntroductionIV Alteplase", "TREATMENT", 0, 24], ["thrombolysis", "TREATMENT", 90, 102], ["ischemic", "OBSERVATION_MODIFIER", 44, 52]]], ["(4) There is no contraindication in the administration of IV Alteplase in patients with communicable diseases.", [["Alteplase", "CHEMICAL", 61, 70], ["communicable diseases", "DISEASE", 88, 109], ["Alteplase", "SIMPLE_CHEMICAL", 61, 70], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["IV Alteplase", "TREATMENT", 58, 70], ["communicable diseases", "PROBLEM", 88, 109], ["no contraindication", "UNCERTAINTY", 13, 32]]], ["(4) COVID-19 infected more than 100,000 individuals worldwide and its numbers are still increasing.", [["COVID-19", "ORGANISM", 4, 12], ["COVID", "TEST", 4, 9], ["increasing", "OBSERVATION_MODIFIER", 88, 98]]], ["(1, 8) Administering IV Alteplase in COVID-19 positive patients poses a risk and challenge to the healthcare professionals.", [["Alteplase", "CHEMICAL", 24, 33], ["COVID-19", "CHEMICAL", 37, 45], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["IV Alteplase in COVID", "TREATMENT", 21, 42]]], ["Respiratory infections can trigger acute coronary events and strokes along with the patient's comorbidities.", [["Respiratory", "ANATOMY", 0, 11], ["coronary", "ANATOMY", 41, 49], ["Respiratory infections", "DISEASE", 0, 22], ["strokes", "DISEASE", 61, 68], ["coronary", "MULTI-TISSUE_STRUCTURE", 41, 49], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Respiratory infections", "PROBLEM", 0, 22], ["acute coronary events", "PROBLEM", 35, 56], ["strokes", "PROBLEM", 61, 68], ["the patient's comorbidities", "PROBLEM", 80, 107], ["infections", "OBSERVATION", 12, 22], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["coronary", "ANATOMY", 41, 49], ["strokes", "OBSERVATION", 61, 68]]], ["(5) A link between COVID-19 and stroke and its outcome when given Intravenous Alteplase has yet to be reported.Case ReportA 62-year old female, known hypertensive, prediabetic, dyslipidemic with a history of transient ischemic attack last 2019 presented to the emergency department with cough and colds of 2 weeks duration associated with shortness of breath.", [["stroke", "DISEASE", 32, 38], ["Alteplase", "CHEMICAL", 78, 87], ["hypertensive", "DISEASE", 150, 162], ["prediabetic", "DISEASE", 164, 175], ["dyslipidemic", "DISEASE", 177, 189], ["cough", "DISEASE", 287, 292], ["colds", "DISEASE", 297, 302], ["shortness of breath", "DISEASE", 339, 358], ["COVID-19", "GENE_OR_GENE_PRODUCT", 19, 27], ["female", "ORGANISM", 136, 142], ["COVID", "TEST", 19, 24], ["stroke", "PROBLEM", 32, 38], ["Intravenous Alteplase", "TREATMENT", 66, 87], ["hypertensive", "PROBLEM", 150, 162], ["prediabetic", "PROBLEM", 164, 175], ["dyslipidemic", "PROBLEM", 177, 189], ["transient ischemic attack", "PROBLEM", 208, 233], ["cough", "PROBLEM", 287, 292], ["colds", "PROBLEM", 297, 302], ["shortness of breath", "PROBLEM", 339, 358], ["hypertensive", "OBSERVATION_MODIFIER", 150, 162], ["prediabetic", "OBSERVATION", 164, 175], ["transient", "OBSERVATION_MODIFIER", 208, 217], ["ischemic", "OBSERVATION_MODIFIER", 218, 226], ["cough", "OBSERVATION", 287, 292]]], ["She was initially managed as a case of Community Acquired Pneumonia, but was tagged as a Person Under Investigation (PUI) due to her occupation as a health provider.", [["Pneumonia", "DISEASE", 58, 67], ["Community Acquired Pneumonia", "PROBLEM", 39, 67], ["Pneumonia", "OBSERVATION", 58, 67]]], ["She was admitted in the Medical Intensive Care Unit, (converted to the hospital's COVID Critical Unit) with necessary precautions undertaken.", [["necessary precautions", "TREATMENT", 108, 129]]], ["During the first hospital day, she developed sudden onset of severe dysarthria and right upper and lower extremity weakness, giving a National Institutes of Health Stroke Scale (NIHSS) of 4.", [["right upper", "ANATOMY", 83, 94], ["lower extremity", "ANATOMY", 99, 114], ["dysarthria", "DISEASE", 68, 78], ["right upper and lower extremity weakness", "DISEASE", 83, 123], ["Stroke", "DISEASE", 164, 170], ["upper", "ORGANISM_SUBDIVISION", 89, 94], ["lower extremity", "ORGANISM_SUBDIVISION", 99, 114], ["severe dysarthria", "PROBLEM", 61, 78], ["right upper and lower extremity weakness", "PROBLEM", 83, 123], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["dysarthria", "OBSERVATION", 68, 78], ["right", "ANATOMY_MODIFIER", 83, 88], ["upper", "ANATOMY_MODIFIER", 89, 94], ["lower extremity", "ANATOMY", 99, 114], ["weakness", "OBSERVATION", 115, 123]]], ["Plain cranial CT scan showed a subtle hypodensity in the left centrum semiovale and corona radiata (Fig 1a) .", [["cranial", "ANATOMY", 6, 13], ["left centrum semiovale", "ANATOMY", 57, 79], ["hypodensity", "DISEASE", 38, 49], ["cranial", "ORGAN", 6, 13], ["centrum semiovale", "CANCER", 62, 79], ["corona radiata", "ORGANISM", 84, 98], ["Plain cranial CT scan", "TEST", 0, 21], ["a subtle hypodensity in the left centrum semiovale", "PROBLEM", 29, 79], ["subtle", "OBSERVATION_MODIFIER", 31, 37], ["hypodensity", "OBSERVATION", 38, 49], ["left", "ANATOMY_MODIFIER", 57, 61], ["centrum semiovale", "ANATOMY", 62, 79], ["corona radiata", "ANATOMY", 84, 98]]], ["CT-angiography showed significant stenosis in the left M1 segment of the Middle Cerebral Artery (Fig 1b) .", [["left M1", "ANATOMY", 50, 57], ["Middle Cerebral Artery", "ANATOMY", 73, 95], ["stenosis", "DISEASE", 34, 42], ["Cerebral Artery", "MULTI-TISSUE_STRUCTURE", 80, 95], ["CT", "TEST", 0, 2], ["angiography", "TEST", 3, 14], ["significant stenosis in the left M1 segment", "PROBLEM", 22, 65], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["stenosis", "OBSERVATION", 34, 42], ["left", "ANATOMY_MODIFIER", 50, 54], ["M1", "ANATOMY_MODIFIER", 55, 57], ["segment", "ANATOMY_MODIFIER", 58, 65], ["Middle Cerebral Artery", "ANATOMY", 73, 95]]], ["Intravenous thrombolysis (IV rTPA) was initiated at a dose of 0.9mg/kg body weight 3.4 hours post ictus with 10% bolus of the total dose given initially, followed by the remaining dose as an infusion over 1 hour.", [["Intravenous", "ANATOMY", 0, 11], ["body", "ANATOMY", 71, 75], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["Intravenous thrombolysis (IV rTPA)", "TREATMENT", 0, 34], ["ictus", "TREATMENT", 98, 103], ["an infusion", "TREATMENT", 188, 199]]], ["Immediately after IV rTPA, the patient's right leg weakness resolved with an NIHSS of 3.", [["right leg", "ANATOMY", 41, 50], ["right leg weakness", "DISEASE", 41, 59], ["patient", "ORGANISM", 31, 38], ["leg", "ORGANISM_SUBDIVISION", 47, 50], ["patient", "SPECIES", 31, 38], ["IV rTPA", "TREATMENT", 18, 25], ["the patient's right leg weakness", "PROBLEM", 27, 59], ["an NIHSS", "TEST", 74, 82], ["right", "ANATOMY_MODIFIER", 41, 46], ["leg", "ANATOMY", 47, 50], ["weakness", "OBSERVATION", 51, 59]]], ["Repeat plain cranial CT scan 24 hours post-IV rTPA showed absence of hemorrhage.", [["cranial", "ANATOMY", 13, 20], ["hemorrhage", "DISEASE", 69, 79], ["cranial", "ORGAN", 13, 20], ["Repeat plain cranial CT scan", "TEST", 0, 28], ["IV rTPA", "TEST", 43, 50], ["hemorrhage", "PROBLEM", 69, 79], ["cranial", "ANATOMY", 13, 20], ["hemorrhage", "OBSERVATION", 69, 79]]], ["Cautious hydration was made and Aspirin 100mg was started.", [["Aspirin", "CHEMICAL", 32, 39], ["Aspirin", "CHEMICAL", 32, 39], ["Aspirin", "SIMPLE_CHEMICAL", 32, 39], ["Cautious hydration", "TREATMENT", 0, 18], ["Aspirin", "TREATMENT", 32, 39]]], ["However, on day 3 post ictus, his right leg was seen to be moving side to side with a cumulative NIHSS of 6.", [["right leg", "ANATOMY", 34, 43], ["leg", "ORGANISM_SUBDIVISION", 40, 43], ["ictus", "PROBLEM", 23, 28], ["a cumulative NIHSS", "TEST", 84, 102], ["right", "ANATOMY_MODIFIER", 34, 39], ["leg", "ANATOMY", 40, 43]]], ["There were fluctuations in motor strength thereafter for which adjustment in IV hydration was made.", [["fluctuations in motor strength", "PROBLEM", 11, 41], ["IV hydration", "TREATMENT", 77, 89], ["fluctuations", "OBSERVATION_MODIFIER", 11, 23], ["motor strength", "OBSERVATION", 27, 41]]], ["She was confirmed COVID-19 positive by reverse transcription polymerase chain reaction (rRT-PCR) along with the classic findings on Highresolution CT (HRCT) of the chest showing areas of ground glass densities with focal areas of consolidation predominantly in both perihilar and peripheral regions of the lung (Fig 2) .", [["chest", "ANATOMY", 164, 169], ["perihilar", "ANATOMY", 266, 275], ["peripheral regions", "ANATOMY", 280, 298], ["lung", "ANATOMY", 306, 310], ["chest", "ORGANISM_SUBDIVISION", 164, 169], ["perihilar", "CANCER", 266, 275], ["lung", "ORGAN", 306, 310], ["COVID-19", "DNA", 18, 26], ["COVID", "TEST", 18, 23], ["reverse transcription polymerase chain reaction", "PROBLEM", 39, 86], ["rRT-PCR", "TEST", 88, 95], ["Highresolution CT", "TEST", 132, 149], ["HRCT) of the chest", "TEST", 151, 169], ["ground glass densities", "PROBLEM", 187, 209], ["consolidation", "PROBLEM", 230, 243], ["chest", "ANATOMY", 164, 169], ["areas", "OBSERVATION_MODIFIER", 178, 183], ["ground glass densities", "OBSERVATION", 187, 209], ["focal", "OBSERVATION_MODIFIER", 215, 220], ["areas", "OBSERVATION_MODIFIER", 221, 226], ["consolidation", "OBSERVATION", 230, 243], ["both", "ANATOMY_MODIFIER", 261, 265], ["perihilar", "ANATOMY_MODIFIER", 266, 275], ["peripheral", "ANATOMY_MODIFIER", 280, 290], ["regions", "ANATOMY_MODIFIER", 291, 298], ["lung", "ANATOMY", 306, 310]]], ["The patient is being managed for the COVID-19 infection and is still admitted with mild dysarthria, right upper extremity falls before 10 seconds and right lower extremity drift (NIHSS of 4).Case ReportLaboratory tests are as follows (please refer to table 1.)DiscussionOn January 30, 2020, the WHO declared COVID-19 as a global emergency.", [["right upper extremity", "ANATOMY", 100, 121], ["right lower extremity", "ANATOMY", 150, 171], ["infection", "DISEASE", 46, 55], ["dysarthria", "DISEASE", 88, 98], ["patient", "ORGANISM", 4, 11], ["upper extremity", "ORGANISM_SUBDIVISION", 106, 121], ["lower extremity", "ORGANISM_SUBDIVISION", 156, 171], ["patient", "SPECIES", 4, 11], ["the COVID-19 infection", "PROBLEM", 33, 55], ["mild dysarthria", "PROBLEM", 83, 98], ["right upper extremity falls", "PROBLEM", 100, 127], ["right lower extremity drift", "PROBLEM", 150, 177], ["NIHSS", "TEST", 179, 184], ["Case ReportLaboratory tests", "TEST", 191, 218], ["infection", "OBSERVATION", 46, 55], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["dysarthria", "OBSERVATION", 88, 98], ["right", "ANATOMY_MODIFIER", 100, 105], ["upper", "ANATOMY_MODIFIER", 106, 111], ["extremity", "ANATOMY", 112, 121], ["falls", "OBSERVATION", 122, 127], ["right", "ANATOMY_MODIFIER", 150, 155], ["lower extremity", "ANATOMY", 156, 171], ["drift", "OBSERVATION", 172, 177]]], ["(2) The most common symptoms are fever, cough and body malaise.", [["body", "ANATOMY", 50, 54], ["fever", "DISEASE", 33, 38], ["cough", "DISEASE", 40, 45], ["body", "ORGANISM_SUBDIVISION", 50, 54], ["The most common symptoms", "PROBLEM", 4, 28], ["fever", "PROBLEM", 33, 38], ["cough", "PROBLEM", 40, 45], ["body malaise", "PROBLEM", 50, 62], ["fever", "OBSERVATION", 33, 38], ["body", "ANATOMY", 50, 54], ["malaise", "OBSERVATION", 55, 62]]], ["(6, 7) Sars-CoV-2 infects the respiratory tract by inducing release of inflammatory cytokines such as interleukin (IL)1\u03b2 and IL-6 by binding to the Toll Like Receptor (TLR), triggering an inflammatory cascade and resulting in Acute Respiratory Distress Syndrome.", [["respiratory tract", "ANATOMY", 30, 47], ["Acute Respiratory Distress Syndrome", "DISEASE", 226, 261], ["Sars-CoV-2", "ORGANISM", 7, 17], ["respiratory tract", "ORGANISM_SUBDIVISION", 30, 47], ["interleukin (IL)1\u03b2", "GENE_OR_GENE_PRODUCT", 102, 120], ["IL-6", "GENE_OR_GENE_PRODUCT", 125, 129], ["Toll Like Receptor", "GENE_OR_GENE_PRODUCT", 148, 166], ["TLR", "GENE_OR_GENE_PRODUCT", 168, 171], ["inflammatory cytokines", "PROTEIN", 71, 93], ["interleukin (IL)1\u03b2 and IL-6", "PROTEIN", 102, 129], ["Toll Like Receptor", "PROTEIN", 148, 166], ["TLR", "PROTEIN", 168, 171], ["Sars-CoV", "TEST", 7, 15], ["the respiratory tract", "PROBLEM", 26, 47], ["inflammatory cytokines", "PROBLEM", 71, 93], ["interleukin (IL)", "TREATMENT", 102, 118], ["Receptor (TLR)", "TREATMENT", 158, 172], ["an inflammatory cascade", "TREATMENT", 185, 208], ["Acute Respiratory Distress Syndrome", "PROBLEM", 226, 261], ["respiratory tract", "ANATOMY", 30, 47], ["inflammatory", "OBSERVATION_MODIFIER", 71, 83], ["inflammatory cascade", "OBSERVATION", 188, 208], ["Acute", "OBSERVATION_MODIFIER", 226, 231], ["Respiratory Distress Syndrome", "OBSERVATION", 232, 261]]], ["Suppression of the inflammatory mediators have been shown to limit injury (12) .", [["inflammatory mediators", "PROTEIN", 19, 41], ["the inflammatory mediators", "PROBLEM", 15, 41], ["inflammatory", "OBSERVATION_MODIFIER", 19, 31]]], ["Increased inflammatory biomarkers (D-dimer, C-Reactive Protein and Fibrinogen) have been shown to increase stroke severity and disability within 30 days (13) , while erythrocyte sedimentation rate has not been shown to predict the outcome of stroke (14) .", [["erythrocyte", "ANATOMY", 166, 177], ["stroke", "DISEASE", 107, 113], ["disability", "DISEASE", 127, 137], ["stroke", "DISEASE", 242, 248], ["D-dimer", "GENE_OR_GENE_PRODUCT", 35, 42], ["C-Reactive Protein", "GENE_OR_GENE_PRODUCT", 44, 62], ["Fibrinogen", "GENE_OR_GENE_PRODUCT", 67, 77], ["erythrocyte", "CELL", 166, 177], ["D-dimer", "PROTEIN", 35, 42], ["C-Reactive Protein", "PROTEIN", 44, 62], ["Fibrinogen", "PROTEIN", 67, 77], ["Increased inflammatory biomarkers", "PROBLEM", 0, 33], ["D-dimer", "TEST", 35, 42], ["C", "TEST", 44, 45], ["Reactive Protein", "TEST", 46, 62], ["Fibrinogen", "TEST", 67, 77], ["stroke severity", "PROBLEM", 107, 122], ["erythrocyte sedimentation rate", "TEST", 166, 196], ["stroke", "PROBLEM", 242, 248], ["inflammatory", "OBSERVATION_MODIFIER", 10, 22], ["stroke", "OBSERVATION", 242, 248]]], ["Chest imaging of COVID-19 patients show consolidation, ground glass opacities and bilateral lung involvement, which were consistent with findings in our patient.", [["lung", "ANATOMY", 92, 96], ["patients", "ORGANISM", 26, 34], ["lung", "ORGAN", 92, 96], ["patient", "ORGANISM", 153, 160], ["patients", "SPECIES", 26, 34], ["patient", "SPECIES", 153, 160], ["Chest imaging", "TEST", 0, 13], ["COVID", "TEST", 17, 22], ["consolidation", "PROBLEM", 40, 53], ["ground glass opacities", "PROBLEM", 55, 77], ["bilateral lung involvement", "PROBLEM", 82, 108], ["consolidation", "OBSERVATION", 40, 53], ["ground glass opacities", "OBSERVATION", 55, 77], ["bilateral", "ANATOMY_MODIFIER", 82, 91], ["lung", "ANATOMY", 92, 96], ["involvement", "OBSERVATION", 97, 108], ["consistent with", "UNCERTAINTY", 121, 136]]], ["(1, 6, 7) Diagnostic parameters of COVID-19 patients show elevated D-dimer, fibrinogen, erythrocyte sedimentation rate, lactate dehydrogenase and C-reactive protein which are seen in our patient (Table 1) To mention, myocarditis, the second common mentioned cause of fatality next to severe lung infection may exacerbate heart failure.", [["erythrocyte", "ANATOMY", 88, 99], ["lung", "ANATOMY", 291, 295], ["heart", "ANATOMY", 321, 326], ["lactate", "CHEMICAL", 120, 127], ["myocarditis", "DISEASE", 217, 228], ["lung infection", "DISEASE", 291, 305], ["heart failure", "DISEASE", 321, 334], ["lactate", "CHEMICAL", 120, 127], ["patients", "ORGANISM", 44, 52], ["D-dimer", "GENE_OR_GENE_PRODUCT", 67, 74], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 76, 86], ["erythrocyte", "CELL", 88, 99], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 120, 141], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 146, 164], ["patient", "ORGANISM", 187, 194], ["lung", "ORGAN", 291, 295], ["heart", "ORGAN", 321, 326], ["D-dimer", "PROTEIN", 67, 74], ["fibrinogen", "PROTEIN", 76, 86], ["lactate dehydrogenase", "PROTEIN", 120, 141], ["C-reactive protein", "PROTEIN", 146, 164], ["patients", "SPECIES", 44, 52], ["patient", "SPECIES", 187, 194], ["Diagnostic parameters", "TEST", 10, 31], ["COVID", "TEST", 35, 40], ["elevated D-dimer", "PROBLEM", 58, 74], ["fibrinogen", "TEST", 76, 86], ["erythrocyte sedimentation rate", "TEST", 88, 118], ["lactate dehydrogenase", "TEST", 120, 141], ["C-reactive protein", "PROBLEM", 146, 164], ["myocarditis", "PROBLEM", 217, 228], ["severe lung infection", "PROBLEM", 284, 305], ["heart failure", "PROBLEM", 321, 334], ["elevated", "OBSERVATION", 58, 66], ["erythrocyte sedimentation", "OBSERVATION", 88, 113], ["reactive protein", "OBSERVATION", 148, 164], ["myocarditis", "OBSERVATION", 217, 228], ["severe", "OBSERVATION_MODIFIER", 284, 290], ["lung", "ANATOMY", 291, 295], ["infection", "OBSERVATION", 296, 305], ["heart", "ANATOMY", 321, 326], ["failure", "OBSERVATION", 327, 334]]], ["Vice versa, acute heart failure should also be evaluated for myocarditis as a primary complication of COVID-19.", [["heart", "ANATOMY", 18, 23], ["heart failure", "DISEASE", 18, 31], ["myocarditis", "DISEASE", 61, 72], ["COVID-19", "CHEMICAL", 102, 110], ["heart", "ORGAN", 18, 23], ["acute heart failure", "PROBLEM", 12, 31], ["myocarditis", "PROBLEM", 61, 72], ["COVID", "TEST", 102, 107], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["heart", "ANATOMY", 18, 23], ["failure", "OBSERVATION", 24, 31]]], ["(10) Whether this is secondary to viral infiltration, or hypoxia and cytokine storm mounting in response to systemic infection (15) , the aggressiveness in stroke management remains a priority because stroke is reversible.DiscussionGiven the current setting however, management of stroke among COVID-19 positive patients is a struggle in most countries due to hindrance from rapid response of the stroke team.", [["hypoxia", "DISEASE", 57, 64], ["systemic infection", "DISEASE", 108, 126], ["aggressiveness", "DISEASE", 138, 152], ["stroke", "DISEASE", 156, 162], ["stroke", "DISEASE", 201, 207], ["stroke", "DISEASE", 281, 287], ["stroke", "DISEASE", 397, 403], ["patients", "ORGANISM", 312, 320], ["cytokine", "PROTEIN", 69, 77], ["patients", "SPECIES", 312, 320], ["viral infiltration", "PROBLEM", 34, 52], ["hypoxia", "PROBLEM", 57, 64], ["cytokine storm mounting", "PROBLEM", 69, 92], ["systemic infection", "PROBLEM", 108, 126], ["stroke management", "TREATMENT", 156, 173], ["stroke", "PROBLEM", 201, 207], ["stroke", "PROBLEM", 281, 287], ["COVID", "TEST", 294, 299], ["viral", "OBSERVATION_MODIFIER", 34, 39], ["infiltration", "OBSERVATION", 40, 52], ["hypoxia", "OBSERVATION_MODIFIER", 57, 64], ["cytokine storm", "OBSERVATION", 69, 83], ["systemic", "OBSERVATION_MODIFIER", 108, 116], ["infection", "OBSERVATION", 117, 126]]], ["This is likely from extrinsic factors such as inadequate Personal Protective Equipment (PPE) as well as lack of imaging modalities solely dedicated for COVID-19 patients to avoid rapid viral transmission.", [["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["extrinsic factors", "PROBLEM", 20, 37], ["imaging modalities", "TEST", 112, 130], ["rapid viral transmission", "PROBLEM", 179, 203], ["likely from", "UNCERTAINTY", 8, 19], ["viral", "OBSERVATION", 185, 190]]], ["Multiple reports of cases will help explore other possibilities of a causal relationship or none, and define guidelines in the management of stroke among COVID-19 positive cases.ConclusionThe management of COVID-19 patients who suffer from stroke poses a challenge to healthcare professionals.", [["stroke", "DISEASE", 141, 147], ["stroke", "DISEASE", 240, 246], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["stroke", "PROBLEM", 141, 147], ["COVID", "TEST", 154, 159], ["stroke", "PROBLEM", 240, 246]]], ["There are no specific clinical guidelines established in handling COVID-19 positive patients who are eligible for thrombolysis.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["thrombolysis", "TREATMENT", 114, 126], ["no", "UNCERTAINTY", 10, 12]]], ["Management of hemodynamic status must always balance the risk and benefits of such treatment in COVID positive cases.ConclusionThere is no direct causal relationship of stroke with COVID-19 as of yet but given the fact that COVID-19 patients are predisposed to developing neurologic complications such as acute vascular events, monitoring these complications in the setting of COVID-19 infection is highly warranted.", [["neurologic", "ANATOMY", 272, 282], ["vascular", "ANATOMY", 311, 319], ["stroke", "DISEASE", 169, 175], ["neurologic complications", "DISEASE", 272, 296], ["infection", "DISEASE", 386, 395], ["patients", "ORGANISM", 233, 241], ["vascular", "MULTI-TISSUE_STRUCTURE", 311, 319], ["patients", "SPECIES", 233, 241], ["such treatment", "TREATMENT", 78, 92], ["stroke", "PROBLEM", 169, 175], ["COVID", "TEST", 181, 186], ["COVID", "TEST", 224, 229], ["developing neurologic complications", "PROBLEM", 261, 296], ["acute vascular events", "PROBLEM", 305, 326], ["these complications", "PROBLEM", 339, 358], ["COVID-19 infection", "PROBLEM", 377, 395], ["no direct", "UNCERTAINTY", 136, 145], ["stroke", "OBSERVATION", 169, 175], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["vascular", "ANATOMY", 311, 319], ["infection", "OBSERVATION", 386, 395]]], ["We therefore propose the following: 1) Development of an Acute Stroke Unit capable of managing COVID-19 patients and 2) Establishment of a clinical pathway and guidelines for the management of these complications in COVID-19 patients.", [["Stroke", "DISEASE", 63, 69], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 225, 233], ["an Acute Stroke", "PROBLEM", 54, 69], ["the management", "TREATMENT", 175, 189], ["these complications", "PROBLEM", 193, 212], ["Acute", "OBSERVATION_MODIFIER", 57, 62], ["Stroke", "OBSERVATION", 63, 69]]]], "6e33bc6f70209a6bf0230dc17e214d3a7cdf5fbe": [["conditions, population demography, social and economic development, and culture.", [["culture", "TEST", 72, 79]]], ["It has one of the highest rates of social inequality according to the World Health Organization (WHO).", [["highest", "OBSERVATION_MODIFIER", 18, 25]]]], "PMC7521369": [["IntroductionCoronavirus Disease 2019 (COVID-19) is forcing people in professional and private life to adhere to serious preventive measures to minimize the possibility of spreading the virus.", [["COVID-19", "CHEMICAL", 38, 46], ["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["IntroductionCoronavirus Disease", "PROBLEM", 0, 31], ["serious preventive measures", "TREATMENT", 112, 139], ["spreading the virus", "PROBLEM", 171, 190], ["virus", "OBSERVATION", 185, 190]]], ["The medically assisted reproduction field is no exception, and guidelines from different professional societies were prepared on how to restart treatments or how to change the work to make it as safe as possible.", [["treatments", "TREATMENT", 144, 154], ["no", "UNCERTAINTY", 45, 47]]], ["In the guidelines, it was suggested that patients spend the shortest possible time at the clinic, indicating that as much communication as possible should be conducted by telephone, email and so on; these guidelines aimed to not have patients spend unnecessary time in waiting rooms, and another way to achieve this was to have them bring the semen sample collected at home.", [["semen sample", "ANATOMY", 343, 355], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 234, 242]]], ["With regard to semen sample collection, the WHO manual recommends that in normal situations, semen samples should be collected at the clinic near the laboratory to lower the chances of negative external influences on semen quality (World Health Organization, 2010).", [["semen sample", "ANATOMY", 15, 27], ["semen samples", "ANATOMY", 93, 106], ["semen samples", "ORGANISM_SUBSTANCE", 93, 106], ["semen", "ORGANISM_SUBSTANCE", 217, 222], ["semen sample collection", "PROBLEM", 15, 38], ["semen samples", "TEST", 93, 106], ["negative", "OBSERVATION", 185, 193]]], ["The WHO manual suggests that semen should be collected at home only when the patient has difficulties providing the sample with masturbation at the clinic or when there is no appropriate room for semen collection near the laboratory.", [["semen", "ANATOMY", 29, 34], ["semen", "ORGANISM_SUBSTANCE", 29, 34], ["patient", "ORGANISM", 77, 84], ["semen", "ORGANISM_SUBSTANCE", 196, 201], ["patient", "SPECIES", 77, 84]]], ["The use of such an approach should take into consideration that even short exposure of spermatozoa to seminal plasma might negatively influence spermatozoa quality (Bj\u00f6rndahl and Kvist, 2003).", [["spermatozoa", "ANATOMY", 87, 98], ["seminal plasma", "ANATOMY", 102, 116], ["spermatozoa", "ANATOMY", 144, 155], ["spermatozoa", "ORGANISM_SUBSTANCE", 87, 98], ["seminal plasma", "ORGANISM_SUBSTANCE", 102, 116], ["spermatozoa", "DEVELOPING_ANATOMICAL_STRUCTURE", 144, 155], ["spermatozoa", "CELL_TYPE", 87, 98], ["such an approach", "TREATMENT", 11, 27], ["seminal plasma", "TEST", 102, 116]]], ["The reason for this impact is that seminal plasma is rich in different endogenous compounds, whose concentrations can vary from man to man, and these compounds can have a varied impact on spermatozoa quality (Bj\u00f6rndahl and Kvist, 2003).", [["seminal plasma", "ANATOMY", 35, 49], ["spermatozoa", "ANATOMY", 188, 199], ["seminal", "ORGANISM_SUBSTANCE", 35, 42], ["plasma", "ORGANISM_SUBSTANCE", 43, 49], ["man", "ORGANISM", 135, 138], ["spermatozoa", "DEVELOPING_ANATOMICAL_STRUCTURE", 188, 199], ["man", "SPECIES", 128, 131], ["man", "SPECIES", 135, 138], ["seminal plasma", "PROBLEM", 35, 49], ["seminal plasma", "ANATOMY", 35, 49], ["endogenous compounds", "OBSERVATION", 71, 91]]], ["Another issue is the presence of somatic cells in seminal plasma.", [["somatic cells", "ANATOMY", 33, 46], ["seminal plasma", "ANATOMY", 50, 64], ["somatic cells", "CELL", 33, 46], ["seminal plasma", "ORGANISM_SUBSTANCE", 50, 64], ["somatic cells", "CELL_TYPE", 33, 46], ["somatic cells in seminal plasma", "PROBLEM", 33, 64], ["somatic cells", "OBSERVATION", 33, 46], ["seminal plasma", "ANATOMY", 50, 64]]], ["These cells are beside abnormal spermatozoa the main source of reactive oxygen species (ROS) (Aitken and Baker, 1995).", [["cells", "ANATOMY", 6, 11], ["spermatozoa", "ANATOMY", 32, 43], ["oxygen", "CHEMICAL", 72, 78], ["ROS", "CHEMICAL", 88, 91], ["oxygen", "CHEMICAL", 72, 78], ["cells", "CELL", 6, 11], ["spermatozoa", "ORGANISM_SUBSTANCE", 32, 43], ["reactive oxygen species", "SIMPLE_CHEMICAL", 63, 86], ["ROS", "SIMPLE_CHEMICAL", 88, 91], ["abnormal spermatozoa", "PROBLEM", 23, 43], ["reactive oxygen species", "PROBLEM", 63, 86], ["abnormal spermatozoa", "OBSERVATION", 23, 43], ["main", "OBSERVATION_MODIFIER", 48, 52], ["reactive", "OBSERVATION_MODIFIER", 63, 71], ["oxygen species", "OBSERVATION", 72, 86]]], ["Small concentrations of ROS are essential for normal sperm functioning, but when the amount exceeds the capacity of cellular defensive mechanisms, there can be oxidative stress with a serious detrimental effect on sperm DNA (Agarwal et al., 2014).", [["sperm", "ANATOMY", 53, 58], ["cellular", "ANATOMY", 116, 124], ["sperm", "ANATOMY", 214, 219], ["ROS", "CHEMICAL", 24, 27], ["ROS", "SIMPLE_CHEMICAL", 24, 27], ["sperm", "DEVELOPING_ANATOMICAL_STRUCTURE", 53, 58], ["cellular", "CELL", 116, 124], ["sperm DNA", "CELLULAR_COMPONENT", 214, 223], ["sperm", "CELL_TYPE", 53, 58], ["sperm", "CELL_TYPE", 214, 219], ["Small concentrations of ROS", "PROBLEM", 0, 27], ["oxidative stress", "PROBLEM", 160, 176], ["a serious detrimental effect on sperm DNA", "PROBLEM", 182, 223], ["concentrations", "OBSERVATION_MODIFIER", 6, 20], ["cellular defensive", "OBSERVATION", 116, 134]]], ["Another important aspect is the temperature at which the semen is transported to the laboratory.", [["semen", "ANATOMY", 57, 62], ["semen", "ORGANISM_SUBSTANCE", 57, 62]]], ["The WHO manual suggests that semen should be kept at temperatures of 20\u00b0C to 37\u00b0C during transport.", [["semen", "ANATOMY", 29, 34], ["semen", "ORGANISM_SUBSTANCE", 29, 34], ["C", "GENE_OR_GENE_PRODUCT", 80, 81]]], ["It was shown more than 40 years ago that if any delay in semen analysis is expected, the semen should be kept at room temperature (20\u00b0C) because the motility and viability decrease significantly faster at 37\u00b0C (Appell and Evans, 1977).", [["semen", "ANATOMY", 89, 94], ["semen", "ORGANISM_SUBSTANCE", 57, 62], ["semen", "ORGANISM_SUBSTANCE", 89, 94], ["any delay", "PROBLEM", 44, 53], ["semen analysis", "TEST", 57, 71], ["the motility", "PROBLEM", 145, 157]]], ["Additionally, Appell and Evans (1977) showed that if semen is kept at 4\u00b0C, then most of the spermatozoa are immotile after 6 hours, although viability decreases more slowly and remains high after 18 hours.", [["semen", "ANATOMY", 53, 58], ["spermatozoa", "ANATOMY", 92, 103], ["semen", "ORGANISM_SUBSTANCE", 53, 58], ["spermatozoa", "CELL", 92, 103], ["spermatozoa", "CELL_TYPE", 92, 103], ["decreases", "OBSERVATION_MODIFIER", 151, 160]]], ["Similarly, Esfandiari et al. confirmed that motility significantly decreases if semen is kept at 4\u00b0C but, in contrast, suggested that motility is the highest and ROS levels are the lowest if semen is kept at 37\u00b0C (Esfandiari et al., 2002).", [["semen", "ANATOMY", 80, 85], ["semen", "ANATOMY", 191, 196], ["semen", "ORGANISM_SUBSTANCE", 80, 85], ["C", "GENE_OR_GENE_PRODUCT", 99, 100], ["ROS", "SIMPLE_CHEMICAL", 162, 165], ["semen", "ORGANISM_SUBSTANCE", 191, 196], ["ROS levels", "TEST", 162, 172], ["motility", "OBSERVATION_MODIFIER", 44, 52], ["significantly", "OBSERVATION_MODIFIER", 53, 66], ["decreases", "OBSERVATION_MODIFIER", 67, 76]]], ["If semen is incubated for only 2 hours at 37\u00b0C, morphological impairment of sperm nuclei (large vacuoles) can also be observed, while if incubated at 21\u00b0C, no such negative effect can be observed (Peer et al., 2007).", [["semen", "ANATOMY", 3, 8], ["sperm nuclei", "ANATOMY", 76, 88], ["vacuoles", "ANATOMY", 96, 104], ["semen", "ORGANISM_SUBSTANCE", 3, 8], ["sperm nuclei", "CELLULAR_COMPONENT", 76, 88], ["vacuoles", "CELLULAR_COMPONENT", 96, 104], ["sperm", "CELL_TYPE", 76, 81], ["morphological impairment of sperm nuclei", "PROBLEM", 48, 88]]], ["Furthermore, the influence of temperature on spermatozoa quality was also studied in native semen as a function of the semen preparation method (density-gradient centrifugation (DGC) versus swim-up technique) and long-term incubation (Thijssen et al., 2014).", [["spermatozoa", "ANATOMY", 45, 56], ["semen", "ANATOMY", 92, 97], ["semen", "ANATOMY", 119, 124], ["spermatozoa", "MULTI-TISSUE_STRUCTURE", 45, 56], ["semen", "ORGANISM_SUBSTANCE", 92, 97], ["spermatozoa quality", "TEST", 45, 64], ["the semen preparation method (density-gradient centrifugation", "TREATMENT", 115, 176], ["long-term incubation", "TREATMENT", 213, 233]]], ["It was revealed that after 24 hours of incubation at room temperature (23\u00b0C), the motility, viability and morphology were significantly higher than they were in samples incubated at 35\u00b0C, but the study could not draw a conclusion regarding which semen preparation method was better in these conditions.IntroductionBased on available data, there is still no firm conclusion regarding whether collecting semen samples at home has any influence on sperm quality or on IVF/ICSI cycle outcome.", [["samples", "ANATOMY", 161, 168], ["semen", "ANATOMY", 246, 251], ["semen samples", "ANATOMY", 402, 415], ["sperm", "ANATOMY", 445, 450], ["semen", "ORGANISM_SUBSTANCE", 246, 251], ["semen samples", "MULTI-TISSUE_STRUCTURE", 402, 415], ["sperm", "DEVELOPING_ANATOMICAL_STRUCTURE", 445, 450], ["the study", "TEST", 192, 201], ["semen preparation method", "TREATMENT", 246, 270], ["collecting semen samples", "PROBLEM", 391, 415], ["IVF", "TREATMENT", 465, 468], ["ICSI cycle outcome", "TREATMENT", 469, 487]]], ["A few years ago, we were in situation (clinic renovation) when patients were strongly encouraged to collect semen samples at home and bring them to the laboratory for IVF/ICSI procedures.", [["semen samples", "ANATOMY", 108, 121], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["IVF/ICSI procedures", "TREATMENT", 167, 186]]], ["Because we did not observe any negative influence on the outcome of IVF/ICSI cycles following this approach, we continued this practice.", [["IVF/ICSI cycles", "TREATMENT", 68, 83], ["this approach", "TREATMENT", 94, 107], ["this practice", "TREATMENT", 122, 135]]], ["Today, due to the COVID-19 situation, this approach is widely advised, but since the data regarding the success of this approach are limited, we decided to analyse our data and present the outcome of the ICSI/IVF cycles in terms of oocytes, embryos and pregnancy rates according to the semen sample collection approach (at home or at clinic).Ovarian stimulation protocols ::: Materials and MethodsAll female patients underwent controlled ovarian hyperstimulation (COH), which was achieved with a GnRH antagonist or a GnRH agonist protocol.", [["oocytes", "ANATOMY", 232, 239], ["embryos", "ANATOMY", 241, 248], ["semen sample", "ANATOMY", 286, 298], ["Ovarian", "ANATOMY", 342, 349], ["ovarian", "ANATOMY", 438, 445], ["ovarian hyperstimulation", "DISEASE", 438, 462], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 232, 239], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 241, 248], ["Ovarian", "ORGAN", 342, 349], ["patients", "ORGANISM", 408, 416], ["ovarian", "ORGAN", 438, 445], ["GnRH antagonist", "GENE_OR_GENE_PRODUCT", 496, 511], ["GnRH", "SIMPLE_CHEMICAL", 517, 521], ["patients", "SPECIES", 408, 416], ["the ICSI/IVF cycles", "TREATMENT", 200, 219], ["embryos", "PROBLEM", 241, 248], ["pregnancy rates", "PROBLEM", 253, 268], ["Ovarian stimulation protocols", "TREATMENT", 342, 371], ["controlled ovarian hyperstimulation", "PROBLEM", 427, 462], ["a GnRH antagonist", "TREATMENT", 494, 511], ["a GnRH agonist protocol", "TREATMENT", 515, 538], ["ovarian", "ANATOMY", 438, 445], ["hyperstimulation", "OBSERVATION", 446, 462]]], ["In the GnRH antagonist protocol, ovarian stimulation started on day 2 of the cycle.", [["ovarian", "ANATOMY", 33, 40], ["GnRH antagonist", "GENE_OR_GENE_PRODUCT", 7, 22], ["ovarian", "ORGAN", 33, 40], ["the GnRH antagonist protocol", "TREATMENT", 3, 31], ["ovarian stimulation", "TREATMENT", 33, 52], ["ovarian", "ANATOMY", 33, 40]]], ["The daily dose of recombinant or urinary gonadotropin was tailored according to the patient's clinical parameters and ranged from doses of 150 IU to 300 IU.", [["urinary", "ANATOMY", 33, 40], ["gonadotropin", "GENE_OR_GENE_PRODUCT", 41, 53], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["recombinant or urinary gonadotropin", "TREATMENT", 18, 53]]], ["Gonadotropin releasing hormone antagonist cetrorelix acetate (Cetrotide; Asta Medica AG.", [["cetrorelix acetate", "CHEMICAL", 42, 60], ["Cetrotide", "CHEMICAL", 62, 71], ["Asta Medica AG", "CHEMICAL", 73, 87], ["cetrorelix acetate", "CHEMICAL", 42, 60], ["Cetrotide", "CHEMICAL", 62, 71], ["Gonadotropin releasing hormone", "GENE_OR_GENE_PRODUCT", 0, 30], ["cetrorelix acetate", "SIMPLE_CHEMICAL", 42, 60], ["Cetrotide", "SIMPLE_CHEMICAL", 62, 71], ["Gonadotropin releasing hormone antagonist cetrorelix acetate", "TREATMENT", 0, 60], ["Cetrotide", "TREATMENT", 62, 71], ["Asta Medica AG", "TREATMENT", 73, 87]]], ["Frankfurt, Germany) or ganirelix (Orgalutran; Organon, Dublin, Ireland) was coadministered subcutaneously daily at a dose of 0.25 mg when the dominant follicle measured \u2265 13 mm in diameter.", [["subcutaneously", "ANATOMY", 91, 105], ["follicle", "ANATOMY", 151, 159], ["ganirelix", "CHEMICAL", 23, 32], ["Orgalutran", "CHEMICAL", 34, 44], ["ganirelix", "CHEMICAL", 23, 32], ["ganirelix", "SIMPLE_CHEMICAL", 23, 32], ["follicle", "MULTI-TISSUE_STRUCTURE", 151, 159], ["ganirelix (Orgalutran", "TREATMENT", 23, 44], ["Organon", "TREATMENT", 46, 53], ["dominant", "OBSERVATION_MODIFIER", 142, 150], ["follicle", "OBSERVATION", 151, 159], ["13 mm", "OBSERVATION_MODIFIER", 171, 176]]], ["When at least three follicles measured \u2265 I7 mm in diameter, 5.000 IU of human chorionic gonadotropin (hCG) (Pregnyl; Organon, Dublin Ireland) or 6.500 IU (250 mcg) of recombinant hCG alpha (Ovitrelle; Merck Serono Europe, London, England) was administered.", [["follicles", "ANATOMY", 20, 29], ["hCG", "CHEMICAL", 102, 105], ["hCG alpha", "CHEMICAL", 179, 188], ["follicles", "MULTI-TISSUE_STRUCTURE", 20, 29], ["human", "ORGANISM", 72, 77], ["chorionic gonadotropin", "GENE_OR_GENE_PRODUCT", 78, 100], ["hCG", "SIMPLE_CHEMICAL", 102, 105], ["Pregnyl", "SIMPLE_CHEMICAL", 108, 115], ["hCG alpha", "GENE_OR_GENE_PRODUCT", 179, 188], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["diameter", "TEST", 50, 58], ["human chorionic gonadotropin (hCG", "TREATMENT", 72, 105], ["Pregnyl", "TREATMENT", 108, 115], ["recombinant hCG alpha", "TREATMENT", 167, 188], ["follicles", "OBSERVATION", 20, 29]]], ["Ultrasound-guided transvaginal oocyte retrieval was carried out 36 hours after hCG administration.Ovarian stimulation protocols ::: Materials and MethodsIn the GnRH agonist protocol, daily administration of 0.6 ml of GnRH agonist buserelin acetate (Suprefact; Sanofi-Aventis, Frankfurt, Germany) was started on the 22nd day of the previous menstrual cycle.", [["oocyte", "ANATOMY", 31, 37], ["Ovarian", "ANATOMY", 98, 105], ["hCG", "CHEMICAL", 79, 82], ["buserelin acetate", "CHEMICAL", 230, 247], ["buserelin acetate", "CHEMICAL", 230, 247], ["transvaginal oocyte", "MULTI-TISSUE_STRUCTURE", 18, 37], ["hCG", "GENE_OR_GENE_PRODUCT", 79, 82], ["Ovarian", "ORGAN", 98, 105], ["GnRH", "SIMPLE_CHEMICAL", 160, 164], ["GnRH", "SIMPLE_CHEMICAL", 217, 221], ["buserelin", "SIMPLE_CHEMICAL", 230, 239], ["acetate", "SIMPLE_CHEMICAL", 240, 247], ["Ultrasound", "TEST", 0, 10], ["transvaginal oocyte retrieval", "TREATMENT", 18, 47], ["hCG administration", "TREATMENT", 79, 97], ["Ovarian stimulation protocols", "TREATMENT", 98, 127], ["Materials", "TREATMENT", 132, 141], ["MethodsIn the GnRH agonist protocol", "TREATMENT", 146, 181], ["GnRH agonist buserelin acetate", "TREATMENT", 217, 247], ["Suprefact", "TREATMENT", 249, 258], ["Sanofi-Aventis", "TREATMENT", 260, 274]]], ["After 15 days of treatment or when the endometrium was thin and the ovaries were dormant, a daily dose of gonadotropin was added.", [["endometrium", "ANATOMY", 39, 50], ["ovaries", "ANATOMY", 68, 75], ["endometrium", "MULTI-TISSUE_STRUCTURE", 39, 50], ["ovaries", "ORGAN", 68, 75], ["gonadotropin", "GENE_OR_GENE_PRODUCT", 106, 118], ["treatment", "TREATMENT", 17, 26], ["a daily dose of gonadotropin", "TREATMENT", 90, 118], ["endometrium", "ANATOMY", 39, 50], ["ovaries", "ANATOMY", 68, 75]]], ["The daily dose of recombinant or urinary gonadotropin was tailored according to the patient's clinical parameters and ranged from 200 to 300 IU.", [["urinary", "ANATOMY", 33, 40], ["gonadotropin", "GENE_OR_GENE_PRODUCT", 41, 53], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["recombinant or urinary gonadotropin", "TREATMENT", 18, 53]]], ["When at least three follicles measured \u2265 20 mm in diameter, 5.000 IU of hCG (Pregnyl; Organon, Dublin Ireland) or 6.500 IU (250 mcg) of recombinant hCG alpha (Ovitrelle; Merck Serono Europe, London, England) was administered.", [["follicles", "ANATOMY", 20, 29], ["hCG alpha", "CHEMICAL", 148, 157], ["follicles", "MULTI-TISSUE_STRUCTURE", 20, 29], ["hCG", "SIMPLE_CHEMICAL", 72, 75], ["hCG alpha", "GENE_OR_GENE_PRODUCT", 148, 157], ["hCG", "TEST", 72, 75], ["Pregnyl", "TREATMENT", 77, 84], ["recombinant hCG alpha", "TREATMENT", 136, 157], ["follicles", "OBSERVATION", 20, 29], ["20 mm", "OBSERVATION_MODIFIER", 41, 46]]], ["Ultrasound-guided transvaginal oocyte retrieval was carried out 36 h after hCG administration.Semen preparation ::: Materials and MethodsIf a semen sample was collected at the clinic, it was incubated for 30 minutes at room temperature to allow liquefaction, and then it was assessed for volume, concentration, and motility.", [["oocyte", "ANATOMY", 31, 37], ["Semen", "ANATOMY", 94, 99], ["semen sample", "ANATOMY", 142, 154], ["hCG", "CHEMICAL", 75, 78], ["transvaginal oocyte", "MULTI-TISSUE_STRUCTURE", 18, 37], ["hCG", "GENE_OR_GENE_PRODUCT", 75, 78], ["Semen", "ORGANISM_SUBSTANCE", 94, 99], ["semen", "ORGANISM_SUBSTANCE", 142, 147], ["Ultrasound", "TEST", 0, 10], ["transvaginal oocyte retrieval", "TREATMENT", 18, 47], ["hCG administration", "TREATMENT", 75, 93], ["Methods", "TREATMENT", 130, 137], ["a semen sample", "TEST", 140, 154], ["liquefaction", "PROBLEM", 245, 257], ["volume, concentration", "TREATMENT", 288, 309]]], ["If the sample was collected at home, the assessment was performed immediately after the laboratory received the sample.", [["the assessment", "TEST", 37, 51], ["the sample", "TEST", 108, 118]]], ["All assessments were performed on room temperature.", [["All assessments", "TEST", 0, 15]]], ["The volume was assessed using a graduated disposable pipette.", [["a graduated disposable pipette", "TREATMENT", 30, 60]]], ["Sperm concentration and total motility were assessed using 20 micron 10 \u00d7 10 grid disposable counting slides (CellVision) according to the manufacturer's instructions.", [["Sperm", "ANATOMY", 0, 5], ["Sperm", "ORGANISM_SUBSTANCE", 0, 5], ["Sperm concentration", "PROBLEM", 0, 19], ["total motility", "OBSERVATION_MODIFIER", 24, 38]]], ["Briefly, 5 microlitres of semen was added to slide, left for 5-10 minutes to stabilize, and then, where possible, at least 200 spermatozoa were counted per slide using phase contrast microscope (400 x magnification).", [["semen", "ANATOMY", 26, 31], ["spermatozoa", "ANATOMY", 127, 138], ["semen", "ORGANISM_SUBSTANCE", 26, 31], ["spermatozoa", "CELL", 127, 138], ["5 microlitres of semen", "TREATMENT", 9, 31], ["left", "ANATOMY_MODIFIER", 52, 56]]], ["Sperm counting was performed single time and when the count was obviously different from sperm count from previous cycles or from spermiogram, the counting was re-done.", [["Sperm", "ANATOMY", 0, 5], ["sperm", "ANATOMY", 89, 94], ["Sperm", "CELL", 0, 5], ["sperm", "ORGANISM_SUBSTANCE", 89, 94], ["sperm", "CELL_TYPE", 89, 94], ["Sperm counting", "TEST", 0, 14], ["the count", "TEST", 50, 59], ["sperm count", "TEST", 89, 100], ["spermiogram", "TEST", 130, 141]]], ["The same stands also for sperm motility assessment, which was evaluated from the same sample as sperm counting and calculated as all counted motile spermatozoa divided by count of all spermatozoa.", [["sperm", "ANATOMY", 25, 30], ["sample", "ANATOMY", 86, 92], ["sperm", "ANATOMY", 96, 101], ["spermatozoa", "ANATOMY", 148, 159], ["spermatozoa", "ANATOMY", 184, 195], ["sperm", "ORGANISM_SUBSTANCE", 25, 30], ["sperm", "ORGANISM_SUBSTANCE", 96, 101], ["spermatozoa", "CELL", 148, 159], ["spermatozoa", "CELL", 184, 195], ["sperm", "CELL_TYPE", 25, 30], ["sperm", "CELL_TYPE", 96, 101], ["motile spermatozoa", "CELL_TYPE", 141, 159], ["spermatozoa", "CELL_TYPE", 184, 195], ["sperm motility assessment", "TEST", 25, 50], ["sperm counting", "TEST", 96, 110], ["all counted motile spermatozoa", "TREATMENT", 129, 159], ["all spermatozoa", "ANATOMY", 180, 195]]], ["Sperm motility was evaluated under phase contrast microscope (400 x magnification) and spermatozoa were classified only as motile or immotile.", [["Sperm", "ANATOMY", 0, 5], ["spermatozoa", "ANATOMY", 87, 98], ["Sperm", "CELL", 0, 5], ["spermatozoa", "ORGANISM_SUBSTANCE", 87, 98], ["Sperm motility", "PROBLEM", 0, 14], ["phase contrast microscope", "TEST", 35, 60], ["spermatozoa", "TREATMENT", 87, 98]]], ["The spermatozoa morphology was not evaluated on the day of oocyte pick-up, although it was evaluated before when diagnostic spermiogram was performed.", [["spermatozoa", "ANATOMY", 4, 15], ["oocyte", "ANATOMY", 59, 65], ["spermatozoa", "CELL", 4, 15], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 59, 65], ["The spermatozoa morphology", "TEST", 0, 26], ["diagnostic spermiogram", "TEST", 113, 135], ["spermatozoa morphology", "OBSERVATION", 4, 26]]], ["At that point, semen smears were stained using a Papanicolaou method to evaluate the morphology (Tygerberg strict criteria were utilized).", [["semen smears", "ANATOMY", 15, 27], ["semen smears", "ORGANISM_SUBSTANCE", 15, 27], ["semen smears", "TEST", 15, 27], ["a Papanicolaou method", "TEST", 47, 68]]], ["Where possible, at least 200 spermatozoa were assessed under 1000 x magnification.", [["spermatozoa", "ANATOMY", 29, 40], ["spermatozoa", "CELL", 29, 40]]], ["Sperm vitality and antisperm antibodies were not examined on the day of oocyte aspiration.Semen preparation ::: Materials and MethodsIn all cases, after initial assessment, the samples were prepared using density gradient centrifugation (100% layer and 40% layer of Pure Sperm (Nidacon)) for 20 minutes at 225 g at room temperature.", [["Sperm", "ANATOMY", 0, 5], ["antisperm", "ANATOMY", 19, 28], ["oocyte", "ANATOMY", 72, 78], ["Semen", "ANATOMY", 90, 95], ["samples", "ANATOMY", 177, 184], ["Sperm", "ANATOMY", 271, 276], ["Sperm", "ORGANISM_SUBSTANCE", 0, 5], ["antisperm antibodies", "GENE_OR_GENE_PRODUCT", 19, 39], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 72, 78], ["Semen", "ORGANISM_SUBSTANCE", 90, 95], ["antisperm antibodies", "PROTEIN", 19, 39], ["Sperm vitality", "TEST", 0, 14], ["antisperm antibodies", "TEST", 19, 39], ["oocyte aspiration", "PROBLEM", 72, 89], ["initial assessment", "TEST", 153, 171], ["the samples", "TEST", 173, 184], ["density gradient centrifugation", "TREATMENT", 205, 236], ["40% layer of Pure Sperm (Nidacon)", "TREATMENT", 253, 286], ["aspiration", "OBSERVATION", 79, 89]]], ["Then, the 100% layer was washed in 4 ml of Sperm Preparation Medium (Origio), which was followed by centrifugation for 10 minutes at 300 g at room temperature.", [["Sperm", "ANATOMY", 43, 48], ["the 100% layer", "TREATMENT", 6, 20], ["Sperm Preparation Medium (Origio)", "TREATMENT", 43, 76]]], ["After centrifugation, the supernatant was discarded, and 0.3-1 ml of Sperm Preparation Medium was added to enable the swim-up.", [["supernatant", "ANATOMY", 26, 37], ["Sperm", "ANATOMY", 69, 74], ["centrifugation", "TREATMENT", 6, 20], ["the supernatant", "TREATMENT", 22, 37], ["Sperm Preparation Medium", "TREATMENT", 69, 93]]], ["The samples were then put into an incubator at 37\u00b0C. After approximately 2 hours of incubation, these samples were either prepared for ICSI or a conventional insemination of cumulus-oocyte complexes was performed.Embryo culture and embryo transfer (ET) ::: Materials and MethodsThe morning after fertilization methods were carried out, the oocytes were examined for the presence of pronuclei.", [["samples", "ANATOMY", 4, 11], ["samples", "ANATOMY", 102, 109], ["cumulus", "ANATOMY", 174, 181], ["oocyte", "ANATOMY", 182, 188], ["Embryo culture", "ANATOMY", 213, 227], ["embryo", "ANATOMY", 232, 238], ["oocytes", "ANATOMY", 340, 347], ["pronuclei", "ANATOMY", 382, 391], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 232, 238], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 340, 347], ["pronuclei", "CELLULAR_COMPONENT", 382, 391], ["The samples", "TEST", 0, 11], ["an incubator", "TREATMENT", 31, 43], ["incubation", "TREATMENT", 84, 94], ["these samples", "TEST", 96, 109], ["ICSI", "TREATMENT", 135, 139], ["a conventional insemination of cumulus-oocyte complexes", "TREATMENT", 143, 198], ["Embryo culture", "TEST", 213, 227], ["fertilization methods", "TEST", 296, 317], ["pronuclei", "PROBLEM", 382, 391], ["pronuclei", "OBSERVATION", 382, 391]]], ["Normally fertilized oocytes (with 2 PN) were further cultured in continuous culture medium, SAGE 1-Step, or in sequential G-series media (Vitrolife).", [["oocytes", "ANATOMY", 20, 27], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 20, 27], ["2 PN", "TREATMENT", 34, 38], ["continuous culture medium", "TEST", 65, 90], ["fertilized oocytes", "OBSERVATION", 9, 27]]], ["In cases of sequential media use, embryos were cultured in G-1 Plus medium until the third day, and then they were transferred to G-2 medium.", [["embryos", "ANATOMY", 34, 41], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 34, 41], ["G-1", "GENE_OR_GENE_PRODUCT", 59, 62], ["sequential media use", "TREATMENT", 12, 32]]], ["In cases when there were only 1 or 2 embryos, they were transferred into the uterus on the third day of development, at the cleavage stage.", [["embryos", "ANATOMY", 37, 44], ["uterus", "ANATOMY", 77, 83], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 37, 44], ["uterus", "ORGAN", 77, 83], ["uterus", "ANATOMY", 77, 83]]], ["In the majority of other cases, when there were more than two embryos, ET was performed on day 5 at the blastocyst stage.", [["embryos", "ANATOMY", 62, 69], ["blastocyst", "ANATOMY", 104, 114], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 62, 69]]], ["ETs were performed using a Guardia Access Embryo Transfer Catheter (Cook Medical), and in all ETs, only 1 or a maximum of 2 embryos were transferred.", [["embryos", "ANATOMY", 124, 131], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 124, 131], ["a Guardia Access Embryo Transfer Catheter", "TREATMENT", 25, 66], ["a maximum of 2 embryos", "TREATMENT", 109, 131], ["Catheter", "OBSERVATION", 58, 66]]], ["Supernumerary embryos of appropriate quality were vitrified.", [["embryos", "ANATOMY", 14, 21], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 14, 21], ["Supernumerary embryos", "PROBLEM", 0, 21], ["embryos", "OBSERVATION", 14, 21]]], ["When calculating the pregnancy rate, the ETs on day 3 and day 5 were combined and were not analysed separately.Statistical analysis ::: Materials and MethodsTo determine the differences between the groups, Pearson's chi-squared and Mann-Whitney U tests were used to analyse the data as appropriate (the normality of data was analysed with Shapiro-Wilk test).", [["the pregnancy rate", "PROBLEM", 17, 35], ["Methods", "TREATMENT", 150, 157], ["Whitney U tests", "TEST", 237, 252], ["the data", "TEST", 274, 282]]], ["P-values of less than 0.05 were recognized as statistically significant.ResultsWe retrospectively analysed the outcome of IVF/ICSI cycles from 2019 when fresh ejaculated semen collected at the clinic or at home was used to fertilize oocytes.", [["semen", "ANATOMY", 170, 175], ["oocytes", "ANATOMY", 233, 240], ["semen", "ORGANISM_SUBSTANCE", 170, 175], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 233, 240], ["P-values", "TEST", 0, 8], ["IVF/ICSI cycles", "TREATMENT", 122, 137], ["fresh ejaculated semen", "PROBLEM", 153, 175]]], ["Altogether, there were 1081 cycles with at least one oocyte retrieved.", [["oocyte", "ANATOMY", 53, 59], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 53, 59]]], ["The mean age of the women was 35.4 \u00b1 4.7 years, and the mean number of oocytes obtained per cycle was 8.7 \u00b1 7.0.", [["oocytes", "ANATOMY", 71, 78], ["women", "ORGANISM", 20, 25], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 71, 78], ["women", "SPECIES", 20, 25]]], ["The fertilization rate per all cumulus-oocyte complexes retrieved was 52.3% and 63.7% if the estimated number of MII oocytes was used for calculation.", [["cumulus", "ANATOMY", 31, 38], ["oocyte", "ANATOMY", 39, 45], ["oocytes", "ANATOMY", 117, 124], ["cumulus-oocyte", "MULTI-TISSUE_STRUCTURE", 31, 45], ["MII oocytes", "MULTI-TISSUE_STRUCTURE", 113, 124], ["The fertilization rate", "TEST", 0, 22], ["MII oocytes", "OBSERVATION", 113, 124]]], ["The cleavage rate of fertilized oocytes was 97.9%, which resulted in 4.5 \u00b1 4.2 embryos per cycle.", [["oocytes", "ANATOMY", 32, 39], ["embryos", "ANATOMY", 79, 86], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 32, 39], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 79, 86], ["The cleavage rate of fertilized oocytes", "TREATMENT", 0, 39]]], ["Some embryos were transferred at the cleavage stage on day 3, but most of them were cultured until day 5/6, and 50.9% of them developed to blastocysts.", [["embryos", "ANATOMY", 5, 12], ["blastocysts", "ANATOMY", 139, 150], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 5, 12], ["blastocysts", "CELL", 139, 150], ["Some embryos", "PROBLEM", 0, 12], ["blastocysts", "PROBLEM", 139, 150], ["embryos", "OBSERVATION", 5, 12], ["blastocysts", "OBSERVATION", 139, 150]]], ["When the utilization rate of embryos (defined as the proportion of all transferred and cryopreserved embryos per number of all obtained embryos (regardless of the day of transfer or of cryopreservation)) was calculated, 55.8% of them were usable.", [["embryos", "ANATOMY", 29, 36], ["embryos", "ANATOMY", 101, 108], ["embryos", "ANATOMY", 136, 143], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 29, 36], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 101, 108], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 136, 143], ["cryopreserved embryos", "TREATMENT", 87, 108], ["cryopreservation", "TREATMENT", 185, 201]]], ["Embryo transfer (ET) was performed in 78.2% of cycles, while the rest of the cycles were either freeze-all (11.5%), or no appropriate embryo for ET or cryopreservation was obtained in the cycle (10.3%).", [["Embryo", "ANATOMY", 0, 6], ["embryo", "ANATOMY", 134, 140], ["Embryo", "MULTI-TISSUE_STRUCTURE", 0, 6], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 134, 140], ["ET or cryopreservation", "TREATMENT", 145, 167]]], ["The mean number of transferred embryos was 1.3\u00b10.4, and the pregnancy rate per ET was 34.0%.", [["embryos", "ANATOMY", 31, 38], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 31, 38], ["the pregnancy rate", "TEST", 56, 74], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Pregnancy was defined as a positive \u03b2HCG test 15 days after ET.ResultsFor the analysis of cycles according to the site of sperm sample collection, there were 837 cycles where semen samples were collected at home and 244 cycles where semen samples were collected at the clinic.", [["sperm sample", "ANATOMY", 122, 134], ["semen samples", "ANATOMY", 175, 188], ["semen samples", "ANATOMY", 233, 246], ["semen samples", "ORGANISM_SUBSTANCE", 175, 188], ["semen samples", "ORGANISM_SUBSTANCE", 233, 246], ["HCG test", "TEST", 37, 45], ["the analysis", "TEST", 74, 86], ["sperm sample collection", "PROBLEM", 122, 145], ["semen samples", "TEST", 175, 188], ["semen samples", "TEST", 233, 246]]], ["The data revealed that samples collected at home had significantly higher mean spermatozoa concentrations (60.7 \u00b1 33.0 million/ml vs. 51.9 \u00b1 36.9 million/ml, respectively; P=0.001), total sperm counts (156.3 \u00b1 113.6 million vs 138.6\u00b1131.4 million, respectively; P=0.004) and better motility (59.5% \u00b1 19.6% vs. 55.1% \u00b1 21.9%, respectively; P=0.005), but the semen volume and morphology did not differ (Table 1).", [["samples", "ANATOMY", 23, 30], ["spermatozoa", "ANATOMY", 79, 90], ["sperm", "ANATOMY", 188, 193], ["semen", "ANATOMY", 357, 362], ["spermatozoa", "ORGANISM_SUBSTANCE", 79, 90], ["sperm", "ORGANISM_SUBSTANCE", 188, 193], ["semen", "ORGANISM_SUBSTANCE", 357, 362], ["The data", "TEST", 0, 8], ["samples", "TEST", 23, 30], ["significantly higher mean spermatozoa concentrations", "PROBLEM", 53, 105], ["P", "TEST", 172, 173], ["total sperm counts", "TEST", 182, 200], ["P", "TEST", 262, 263], ["P", "TEST", 339, 340], ["the semen volume", "TEST", 353, 369]]], ["When the laboratory outcome of cycles was analysed (Table 2), some significant differences were revealed as well.", [["significant", "OBSERVATION_MODIFIER", 67, 78]]], ["The number of retrieved oocytes per cycle was similar (semen collected at home vs. at clinic; 8.6\u00b17.1 vs. 9.1\u00b16.4; P=0.131), but the proportion of immature oocytes differed (17.3% vs. 19.6%, respectively; P=0.011).", [["oocytes", "ANATOMY", 24, 31], ["semen", "ANATOMY", 55, 60], ["oocytes", "ANATOMY", 156, 163], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 24, 31], ["semen", "ORGANISM_SUBSTANCE", 55, 60], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 156, 163], ["P", "TEST", 115, 116], ["immature oocytes", "PROBLEM", 147, 163], ["P", "TEST", 205, 206], ["immature oocytes", "OBSERVATION", 147, 163]]], ["The mean number of embryos was similar between the groups (at home vs. at clinic; 4.4\u00b14.3 vs. 4.5\u00b13.8; P=0.301), but the blastocyst rate was significantly higher if semen was collected at home (52.2% vs. 46.4%; P=0.001).", [["embryos", "ANATOMY", 19, 26], ["blastocyst", "ANATOMY", 121, 131], ["semen", "ANATOMY", 165, 170], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 19, 26], ["semen", "ORGANISM_SUBSTANCE", 165, 170], ["P", "TEST", 103, 104], ["the blastocyst rate", "TEST", 117, 136], ["P", "TEST", 211, 212], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["embryos", "OBSERVATION", 19, 26]]], ["Similarly, the cryopreserved embryo rate (34.7% vs. 30.0%; P=0.003) and embryo utilization rate (56.7% vs. 52.4%; P=0.011) were significantly higher in the group of patients in which semen samples were collected at home.", [["embryo", "ANATOMY", 29, 35], ["embryo", "ANATOMY", 72, 78], ["semen samples", "ANATOMY", 183, 196], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 29, 35], ["embryo", "ORGAN", 72, 78], ["patients", "ORGANISM", 165, 173], ["semen samples", "ORGANISM_SUBSTANCE", 183, 196], ["patients", "SPECIES", 165, 173], ["the cryopreserved embryo rate", "TEST", 11, 40], ["P", "TEST", 59, 60], ["embryo utilization rate", "TEST", 72, 95], ["P", "TEST", 114, 115], ["semen samples", "TEST", 183, 196]]], ["Despite these differences, there was no difference in pregnancy rate (collected at home vs. at clinic; 33.8% vs. 34.4%; P=0.888).", [["difference in pregnancy rate", "PROBLEM", 40, 68], ["P", "TEST", 120, 121], ["no", "UNCERTAINTY", 37, 39]]], ["Additional analysis of pregnancy rates also accounted for the methods used to fertilize oocytes (conventional IVF vs. ICSI) and did not reveal any significant difference (Table 3).ResultsTo further reveal what could be the cause of the observed significant differences, we analysed different subgroups of patients.", [["oocytes", "ANATOMY", 88, 95], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 88, 95], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 305, 313], ["Additional analysis", "TEST", 0, 19], ["pregnancy rates", "PROBLEM", 23, 38], ["the methods", "TEST", 58, 69], ["conventional IVF vs. ICSI", "TREATMENT", 97, 122]]], ["To determine whether a significantly higher proportion of immature oocytes in the group of patients who collected semen at the clinic influenced preimplantation embryo development, we analysed only cycles where the number of retrieved oocytes was greater than the overall mean number, and we excluded patients who had a proportion of immature oocytes that was higher than the average overall proportion from this group.", [["oocytes", "ANATOMY", 67, 74], ["semen", "ANATOMY", 114, 119], ["embryo", "ANATOMY", 161, 167], ["oocytes", "ANATOMY", 235, 242], ["oocytes", "ANATOMY", 343, 350], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 67, 74], ["patients", "ORGANISM", 91, 99], ["semen", "ORGANISM_SUBSTANCE", 114, 119], ["preimplantation embryo", "MULTI-TISSUE_STRUCTURE", 145, 167], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 235, 242], ["patients", "ORGANISM", 301, 309], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 343, 350], ["immature oocytes", "CELL_TYPE", 58, 74], ["immature oocytes", "CELL_TYPE", 334, 350], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 301, 309], ["immature oocytes", "PROBLEM", 58, 74], ["immature oocytes", "PROBLEM", 334, 350], ["immature oocytes", "OBSERVATION", 58, 74], ["immature oocytes", "OBSERVATION", 334, 350], ["higher", "OBSERVATION_MODIFIER", 360, 366]]], ["This means that we included only cycles with 9 or more retrieved oocytes and with a proportion of immature oocytes that was less than 17.8%.", [["oocytes", "ANATOMY", 65, 72], ["oocytes", "ANATOMY", 107, 114], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 65, 72], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 107, 114], ["immature oocytes", "CELL_TYPE", 98, 114], ["immature oocytes", "PROBLEM", 98, 114], ["immature oocytes", "OBSERVATION", 98, 114]]], ["Briefly, the mean number of oocytes and embryos was similar between groups, as was the proportion of immature oocytes and the pregnancy rate.", [["oocytes", "ANATOMY", 28, 35], ["embryos", "ANATOMY", 40, 47], ["oocytes", "ANATOMY", 110, 117], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 28, 35], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 40, 47], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 110, 117], ["immature oocytes", "CELL_TYPE", 101, 117], ["embryos", "PROBLEM", 40, 47], ["immature oocytes", "PROBLEM", 101, 117], ["the pregnancy rate", "PROBLEM", 122, 140], ["immature oocytes", "OBSERVATION", 101, 117]]], ["For the main categories of interest (blastocyst rate, utilization rate and embryo cryopreservation rate), the differences remained significantly different, with higher rates of each category in group that performed semen collection at home.DiscussionThe results of this study indicate that IVF laboratory outcomes are at least comparable, if not better, if semen samples for IVF/ICSI procedures are collected at home and not at the clinic.", [["blastocyst", "ANATOMY", 37, 47], ["embryo", "ANATOMY", 75, 81], ["semen", "ANATOMY", 215, 220], ["semen samples", "ANATOMY", 357, 370], ["blastocyst", "MULTI-TISSUE_STRUCTURE", 37, 47], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 75, 81], ["semen", "ORGANISM_SUBSTANCE", 215, 220], ["blastocyst rate", "TEST", 37, 52], ["utilization rate", "TREATMENT", 54, 70], ["embryo cryopreservation rate", "TREATMENT", 75, 103], ["this study", "TEST", 265, 275], ["IVF laboratory outcomes", "PROBLEM", 290, 313], ["semen samples", "TEST", 357, 370], ["IVF/ICSI procedures", "TREATMENT", 375, 394], ["main", "OBSERVATION_MODIFIER", 8, 12]]], ["Our data suggest that fertilization and embryo cleavage rates are the same regardless of the site of semen sample collection, but the blastocyst rate and embryo utilization rate are improved if a semen sample is collected at home.", [["embryo", "ANATOMY", 40, 46], ["semen sample", "ANATOMY", 101, 113], ["blastocyst", "ANATOMY", 134, 144], ["embryo", "ANATOMY", 154, 160], ["semen sample", "ANATOMY", 196, 208], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 40, 46], ["semen", "ORGANISM_SUBSTANCE", 101, 106], ["blastocyst", "DEVELOPING_ANATOMICAL_STRUCTURE", 134, 144], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 154, 160], ["Our data", "TEST", 0, 8], ["fertilization", "TREATMENT", 22, 35], ["embryo cleavage rates", "TREATMENT", 40, 61], ["semen sample collection", "PROBLEM", 101, 124], ["the blastocyst rate", "TEST", 130, 149], ["embryo utilization rate", "TEST", 154, 177], ["a semen sample", "TEST", 194, 208], ["fertilization", "OBSERVATION", 22, 35]]], ["Because we analysed only data for the previous year (2019), we could not determine if there was any influence on the abortion and birth rate, although the current data suggest that pregnancy rates were similar between the compared groups.DiscussionBecause there are several possible external influences that can negatively affect the quality of spermatozoa and consequently the outcome of the IVF/ICSI procedure, our results are somewhat surprising.", [["spermatozoa", "ANATOMY", 345, 356], ["spermatozoa", "DEVELOPING_ANATOMICAL_STRUCTURE", 345, 356], ["birth rate", "TEST", 130, 140], ["pregnancy rates", "PROBLEM", 181, 196], ["the IVF/ICSI procedure", "TREATMENT", 389, 411]]], ["Furthermore, we could not find any study addressing the question if there is any influence on the outcome of IVF/ICSI procedure if semen sample is collected at home.", [["semen sample", "ANATOMY", 131, 143], ["semen", "ORGANISM_SUBSTANCE", 131, 136], ["any study", "TEST", 31, 40], ["IVF/ICSI procedure", "TREATMENT", 109, 127], ["semen sample", "TEST", 131, 143]]], ["On the other hand, two studies explored whether there was any influence on intrauterine insemination (IUI) outcome regarding the location of semen collection (Song et al., 2007; Yavas and Selub, 2004).", [["intrauterine", "ANATOMY", 75, 87], ["semen", "ANATOMY", 141, 146], ["semen", "ORGANISM_SUBSTANCE", 141, 146], ["two studies", "TEST", 19, 30], ["intrauterine insemination (IUI", "TREATMENT", 75, 105], ["semen collection", "PROBLEM", 141, 157]]], ["Yavas and Selub (2004) concluded that in their study, semen collection at the clinic led to a better pregnancy rate, but this occurred only when women were stimulated with hMG.", [["semen", "ANATOMY", 54, 59], ["hMG", "CHEMICAL", 172, 175], ["semen", "ORGANISM_SUBSTANCE", 54, 59], ["women", "ORGANISM", 145, 150], ["hMG", "SIMPLE_CHEMICAL", 172, 175], ["women", "SPECIES", 145, 150], ["their study", "TEST", 41, 52], ["semen collection", "PROBLEM", 54, 70], ["hMG", "TREATMENT", 172, 175]]], ["When women were stimulated with clomiphene citrate, there was no difference in pregnancy rates based on the site of semen collection.", [["semen", "ANATOMY", 116, 121], ["clomiphene citrate", "CHEMICAL", 32, 50], ["clomiphene citrate", "CHEMICAL", 32, 50], ["women", "ORGANISM", 5, 10], ["clomiphene", "SIMPLE_CHEMICAL", 32, 42], ["citrate", "SIMPLE_CHEMICAL", 43, 50], ["semen", "ORGANISM_SUBSTANCE", 116, 121], ["women", "SPECIES", 5, 10], ["clomiphene citrate", "TREATMENT", 32, 50], ["difference in pregnancy rates", "PROBLEM", 65, 94], ["semen collection", "PROBLEM", 116, 132], ["no", "UNCERTAINTY", 62, 64], ["collection", "OBSERVATION", 122, 132]]], ["Furthermore, they suggested that if the start of semen preparation is delayed from 30 minutes to 1 hour or more, then the pregnancy rate can be impaired.", [["semen", "ANATOMY", 49, 54], ["semen", "ORGANISM_SUBSTANCE", 49, 54], ["semen preparation", "TREATMENT", 49, 66], ["the pregnancy rate", "PROBLEM", 118, 136]]], ["They suggested that the pregnancy rate can also be impaired if IUI is performed more than 90 minutes after the semen is prepared for treatment.", [["semen", "ANATOMY", 111, 116], ["semen", "ORGANISM_SUBSTANCE", 111, 116], ["the pregnancy rate", "PROBLEM", 20, 38], ["IUI", "TEST", 63, 66], ["treatment", "TREATMENT", 133, 142]]], ["On the other hand, a study by Song et al. (2007) did not find any difference in the ongoing pregnancy rate when patients collecting semen at the clinic were compared with those who collected semen at home.", [["semen", "ANATOMY", 132, 137], ["semen", "ANATOMY", 191, 196], ["patients", "ORGANISM", 112, 120], ["semen", "ORGANISM_SUBSTANCE", 132, 137], ["semen", "ORGANISM_SUBSTANCE", 191, 196], ["patients", "SPECIES", 112, 120], ["a study", "TEST", 19, 26], ["the ongoing pregnancy rate", "PROBLEM", 80, 106]]], ["There was also no difference in semen parameters, although the time from semen collection to the IUI procedure was significantly longer in patients who performed semen collection at home.", [["semen", "ANATOMY", 32, 37], ["semen", "ANATOMY", 73, 78], ["semen", "ANATOMY", 162, 167], ["semen", "ORGANISM_SUBSTANCE", 32, 37], ["semen", "ORGANISM_SUBSTANCE", 73, 78], ["patients", "ORGANISM", 139, 147], ["semen", "ORGANISM_SUBSTANCE", 162, 167], ["patients", "SPECIES", 139, 147], ["difference in semen parameters", "PROBLEM", 18, 48], ["the IUI procedure", "TREATMENT", 93, 110], ["semen collection", "PROBLEM", 162, 178], ["no", "UNCERTAINTY", 15, 17], ["difference", "OBSERVATION_MODIFIER", 18, 28]]], ["We do not have data for our patients regarding the time from semen collection at home to semen processing.", [["semen", "ANATOMY", 61, 66], ["semen", "ANATOMY", 89, 94], ["patients", "ORGANISM", 28, 36], ["semen", "ORGANISM_SUBSTANCE", 61, 66], ["semen", "ORGANISM_SUBSTANCE", 89, 94], ["patients", "SPECIES", 28, 36], ["semen collection", "PROBLEM", 61, 77]]], ["We can only estimate that is probably longer than the time lapse for patients who performed semen collection at the clinic; nevertheless, we observed that semen parameters, in terms of concentration and motility, were better when semen was collected at home.DiscussionOur observation that semen parameters were better when semen was collected at home is consistent with the results of a study by Elzanaty and Malm (2008).", [["semen", "ANATOMY", 92, 97], ["semen", "ANATOMY", 155, 160], ["semen", "ANATOMY", 230, 235], ["semen", "ANATOMY", 289, 294], ["semen", "ANATOMY", 323, 328], ["patients", "ORGANISM", 69, 77], ["semen", "ORGANISM_SUBSTANCE", 92, 97], ["semen", "ORGANISM_SUBSTANCE", 155, 160], ["semen", "ORGANISM_SUBSTANCE", 230, 235], ["semen", "ORGANISM_SUBSTANCE", 289, 294], ["semen", "ORGANISM_SUBSTANCE", 323, 328], ["patients", "SPECIES", 69, 77], ["semen parameters", "TEST", 155, 171], ["semen parameters", "TEST", 289, 305], ["a study", "TEST", 385, 392]]], ["Their study showed that home-collected semen samples had a significantly higher spermatozoa concentration, total sperm count, and motility, while there was no difference in the morphology or the concentration of biochemical substances (neutral alpha-glucosidase, prostate-specific antigen, zinc, and fructose).", [["semen samples", "ANATOMY", 39, 52], ["spermatozoa", "ANATOMY", 80, 91], ["sperm", "ANATOMY", 113, 118], ["prostate", "ANATOMY", 263, 271], ["neutral alpha-glucosidase", "CHEMICAL", 236, 261], ["zinc", "CHEMICAL", 290, 294], ["fructose", "CHEMICAL", 300, 308], ["zinc", "CHEMICAL", 290, 294], ["fructose", "CHEMICAL", 300, 308], ["semen samples", "ORGANISM_SUBSTANCE", 39, 52], ["spermatozoa", "ORGANISM_SUBSTANCE", 80, 91], ["sperm", "ORGANISM_SUBSTANCE", 113, 118], ["alpha-glucosidase", "GENE_OR_GENE_PRODUCT", 244, 261], ["prostate-specific antigen", "GENE_OR_GENE_PRODUCT", 263, 288], ["zinc", "SIMPLE_CHEMICAL", 290, 294], ["fructose", "SIMPLE_CHEMICAL", 300, 308], ["sperm", "CELL_TYPE", 113, 118], ["neutral alpha-glucosidase", "PROTEIN", 236, 261], ["prostate-specific antigen", "PROTEIN", 263, 288], ["Their study", "TEST", 0, 11], ["semen samples", "TEST", 39, 52], ["a significantly higher spermatozoa concentration", "PROBLEM", 57, 105], ["total sperm count", "TEST", 107, 124], ["biochemical substances", "TEST", 212, 234], ["neutral alpha", "TEST", 236, 249], ["glucosidase", "TEST", 250, 261], ["prostate", "ANATOMY", 263, 271]]], ["Furthermore, significantly fewer home-collected samples had abnormal sperm concentration or abnormal rapid progressive motility.", [["samples", "ANATOMY", 48, 55], ["sperm", "ANATOMY", 69, 74], ["sperm", "ORGANISM_SUBSTANCE", 69, 74], ["collected samples", "TEST", 38, 55], ["abnormal sperm concentration", "PROBLEM", 60, 88], ["abnormal rapid progressive motility", "PROBLEM", 92, 127], ["abnormal", "OBSERVATION_MODIFIER", 92, 100], ["rapid", "OBSERVATION_MODIFIER", 101, 106], ["progressive", "OBSERVATION_MODIFIER", 107, 118], ["motility", "OBSERVATION_MODIFIER", 119, 127]]], ["While this study showed a positive effect on semen quality when samples were collected at home, a study by Shetty Licht (2008) did not find any statistically significant difference in sperm count, sperm motility, total count, or total motile count between those samples collected at home and those collected at clinic.", [["semen", "ANATOMY", 45, 50], ["samples", "ANATOMY", 64, 71], ["sperm", "ANATOMY", 184, 189], ["sperm", "ANATOMY", 197, 202], ["samples", "ANATOMY", 262, 269], ["semen", "ORGANISM_SUBSTANCE", 45, 50], ["sperm", "ORGANISM_SUBSTANCE", 184, 189], ["sperm", "ORGANISM_SUBSTANCE", 197, 202], ["sperm", "CELL_TYPE", 184, 189], ["sperm", "CELL_TYPE", 197, 202], ["this study", "TEST", 6, 16], ["a study", "TEST", 96, 103], ["sperm count", "TEST", 184, 195], ["sperm motility", "TEST", 197, 211], ["total count", "TEST", 213, 224], ["total motile count", "TEST", 229, 247], ["those samples", "TEST", 256, 269], ["positive", "OBSERVATION_MODIFIER", 26, 34], ["effect", "OBSERVATION_MODIFIER", 35, 41]]], ["The reason for such observation may be derived from the study design because the patients could decide for themselves if they preferred to perform the collection at home or at the clinic.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["such observation", "TEST", 15, 31], ["the study", "TEST", 52, 61]]], ["In this way, the semen was collected at the clinic only by patients who were comfortable with this option, while the patients who could be under elevated stress performed semen collection at home.", [["semen", "ANATOMY", 17, 22], ["semen", "ANATOMY", 171, 176], ["semen", "ORGANISM_SUBSTANCE", 17, 22], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 117, 125], ["semen", "ORGANISM_SUBSTANCE", 171, 176], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 117, 125], ["this option", "TREATMENT", 94, 105], ["elevated stress", "PROBLEM", 145, 160]]], ["The first studies evaluating the relationship between psychological stress and semen quality suggested that stress negatively affects the quality of semen in patients who are involved in IVF treatment (Clarke, 1999; Harrison et al., 1987; Ragni and Caccamo, 1992), but later, this conclusion was challenged (Nouri et al., 2014).", [["semen", "ANATOMY", 149, 154], ["semen", "ORGANISM_SUBSTANCE", 79, 84], ["semen", "ORGANISM_SUBSTANCE", 149, 154], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["The first studies", "TEST", 0, 17], ["psychological stress", "PROBLEM", 54, 74], ["stress negatively", "PROBLEM", 108, 125], ["IVF treatment", "TREATMENT", 187, 200]]], ["Nouri et al. (2014) suggested that semen quality indeed declines during IVF, but this is probably not due to subjective stress.", [["semen", "ANATOMY", 35, 40], ["semen", "ORGANISM_SUBSTANCE", 35, 40], ["IVF", "TREATMENT", 72, 75], ["subjective stress", "PROBLEM", 109, 126]]], ["Despite this, they showed that in couples with subjective male stress, there were more poor responders, more miscarriages and fewer live births.", [["miscarriages", "DISEASE", 109, 121], ["subjective male stress", "PROBLEM", 47, 69]]], ["Haidl (2014) further suggested that poorer outcome of IVF treatment may occur due to acute stress in males and because functional parameters of semen quality could be impaired in addition to basic parameters.", [["semen", "ANATOMY", 144, 149], ["semen", "ORGANISM_SUBSTANCE", 144, 149], ["IVF treatment", "TREATMENT", 54, 67], ["acute stress in males", "PROBLEM", 85, 106], ["basic parameters", "TEST", 191, 207], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["stress", "OBSERVATION", 91, 97]]], ["For instance, (Vellani et al., 2013) showed that male stress was associated with increased sperm DNA fragmentation in IVF patients.DiscussionAn additional factor that could potentially influence the quality of semen is the period of sexual abstinence.", [["sperm", "ANATOMY", 91, 96], ["sperm DNA", "CELLULAR_COMPONENT", 91, 100], ["patients", "ORGANISM", 122, 130], ["semen", "ORGANISM_SUBSTANCE", 210, 215], ["sperm", "CELL_TYPE", 91, 96], ["patients", "SPECIES", 122, 130], ["male stress", "PROBLEM", 49, 60], ["increased sperm DNA fragmentation", "PROBLEM", 81, 114], ["IVF patients", "TREATMENT", 118, 130], ["increased sperm", "OBSERVATION", 81, 96], ["DNA fragmentation", "OBSERVATION", 97, 114]]], ["Some semen quality parameters can improve with longer periods, but others improve with shorter periods (Hanson et al., 2018).", [["semen", "ANATOMY", 5, 10], ["Some semen quality parameters", "PROBLEM", 0, 29]]], ["Meta-analysis by Hanson et al. (2018) suggests that longer abstinence increases semen volume and sperm count, but motility, morphology, and DNA fragmentation seem to improve with shorter periods of abstinence.", [["semen", "ANATOMY", 80, 85], ["sperm", "ANATOMY", 97, 102], ["semen", "ORGANISM_SUBSTANCE", 80, 85], ["sperm", "ORGANISM_SUBSTANCE", 97, 102], ["DNA", "CELLULAR_COMPONENT", 140, 143], ["sperm", "CELL_TYPE", 97, 102], ["longer abstinence", "PROBLEM", 52, 69], ["semen volume", "TEST", 80, 92], ["sperm count", "TEST", 97, 108], ["DNA fragmentation", "PROBLEM", 140, 157], ["DNA fragmentation", "OBSERVATION", 140, 157]]], ["These studies mostly focused only on sperm quality parameters, so there is not much data in the literature on how the sexual abstinence period influences the outcome of an ART cycle.", [["sperm", "ANATOMY", 37, 42], ["sperm", "ORGANISM_SUBSTANCE", 37, 42], ["sperm", "CELL_TYPE", 37, 42], ["These studies", "TEST", 0, 13], ["sperm quality parameters", "TEST", 37, 61]]], ["Periyasamy et al. (2017) showed that clinical pregnancy rates were significantly higher if the abstinence period was less than 8 days; furthermore, the positive effect of a shorter abstinence period was also revealed in a higher live-birth rate per ET.", [["clinical pregnancy rates", "PROBLEM", 37, 61]]], ["There are other studies showing that a shorter abstinence period positively influenced ART cycle outcomes.", [["other studies", "TEST", 10, 23]]], ["Jurema et al. (2005) suggested that pregnancy rates in IUI are improved if abstinence is less than 4 days (Jurema et al., 2005), while Colturato et al. (2007) further suggested that in ICSI cycles, the best quality of embryos and the highest pregnancy rate are achieved after abstinence period of 1 day; a similar result was confirmed by Borges et al. (2019).", [["embryos", "ANATOMY", 218, 225], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 218, 225], ["pregnancy rates in IUI", "PROBLEM", 36, 58], ["ICSI cycles", "TREATMENT", 185, 196], ["embryos", "PROBLEM", 218, 225], ["the highest pregnancy rate", "PROBLEM", 230, 256]]], ["Furthermore, recurrent ejaculation for 4 days with a final abstinence period of 12 hours was shown to improve the pregnancy rate in ICSI cycles (S\u00e1nchez-Mart\u00edn et al., 2013).", [["recurrent ejaculation", "PROBLEM", 13, 34], ["the pregnancy rate", "PROBLEM", 110, 128], ["ICSI cycles", "TREATMENT", 132, 143], ["recurrent", "OBSERVATION_MODIFIER", 13, 22], ["ejaculation", "OBSERVATION", 23, 34]]], ["Because we want to avoid a long sexual abstinence period in our IVF programme, which can potentially impair the quality of semen, we aimed to \u2018\u2018synchronize\u2019\u2019 the abstinence period with the planned oocyte pick-up.", [["oocyte", "ANATOMY", 197, 203], ["semen", "ORGANISM_SUBSTANCE", 123, 128], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 197, 203], ["our IVF programme", "TREATMENT", 60, 77]]], ["This can be optimally carried out by advising the patients to ejaculate on the day when the follicles are large enough to administer hCG, meaning that usually approximately 2 days pass before men collect semen for the IVF/ICSI procedure.", [["follicles", "ANATOMY", 92, 101], ["semen", "ANATOMY", 204, 209], ["patients", "ORGANISM", 50, 58], ["follicles", "MULTI-TISSUE_STRUCTURE", 92, 101], ["hCG", "GENE_OR_GENE_PRODUCT", 133, 136], ["men", "ORGANISM", 192, 195], ["semen", "ORGANISM_SUBSTANCE", 204, 209], ["patients", "SPECIES", 50, 58], ["men", "SPECIES", 192, 195], ["hCG", "TREATMENT", 133, 136], ["the IVF", "TREATMENT", 214, 221], ["ICSI procedure", "TREATMENT", 222, 236], ["large", "OBSERVATION", 106, 111]]], ["Therefore, we can say that the abstinence period is most likely similar for all patients and does not influence the results of our analysis and this is also one of the strengths of our study.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["our analysis", "TEST", 127, 139], ["our study", "TEST", 181, 190], ["most likely", "UNCERTAINTY", 52, 63]]], ["Another strength is the large number of included cycles, which are distributed throughout the entire year.", [["large", "OBSERVATION_MODIFIER", 24, 29], ["number", "OBSERVATION_MODIFIER", 30, 36], ["distributed", "OBSERVATION_MODIFIER", 67, 78]]], ["In this way, the influence of external factors (e.g., temperature) or other factors (fluctuations in the outcome of IVF/ICSI cycles) is minimized.", [["external factors", "PROTEIN", 30, 46], ["external factors", "PROBLEM", 30, 46], ["temperature", "TEST", 54, 65], ["other factors", "PROBLEM", 70, 83], ["IVF/ICSI cycles", "TREATMENT", 116, 131]]], ["On the other hand, because this is a retrospective study and we included all patients regardless of their diagnosis, there could be a bias to our results.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["a retrospective study", "TEST", 35, 56]]], ["Another bias could be the analysis of all cycles and not only the first cycles.", [["the analysis", "TEST", 22, 34]]], ["The prognosis is better for the first cycle than subsequent cycles and unbalanced distribution of first-cycle patients between the two arms may lead to bias.", [["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118]]], ["Therefore, we suggest that a prospective randomized trial taking all these limitations into account should be performed in the future.DiscussionIn conclusion, in this study, we retrospectively analysed whether collecting semen samples at home influences sperm quality or IVF/ICSI cycle outcome in terms of oocytes, embryos and pregnancy rates.", [["semen samples", "ANATOMY", 221, 234], ["sperm", "ANATOMY", 254, 259], ["oocytes", "ANATOMY", 306, 313], ["embryos", "ANATOMY", 315, 322], ["semen samples", "MULTI-TISSUE_STRUCTURE", 221, 234], ["sperm", "DEVELOPING_ANATOMICAL_STRUCTURE", 254, 259], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 306, 313], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 315, 322], ["a prospective randomized trial", "TREATMENT", 27, 57], ["this study", "TEST", 162, 172], ["collecting semen samples", "PROBLEM", 210, 234], ["sperm quality", "PROBLEM", 254, 267], ["IVF/ICSI cycle outcome", "TREATMENT", 271, 293], ["embryos and pregnancy rates", "PROBLEM", 315, 342]]], ["The results revealed that collecting semen at home has a positive effect on sperm quality (sperm concentration, total sperm count and motility were all higher), blastocyst rate and embryo utilization rate.", [["semen", "ANATOMY", 37, 42], ["sperm", "ANATOMY", 76, 81], ["sperm", "ANATOMY", 91, 96], ["sperm", "ANATOMY", 118, 123], ["blastocyst", "ANATOMY", 161, 171], ["embryo", "ANATOMY", 181, 187], ["semen", "ORGANISM_SUBSTANCE", 37, 42], ["sperm", "ORGANISM_SUBSTANCE", 76, 81], ["sperm", "ORGANISM_SUBSTANCE", 91, 96], ["sperm", "ORGANISM_SUBSTANCE", 118, 123], ["blastocyst", "DEVELOPING_ANATOMICAL_STRUCTURE", 161, 171], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 181, 187], ["sperm", "CELL_TYPE", 76, 81], ["sperm", "CELL_TYPE", 91, 96], ["collecting semen", "PROBLEM", 26, 42], ["a positive effect on sperm quality", "PROBLEM", 55, 89], ["sperm concentration", "TEST", 91, 110], ["total sperm count", "TEST", 112, 129], ["blastocyst rate", "TEST", 161, 176], ["embryo utilization rate", "TEST", 181, 204], ["positive effect", "OBSERVATION", 57, 72]]], ["The number of transferred embryos was similar in both groups, but the proportion of cryopreserved embryos was significantly higher in the home-collected semen group; therefore, we propose that this could potentially lead to a higher cumulative pregnancy/birth rate in this group.", [["embryos", "ANATOMY", 26, 33], ["embryos", "ANATOMY", 98, 105], ["semen", "ANATOMY", 153, 158], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 26, 33], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 98, 105], ["semen", "ORGANISM_SUBSTANCE", 153, 158], ["cryopreserved embryos", "PROBLEM", 84, 105], ["a higher cumulative pregnancy", "PROBLEM", 224, 253], ["embryos", "OBSERVATION", 26, 33], ["cryopreserved embryos", "OBSERVATION", 84, 105]]], ["Based on these data, we suggest that collecting semen at home for IVF/ICSI procedures is safe and positively influences treatment outcomes.Key MessageCollecting semen at home for IVF/ICSI procedure has positive effect on sperm quality, blastocyst rate and embryo utilization rate.", [["semen", "ANATOMY", 48, 53], ["sperm", "ANATOMY", 221, 226], ["blastocyst", "ANATOMY", 236, 246], ["embryo", "ANATOMY", 256, 262], ["semen", "ORGANISM_SUBSTANCE", 48, 53], ["sperm", "ORGANISM_SUBSTANCE", 221, 226], ["blastocyst", "DEVELOPING_ANATOMICAL_STRUCTURE", 236, 246], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 256, 262], ["these data", "TEST", 9, 19], ["IVF/ICSI procedures", "TREATMENT", 66, 85], ["Key MessageCollecting semen", "TREATMENT", 139, 166], ["IVF/ICSI procedure", "TREATMENT", 179, 197], ["positive effect", "PROBLEM", 202, 217], ["sperm quality", "PROBLEM", 221, 234], ["blastocyst rate", "TEST", 236, 251], ["embryo utilization rate", "TEST", 256, 279]]], ["Pregnancy rate after fresh ET is similar, but the proportion of cryopreserved embryos was significantly higher in home-collected semen group, which could lead to higher cumulative pregnancy/birth rate.", [["embryos", "ANATOMY", 78, 85], ["semen", "ANATOMY", 129, 134], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 78, 85], ["semen", "ORGANISM_SUBSTANCE", 129, 134], ["Pregnancy rate", "PROBLEM", 0, 14], ["cryopreserved embryos", "PROBLEM", 64, 85], ["higher cumulative pregnancy/birth rate", "PROBLEM", 162, 200], ["cryopreserved embryos", "OBSERVATION", 64, 85]]]]}